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Abstract 
 
 
Pulmonary hypertension (PH) is a progressive and fatal haemodynamic state 
defined by a resting mean pulmonary arterial pressure close to or more than 25 
mmHg. Pulmonary arterial hypertension (PAH), the first category in the 
classification of PH, is a rare and serious condition of unknown cause that is 
associated a huge variety of medical conditions. It has a poor prognosis and is 
characterised by a progressive increase in pulmonary vascular resistance (PVR) 
leading to right ventricular failure or a premature death. Its prevalence varies from 
15-50 patients per million populations with an average age of 45 years.  
 
Prostacyclin (PGI2) analogues are used to treat PAH, but do not cure the 
condition. PGI2 binds to prostacyclin receptors (IP) in the cell membrane 
stimulating adenylate cyclase to increase intracellular cyclic 3’5’-adenosine 
monophosphate (cAMP). Once elevated, cAMP is rapidly broken down by 
phosphodiesterases (PDEs), specifically 1, 3, 4 which appear responsible for 
regulating levels in the lungs. One of the reasons for the ineffectiveness of PGI2 in 
PAH could be high activity of these PDE isoforms that specifically break down 
cAMP. So in chapter 3, I sought to evaluate the effect of prostacyclin analogues 
(e.g. treprostinil) on cAMP and cell proliferation in PAH. I was also interested to 
check whether phosphodiesterase inhibitors could potentiate the effects of PGI2 
analogues.   
Elevated levels of endothelial ET-1 in idiopathic pulmonary arterial hypertension 
(IPAH) have been shown to be correlated with increased right atrial pressure, 
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pulmonary artery oxygen saturation and pulmonary vascular resistance  (Cacoub 
et al., 1993b). This has led to the use of ET-1 antagonists to treat PAH alone or in 
combination with other classical drugs. In chapter 4, I investigated the interaction 
between treprostinil, and endothelin antagonists on the ET-1 levels and growth 
characteristics of pulmonary smooth muscle cell cells (PASMCs) derived from 
IPAH patients.  
 
Vascular remodelling has been considered a pseudo-malignant disorder and 
mediators from cancer research have been described as targets for therapeutic 
interventions for PAH (Paulin et al., 2011). In chapter 5 I evaluated the 
antiproliferative effects of an already established anti-cancer drug ispinesib 
(Purcell et al., 2010) and thus established a rationale for investigating this agent in 
PAH settings. 
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 Introduction and classification 1.1
 
Pulmonary hypertension (PH) is a progressive and fatal haemodynamic state 
defined by a resting pulmonary arterial pressure of 25 mm Hg or greater. 
Pulmonary arterial hypertension (PAH) is the first category of PH characterised by 
vasoconstriction and remodelling of the small arteries of the pulmonary 
vasculature. PAH is frequently present in association with various cardiopulmonary 
diseases and can be characterised by sustained elevation of pulmonary artery 
pressure (PAP) and pulmonary vascular resistance (PVR) leading to impaired right-
heart function and eventual failure (Barst et al., 2004; Galie et al., 2009). Unlike in 
most of the diseases where the left ventricle is affected, in PAH the right ventricle 
is the one which is primarily affected. The secondary right heart ventricular 
hypertrophy develops in response to the increased afterload and the subsequent heart 
failure is an important cause of mortality in patients, particularly those with 
congenital heart diseases. There are no treatments existing at present that cure PAH, 
however new therapeutic options have become available that helps to improve the 
life expectancy and quality of life of the patients (McLaughlin & McGoon, 2006; 
Diller & Gatzoulis, 2007). 
 
In the early 1950s, Dresdale and colleagues were the first investigators to use the 
term “primary pulmonary hypertension” (PPH) to describe a disease distinguished 
from “secondary pulmonary hypertension” (SPH) by the absence of intrinsic heart 
or lung diseases in patients with unexplained PH (Dresdale et al., 1951). Because 
of the diversity of the disease, a classification into various groups was needed. 
Therefore the World Health Organisation (WHO) held World Symposiums on PH 
1. Introduction 
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at Evian in 1998 and Venice in 2003 and from these classified PH into five clinical 
categories. Before 2003, PAH without any known cause was termed PPH. 
However, at the third WHO meeting held in 2003 a major modification was made 
replacing the term “primary PH” with “idiopathic PAH” (IPAH). IPAH is a rare 
condition with an incidence of approximately one to two per million (McLaughlin 
et al., 2009). Likewise, the comprehensive register in France documents a 
prevalence and incidence of PAH, being 15 cases per million adult inhabitants and 
2.4 cases per million adults each year, respectively (Humbert et al., 2006). 
Moreover, females are affected twice as often as males. The National Institutes of 
Health Prospective Trial in the USA, which looked at patients with a diagnosis of 
PAH, found, more than 80% of cases to be idiopathic and 6% of that to be familial 
(Rich & Brundage, 1984; Rich et al., 1987; Rich, 2000).  
 
Further, the fourth world symposium on PH was held in Dana Point, CA in 2008 
and provided slight modification in the classification table, in that the “Familial 
PAH” group was now termed  “hereditable PAH” with further breakdown into 
genetic factors related to abnormalities in PH (Table 1 and 2).  
 
The bone morphogenetic protein receptor type II (BMPRII) gene was identified in 
2000 as the gene most likely causing familial/hereditable PAH and whose protein 
product was further recognised as belonging to the transforming growth factor β 
(TGF-β) receptor family. Surprisingly the loss of function of BMPRII was also 
found in about 26% of patients with IPAH, suggesting the receptor plays an 
important role in the disease (Deng et al., 2000; Thomson et al., 2000; Lane et al., 
1. Introduction 
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2000). In rare cases of familial PAH mutations, genes that encode for 2 other cell 
surface receptors of the TGF-β superfamily found in endothelium, activin-like 
kinase-type I (ALK-1) and endoglin (ENG), were found to be associated with 
hereditary hemorrhagic telangiectasia (Abdalla et al., 2004). There may be other 
genes, which are yet to be identified, that cause PAH. A point to be noted is that the 
presence of the mutation alone does not necessarily lead to PAH; suggesting onset 
of the disease requires a second hit and/or contribution from other risk factors 
(Morrell, 2006). 
 
 A number of risk factors involved in the development of PAH have been identified 
and are defined as any factor or condition that is suspected to play a predisposing or 
facilitating role in the development of the disease. Mutations in other signalling 
pathways have been also described. Serotonin (5-hydroxytriptamine, 5-HT) is a 
potent vasoconstrictor and when pulmonary arterial smooth muscle cells 
(PASMCs) of patients were exposed to this agent, cell proliferation increased 
extensively compared to normal cells (Eddahibi et al., 2001; Marcos et al., 2004). 
This abnormal response to 5-HT was thought to result from over expression of the 
serotonin transporter (5-HTT), as excessive proliferation was substantially 
reduced by 5-HTT inhibitors (Eddahibi et al., 2001; Marcos et al., 2004) .  
 
Furthermore, in this study the homozygous presence of an L-allelic variant of the 
5-HTT gene promoter was found in two thirds of patients with IPAH as opposed 
to 27% in control patients (Eddahibi et al., 2001). Finally a miscellaneous 
1. Introduction 
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category of PH was expanded and includes the remaining classes which were 
originally listed under ‘other’ categories of PH.   
 
With more understanding of the disease, the classification of PH has gone through 
a series of changes. The latest and most comprehensive classification published is 
the Dana Point Classification made at the 4th World Symposium on PH held in 
2008 in Dana Point, California, which divided the PH into five groups (Table 1) 
that shared similar pathophysiologic mechanisms and clinical presentation as well 
as therapeutic approaches. The recommendations of the 5
th
 World symposium have 
yet to be made available public. Untreated medial survival, following diagnosis 
rarely exceeds three years (D'Alonzo et al., 1991).  
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Table 1 - Clinical Classification of Pulmonary Hypertension: 4th World Health Organisation 
Symposium on Pulmonary Hypertension, Dana Point 2008 (Adapted from (Galie et al., 2009)). 
 
1. Pulmonary arterial hypertension (PAH) 
1.1. Idiopathic PAH 
1.2. Heritable 
       1.2.1. BMPR2 
       1.2.2. ALK1, endoglin (with or without hereditary hemorrhagic 
                  telangiectasia) 
       1.2.3. Unknown 
1.3. Drug- and toxin-induced 
1.4. Associated with: 
        1.4.1. Connective tissue diseases 
        1.4.2. HIV infection 
        1.4.3. Portal hypertension 
        1.4.4. Congenital heart diseases 
        1.4.5. Schistosomiasis 
        1.4.6. Chronic hemolytic anemia 
1.5 Persistent pulmonary hypertension of the newborn 
1.6 Pulmonary veno-occlusive disease (PVOD) and/or pulmonary capillary 
       hemangiomatosis (PCH) 
2. Pulmonary hypertension owing to left heart disease 
2.1. Systolic dysfunction 
2.2. Diastolic dysfunction 
2.3. Valvular disease 
3. Pulmonary hypertension owing to lung diseases and/or hypoxia 
3.1. Chronic obstructive pulmonary disease 
3.2. Interstitial lung disease 
3.3. Other pulmonary diseases with mixed restrictive and obstructive pattern 
3.4. Sleep-disordered breathing 
3.5. Alveolar hypoventilation disorders 
3.6. Chronic exposure to high altitude 
3.7. Developmental abnormalities 
4. Chronic thromboembolic pulmonary hypertension (CTEPH) 
5. Pulmonary hypertension with unclear multifactorial mechanisms 
5.1. Hematologic disorders: myeloproliferative disorders, splenectomy 
5.2. Systemic disorders: sarcoidosis, pulmonary Langerhans cell histiocytosis: 
        lymphangioleiomyomatosis, neurofibromatosis, vasculitis 
5.3. Metabolic disorders: glycogen storage disease, Gaucher disease, thyroid 
        disorders 
5.4. Others: tumoral obstruction, fibrosing mediastinitis, chronic renal failure on                           
        dialysis 
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Class I: Patients with PH without limitation of usual activity. Ordinary 
physical activity does not cause increased dyspnoea, fatigue, chest 
pain or pre-syncope. 
 
Class II: Patients with PH with slight limitation of usual physical activity, there 
is no discomfort at rest, but normal physical activity causes increased 
dyspnoea, fatigue, chest pain or pre-syncope. 
 
Class III: Patients with PH with marked limitation of usual physical activity. 
There is no discomfort at rest, but less than ordinary activity causes 
increased dyspnoea, fatigue, chest pain or pre-syncope. 
 
Class IV: Patients with PH with inability to perform any physical activity without 
symptoms and who may have signs of right ventricular failure. 
Dyspnoea and/or fatigue may be present at rest and symptoms are 
increased by almost any physical activity. 
 
Table 2 - Current World Health Organisation & New York Heart Association (NYHA) 
classification of functional status in patients with pulmonary hypertension. The classification 
refers to the impact of the disease on the functional capacity of the patient. The severity of PH in 
patients can be categorized using the NYHA (class I – IV) functional classification system. It is the 
physical limitations imposed on the patient by the disease which determines the functional 
classification. For example, patients with early-stage PAH are placed in class I and those most 
affected (late-stage PAH with right heart failure) are placed in class IV. The NYHA (class I – IV) 
system helps in making the choice of PAH therapy and also in an accurate predictor of patient 
mortality (Adapted from Galie et al., 2009)). 
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 Pathophysiology of PAH 1.2
1.2.1 Pulmonary arterial pressure (PAP) and pulmonary 
vascular resistance (PVR) 
 
PAH is defined by sustained elevated PVR and PAP. This leads to impaired right-
heart function, eventual failure and ultimately death (Barst et al., 2004). PVR is the 
differentiating feature between the pulmonary and systemic circulation, in that the 
flow of blood in the pulmonary arteries of the lung has greater resistance compared 
to the systemic pulmonary arteries. PAP normally is low. The mean in the normal 
subject is about 15 mm Hg which rarely, if at all, exceeds a mean pressure of 20 
mm Hg. In contrast patients with PAH have a PAP more than or equal to 25mm Hg 
at rest. PAH may also be defined as patients having a PVR ≥ 3 Woods Units (240 
dynes/sec/cm5) and a trans-pulmonary gradient ≥ 12 mmHg (Humbert et al., 2001). 
The evolution of pulmonary vascular disease in children with congenital heart 
defects differs from person to person depending on the type of underlying cardiac 
lesions. However, the presence of increased pulmonary blood flow seems to be an 
essential trigger in the development of PAH. Children with extensive systemic-to-
pulmonary shunts, whose pulmonary vascular bed is exposed to a combination of 
increased pulmonary arterial pressure and increased pulmonary blood flow, may 
develop PAH (Duffels et al., 2007). More than half of these children develop 
irreversible pulmonary vascular disease in the first years of life (Rudolph & 
NADAS, 1962; Ikawa et al., 1995), whilst in patients that have an isolated 
increased pulmonary blood flow, this is only 10 to 20%. Increases in PVR are 
associated with pulmonary vascular remodelling. The increased right ventricular 
work load leads to right ventricular hypertrophy and eventually to right ventricular 
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failure as is illustrated in figure 1.1. Due to an on-going pulmonary vascular 
remodelling, PVR rises to systemic levels resulting in bi-directional blood flow 
across the chambers. This eventually leads to a condition where the original left-to-
right shunt is reversed, a phenomenon called the Eisenmenger syndrome. 
 
1.2.2 Endothelial dysfunction in PAH 
 
Endothelial dysfunction is common place in PAH and results from an imbalance in 
the production of vasodilators like prostacyclin (PGI2), nitric oxide (NO) and 
vasoconstrictors like endothelin (ET-1), 5-HT and thromboxane A2 (TXA2). In 
PAH there is insufficiency of vasodilators and an over production of 
vasoconstrictors (Christman et al., 1992). This leads to constriction of the 
pulmonary arteries causing the pressure to increase and the PVR to rise resulting in 
vascular remodelling.   
 
In PAH, PGI2 levels have been found to be decreased in endothelial cells derived 
from patients due to a reduction in the expression of PGI2 synthase, the enzyme 
which is responsible for its synthesis (Christman et al., 1992; Tuder et al., 1999).  
 
Other endothelium-derived vasodilators are further decreased in PAH. A reduction 
of endothelial NO synthase (eNOS) expression has been reported in endothelial 
cells of patients with PAH (Giaid & Saleh, 1995) as has reduced serum levels of 
vasoactive interstitial peptide (VIP), a potent pulmonary vasodilator (Petkov et al., 
2003).  
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1.  Risk Factors and Associated Conditions 
 Collagen vascular disease 
 Congenital heart disease 
 Portal hypertension 
 HIV infection 
 Drugs and toxins 
 Susceptibility 
 Abnormal BMPR2 gene 
 Other genetic factors 
  
 
 
2.  Vascular Injury 
 Endothelial dysfunction 
 ↓ NOS, PGI2, 
 ↑ TXA2, ET-1 
 Vascular smooth muscle dysfunction 
  Impaired Kv1.5  Channel. 
 
                                               
3. Disease progression 
 Loss of response to short- 
Acting vasodilator trial 
   
 
 
 
 
 
 
Early detection 
may be 
reversed with 
drugs 
Irreversible 
damage 
Figure 1.1. Endothelial dysfunction and vascular remodelling in pulmonary arterial 
hypertension. Pulmonary arterial hypertension occurs in susceptible patients as a result of an 
insult to the pulmonary vascular bed resulting in an injury that progresses to produce characteristic 
pathological features. Histology showing Van Gieson stain which stains the collagen in red and 
elastase in black are shown for normal (top left) and PAH lung (middle and bottom left) (Extreme 
right panels adapted with prior permission from  (Gaine, 2000). 
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There is a further contribution to the pathology, as ET-1, a potent vasoconstrictor, 
is increased in both animal models and in PAH patients (Giaid et al., 1993). ET-1 
also acts as a growth factor and mitogen and plays a vital role in vascular 
remodelling in PAH (Yanagisawa, 1994). Thus endothelial dysfunction and 
imbalance in the vascular homoeostasis plays an important role in the 
pathophysiology of PAH (figure 1.1). 
1.2.3 Pulmonary vascular remodelling 
 
The common histological features of PAH are remodelling of all three layers of the 
pulmonary vasculature (intimal, medial and adventitia layers) as well as the 
formation of plexiform lesions (Gaine & Rubin, 1998). The abnormalities of the 
pulmonary vasculature comprise: 
1) medial hypertrophy of large pulmonary arteries and muscularization of distal 
precapillary arteries. 
2) Proliferation in the adventitia of small pulmonary arteries and arterioles. 
3) Intimal hyperplasia that is particularly occlusive in vessels around 100–500 μm 
in diameter. 
4) Plexiform lesions of arterial branches distal to a partially obstructed larger 
artery. 
5) Loss of pre-capillary arteries (Stenmark & Mecham, 1997; Rabinovitch, 2007).   
 
In a normal lung, the thickness of the arterial wall is maintained relatively constant 
by the balance between proliferation and apoptosis of the cells present in the vessel 
wall i.e. PASMCs, pulmonary artery endothelial cells (PAECs) and pulmonary 
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arterial fibroblasts (PAFs). A disruption in this balance towards a pro-proliferative 
phenotype of these different cell types may lead to vascular wall thickening and 
lumen occlusion, further increasing PVR (Mandegar et al., 2004). Morphological 
analysis of pulmonary hypertensive lungs reveals excessive remodelling of smooth 
muscle layer from previously non muscularised thin vessels. In PAH, adventitial 
thickening with increased extracellular matrix deposition is prominent in the distal 
muscular pulmonary arteries (Das et al., 1997; Frid et al., 1997).   
 
 
 
 
 
 
Figure 1.2. Scheme of pathological abnormalities in PH throughout the pulmonary 
circulation. Exposure of the pulmonary vasculature to increased pressure leads to vascular 
progressive remodelling (Reproduced with permission from Rabinovitch, 2008). 
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1.2.3.1 Intimal thickening and plexiform lesions 
 
Complex plexiform lesions which occur more frequently in severe PAH are 
associated with a poor prognosis for the patient (Strange et al., 2002). Due to 
extensive intimal thickening there is a reduction in the lumen of the blood vessels 
(Chazova et al., 1995). Intimal lesions are often associated with localised thrombi 
which might be responsible for the formation of more advanced lesions which can 
become fibrotic (Tuder et al., 2007). Plexiform lesions are damaging as they 
obstruct normal blood flow, with a single lesion affecting and blocking blood flow 
along the rest of the length of the vessel (Cool et al., 1999). The concentric intimal 
lesions show the presence and staining of endothelial cells and these can occur in 
association with plexiform lesions which will end up forming  mixed lesions in the 
pulmonary hypertensive lung that share both concentric and plexiform lesion 
features (Cool et al., 1997). It has been demonstrated that endothelial cells within 
plexiform lesions of IPAH patients expand in a monoclonal fashion, arising from a 
single cell, whereas those in secondary PAH they develop via a polyclonal 
expansion (Tuder et al., 1998).  
 
Although the cellular and molecular causes of the intimal lesions in PAH are not 
well understood, they are likely to be caused by a combination of injury to the 
vascular endothelium, increased proliferation and reduced apoptosis of PAECs, 
smooth muscle cell growth, migration, reduced apoptosis of PAECs, extracellular 
matrix (ECM) deposition and/or reorganised thrombi (Tuder et al., 1998).  
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Formation of plexiform lesions is most likely due to abnormal proliferation. For 
example, there is evidence which suggests that loss of the tumour suppressor gene 
peroxisome proliferator-activated receptor-γ (PPAR-γ) in plexiform lesions of PAH 
patients may be responsible for apoptotic-resistant, highly proliferative phenotype 
of endothelial cells contained within these lesions (Ameshima et al., 2003). PPAR-
γ is an antiproliferative and anti-inflammatory mediator (Jiang et al., 1998) and has 
been shown to mediate an important protective role in experimental PAH 
(Hansmann et al., 2008). Restoring function of such apoptotic pathways would be 
predicted to inhibit progressive pulmonary vascular remodelling and is considered 
by investigators to likely be the most effective therapeutic strategy in PAH. The 
frequency of lesions is greater in smaller arteries (<200 μm) than in the arteries 
with bigger diameter (>400 μm) (Yi et al., 2000). Yi and colleagues described 
concentric lesions to indicate a more severe pathology than eccentric lesions 
because they can completely obstruct the vessel lumen whereas eccentric lesions 
cause only partial luminal obstruction (Yi et al., 2000). Plexiform lesions are a 
complex form of intimal lesion and are said to occur at the branching points of the 
smaller arteries (Chazova et al., 1995). They are glomeruloid structures containing 
many small vessels with PAECs lining (Tuder et al., 1994).  
 
Myofibroblasts are also present in the core of plexiform lesions, but there is some 
debate about the source and origin of these cells. Some studies suggest that 
proliferative vascular smooth muscle cells migrating from the inner media into the 
intima lead to the pathogenesis of plexiform lesions (Heath et al., 1990) while 
others suggest a role of endothelial dysfunction leading to PAEC growth following 
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vascular injury (Cool et al., 1999). PAECs are present in both the concentric 
intimal and plexiform lesions (Cool et al., 1997; Cool et al., 1999). Similarly 
studies also suggest the presence of myofibroblasts in plexiform and concentric 
lesions (Smith et al., 1990). 
1.2.3.2 Contribution of PASMC to vascular remodelling in PAH 
 
Pulmonary hypertension leads to enhanced muscularization and thickening of small 
arterioles, whose walls usually consist of a single elastic layer. Hypoxia in PAH is 
the suspected cause for remodelling of the vessels closest to the alveolar spaces 
(Heath & Williams, 1991). The arterial medial thickening due to this proliferation 
positively correlates with the pulmonary arterial pressure (Rich et al., 1987). Due to 
this excessive proliferation, smooth muscle cells (SMCs) change their morphology 
and their cellular phenotype (Heath et al., 1987). In normal circumstances SMCs 
are contractile, but in PAH, they change to become abnormally proliferative, 
migratory and synthetic in phenotype (Boudreau et al., 1991). PASMCs show an 
increased proliferation and decreased apoptosis which can result and/or contribute 
to the thickening of the vessel wall and to vascular remodelling (Stenmark & 
Mecham, 1997). PASMCs from patients with PAH have been shown to be resistant 
to apoptotic inducers such as BMP 2, 5 and 7 (Zhang et al., 2003). A reduction in 
Kv channel (Kv 1.5) expression and function in PASMCs decreases the 
programmed cell death process by affecting apoptotic volume decrease and 
inhibiting cytoplasmic caspases (Zhang et al., 2003). The anti-apoptotic protein 
Bcl-2 is also increased in the lungs of PAH patients (Postolow et al., 2011; Tu et 
al., 2011) .  
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 Humoral regulators and therapeutic pathways 1.3
targeted in PAH 
 
To target the loss of NO and prostacyclin and to block the action of ET-1 in PAH, 
therapies directed towards three main pathways have been developed. Thus 
prostacyclin and stable derivatives, phosphodiesterase inhibitors and ET-1 receptor 
antagonists have been developed for the treatment of PAH. 
 
 
 
 
 
 
Figure 1.3. Therapeutic pathways targeted in PAH. The pulmonary vasculature is regulated by 
prostaglandins, nitric oxide, endothelin, serotonin and thromboxane. The first important pathway is prostacyclin. 
This agent is a powerful vasodilator and inhibitor of platelet aggregation but also a potent pulmonary vasodilator 
and inhibitor of smooth muscle proliferation. Second important pathway is the nitric oxide pathway. The 
biological action of nitric oxide (NO) is similar to that of prostacyclin. The third important pathway to be 
targeted is the endothelin pathway. Endothelin-1 is a potent mitogenic and vasoconstrictor peptide that plays an 
important role in the regulation of pulmonary vascular tone; both selective (ETA) and mixed (ETA & ETB) 
receptor antagonists have been developed. (Reproduced with permission from (Humbert, 2004b). 
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1.3.1 Nitric Oxide pathway. 
 
Nitric oxide is a potent endothelial-derived vasodilator synthesised by eNOS 
utilising two substrates, the terminal guanidine nitrogen of L-arginine and 
molecular oxygen. The enzyme also requires a variety of co-factors including 
nicotinamide-adenine-dinucleotide phosphate (NADPH), flavin adenine 
dinucleotide (FAD), flavin mononucleotide (FMN), and (6R-)5,6,7,8-
tetrahydrobiopterin (BH4) for NO synthesis (Zapol et al., 1994). Nitric oxide causes 
vasodilation by binding to and activating soluble guanylate cyclase (sGC) which in 
turn increases intracellular cGMP and activates protein kinase G (Kwan et al., 
2000). Relaxation occurs through a number of routes, including reducing calcium 
entry by activation of plasma membrane potassium channels, by increasing calcium 
extrusion and/or calcium sequestering within the sarcoplasmic reticulum and by 
inhibition of inositol triphosphate (IP3) turnover (Twort & van, 1988; Archer et al., 
1994; Bolotina et al., 1994). A reduction in cytosolic calcium will lead to decreased 
calcium/calmodulin and stimulation of myosin light chain kinase. This, in turn, 
reduces the phosphorylation of myosin light chain, lowers smooth muscle tone, and 
results in vasodilation (Bode-Boger et al., 2000; Galley & Webster, 2004). 
 
Studies with knockout male mice have supported the significant impact of eNOS 
on pulmonary vascular homeostasis. Indeed, eNOS-deficient mice exhibit mild 
pulmonary hypertension under normobaric normoxia, and increased susceptibility 
to hypoxia induced pulmonary hypertension (Fagan et al., 1999; Strange et al., 
2002). In contrast, overexpression of eNOS in transgenic mice prevents hypoxia-
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induced vascular remodelling in the lung (Ozaki et al., 2001). However, human 
studies suggested variable production of eNOS in patients with IPAH with reduced 
expression in pulmonary vessels (Giaid & Saleh, 1995) or increased expression in 
the endothelium of plexiform lesions, (Mason et al., 1998), perhaps indicating a 
preferential regional distribution of the enzyme (Giaid & Saleh, 1995; Mason et al., 
1998; Demoncheaux et al., 2005). Limitation of L-arginine might modulate NO 
concentrations in humans. Indeed, PAH patients with reported decreased NO levels 
have lower L-arginine content in their serum due to enhanced activity of arginase, 
an enzyme that converts L-arginine to ornithine and urea (Xu et al., 2004). Oral L-
arginine supplementation reduces pulmonary pressures in these patients, but does 
not halt the progression of the disease (Mori & Gotoh, 2000; Morris et al., 2003). 
Besides exogenous NO, several other targets in the NO pathway have shown 
promising results as potential therapies (Coggins & Bloch, 2007). Firstly, inhibition 
of the enzyme, phosphodiesterase type 5 prevents the breakdown of cGMP, 
increasing the levels of cGMP and thus will potentiate the effects of NO and atrial 
natriuretic peptide (ANP), an activator of particulate guanylate cyclase (GC). 
Secondly, direct activation of soluble GC by compounds like BAY 41-2272 has 
been shown to reduce pulmonary vascular resistance in foetal and neonatal sheep 
with severe PH (Deruelle et al., 2005a; Deruelle et al., 2005b). Thirdly, the 
presence and availability of the NOS cofactor, BH4 protects mice from hypoxia 
induced PH, decreasing  pulmonary vascular tone and remodelling in this PH 
model (Khoo et al., 2005). 
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1.3.2 Prostacyclin pathway: 
 
Synthetic prostacyclin (epoprostenol) was one of the first FDA-approved drugs to 
be used in the treatment of PAH (Rubin et al., 1990). To date, it appears to be the 
most efficacious drug for severe forms of PAH and the only agent shown to 
improve long term survival in randomised trials (Wozencraft et al., 2012). 
Prostacyclin (PGI2) is a 20 carbon prostanoid derivative of the arachidonic acid 
metabolic pathway. PGI2 has for a long while been thought to be a cyclooxygenase-
2 (COX 2) derived product in vascular endothelial cells and smooth muscle cells, 
although increasing evidence suggests that PGI2 may be produced mainly from 
COX-1, at least under physiological conditions (Flavahan, 2007). PGI2 is a potent 
vasodilator in the pulmonary circulation and exhibits anti-mitogenic and 
antithrombotic properties in experimental PAH (Hoshikawa et al., 2001).  
 
The half-life of PGI2 is approximately 3 minutes when kept in a physiological 
buffer at 37 °C, the vinyl-ether linkage being susceptible to hydrolysis to 6-keto-
PGF1α, a chemically stable product but weak inhibitor of platelet function and 
vascular tone (Figure 1.5). The metabolism is complex, but 6-keto-PGF1α can be 
further metabolised in the kidney to the 2,3-dinor derivative (Whittle & Moncada, 
1984) Therefore, PGI2 is typically monitored by measurement of 6-keto-PGF1α in 
plasma or its derivative in urine, 2,3-dinor-6-keto-PGF1α. Thromboxane A2, another 
COX-derived prostaglandin produced by endothelial cells and platelets, is 
responsible for increasing vasoconstriction and activation of platelets and thus 
opposes the biological effects of PGI2. 
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Figure 1.4. Structures of prostacyclin and its analogues.  Prostacyclin is a chemically 
unstable prostaglandin which is readily hydrolysed in a physiological buffer to 6-keto- PGF1α. 
It is also subject to metabolism by 15 hydroxyl prostaglandin dehydrogenase and β-oxidation 
yielding the urinary metabolite 2,3-dinor-6-keto- PGF1α. To increase stability, a series of 
modifications in the structure of prostacyclin have been made, giving rise to chemically stable 
analogues with longer plasma half-lives (given as terminal). Stability comes from a hindered 
alcohol group at carbon 15 as well as an ether moiety replacing the methyl group at carbon 3 of 
the carboxylic acid side chain.  
 
  
 
 
In patients with PAH, decreased urinary metabolites of prostacyclin was 
accompanied by increased levels of urinary metabolites of thromboxane A2 
(Christman et al., 1992). It is also reported that a deficiency in circulating PGI2, due 
to decreased expression of PGI2 synthase, contributes to the pathogenesis of PAH 
(Tuder et al., 1999; Tuder et al., 2007). Therefore the imbalance between 
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prostacyclin and thromboxane A2 favours vasoconstriction, thrombosis, as well as 
vessel wall remodelling associated with PAH development.  
 
Clinical trials confirm that patients receiving chronic administration of exogenous 
epoprostenol demonstrate a marked improvement in haemodynamic function, 
exercise capacity and survival time in NYHA class III and class IV PAH patients 
(Barst et al., 1996; Sitbon et al., 2002). However, the major limitation with 
epoprostenol is that it has to be given by chronic intravenous infusion due to its 
short half-life (< 3-6min), and additionally in some countries, requires an ice pack 
to maintain stability. Its side effects include flushing, jaw pain, headache and 
special mixing in vivo is required to prevent sepsis resulting from the indwelling 
catheter.  
Treprostinil is a modern generation PGI2 analogue with similar haemodynamic 
effects to epoprostenol, but with an improved half-life (~3 hours) and the ability to 
be administered subcutaneously (Sadushi-Kolici et al., 2012). Iloprost, another 
prostacyclin analogue is typically given by inhalation, has been FDA approved for 
therapeutic use and this route of administration may reduce systemic side effects 
and minimise sepsis associated complications with IV administration. The main 
drawback of various prostacyclin analogues are their relatively short biological 
half-lives: epoprostenol (3-5min) < iloprost and beraprost (~ 30min) < treprostinil 
(4-5 h). The chemical stability order of various analogues is iloprost < beraprost < 
cicaprost << treprostinil. Treprostinil is the most stable amongst all these 
analogues, and has shown favourable effects in the treatment of PAH (Baskurt & 
Kucukoglu, 2010), including long-term survival (Sadushi-Kolici et al., 2012). 
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Prostacyclin and its analogues have been the most successful treatments for 
improving the symptoms of PAH in humans to date. Epoprostenol (IV), beraprost 
(oral), iloprost (inhalation, IV) and treprostinil (subcutaneous infusion, inhalation, 
IV) have all been used with varying degrees of success in PAH patients in all 
clinical categories (Saji et al., 1996; Nagaya et al., 1999; Humbert et al., 2011). 
Recently selexipag, an oral IP receptor agonist is in clinical development for the 
treatment of PAH (Simonneau et al., 2012). Selexipag is highly selective for the IP 
receptor and does not bind to other prostanoid receptors and therefore can be 
distinguished from the above PGI2 analogues currently used in the management of 
PAH (Kuwano et al., 2007). 
1.3.2.1 Cellular targets for prostacyclins 
 
The mode of action of PGI2 (or its stable analogues) is thought to be through 
activation of plasma membrane prostacyclin (IP) receptors coupled via the Gs 
protein to adenylyl cyclase and cAMP production (Narumiya, 1994). Once 
elevated, cAMP is rapidly broken down by specific phosphodiesterases (PDE). In 
the normal lung PDE 1, 3, 4 appear responsible for regulating basal levels and 
analogue-induced elevation in cAMP (Phillips et al., 2005; Murray et al., 2007). 
However, PGI2 synthase is also expressed in the perinuclear regions of cells, 
including in smooth muscle. Once formed, prostacyclin can then directly interact 
with the ligand-binding domain of a family of transcription factors called 
peroxisome proliferator-activated receptors (PPARs) to regulate a number of 
cellular processes including cell growth, insulin sensitivity and inflammation (Lim 
& Dey, 2002).  
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PGI2 has poor selectivity for prostanoid receptors, binding to and activating EP1, 
EP3 and TP receptors, albeit at higher concentrations (15–45-fold for EP1 and EP3 
and <100-fold for TP) compared with the corresponding natural ligand (Kennedy et 
al., 1982; Coleman et al., 1995; Alexander et al., 2005). Activation of EP1 and EP3 
receptors would tend to elevate Ca
2+
 and/or lower cAMP through different G 
protein pathways, leading to vasoconstriction, thrombosis and cell proliferation.  
While stable analogues also bind potently to the IP receptor with an affinity in a 
nanomolar range (Table 3), iloprost like prostacyclin, has poor selectivity for 
prostanoid receptors, being essentially equipotent at activating IP and EP1 receptors 
(Narumiya et al., 1999 ; Abramovitz et al., 2000). Thus, it is not surprising that 
iloprost-induced vasorelaxation can be enhanced by an EP1 receptor blockade in the 
isolated rabbit perfused lungs (Schermuly et al., 2007a) or in guinea pig aorta 
(Clapp et al., 1998). On the other hand, all analogue responses in rat tail artery are 
enhanced by blocking Gi/Go with pertussis toxin (PTX), presumed to relate to the 
EP3 receptor, the main splice variant being negatively coupled to adenylyl cyclase 
via Gi (Orie & Clapp, 2011). In addition, cicaprost has significant activity at the 
EP4 receptor, as does iloprost for the human and rat but little for the mouse receptor 
(Table 3). Until very recently, far less was known about treprostinil binding affinity 
for different receptors.  
 
A recent study by Whittle and his colleagues showed treprostinil had low 
nanomolar potency in human embryonic kidney 293 cells (HEK-293) expressing 
human DP1, IP and EP2 receptors, whereas it showed much lower activity at the 
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other prostanoid receptors (Whittle et al., 2012). Thus, treprostinil seems to differ 
from iloprost in its pharmacological profile, and this may have therapeutic 
implications in the treatment of PAH. 
It is difficult to obtain similar data to the above for PGI2, because radioligand 
binding competition studies requires that binding reaches equilibrium, which can 
take at least 20 min. Over this period PGI2 will be almost completely hydrolysed at 
physiological temperature and pH to a metabolite that has little or no affinity at the 
IP receptor. Thus binding experiments are not possible to do with PGI2 except at 
very high pH (>10) and lower temperatures. If instead one uses historical dose-ratio 
studies and compare potency of biological effects with the natural ligand, this 
would predict a rank order potency for PGI2 at various prostanoid receptors to be 
IP>EP3>EP1TP. Iloprost, carbacyclin and beraprost all bind to peroxisome 
proliferator-activated receptors (nuclear transcription factors known as PPARs), 
cicaprost does not, thus highlighting another pharmacological difference. 
Prostacyclin will also bind to PPARs although other prostaglandin and 
lipoxygenase metabolites may be the natural ligand (Forman et al., 1997).. There is 
no information available about whether treprostinil binds, but PPARs appear to 
underlie some of the biological effects of treprostinil (Falcetti et al., 2010).  None 
of the above receptor selectivity would be predicted based on the initial chemistry 
of the analogues in relation to PGI2. Treprostinil does not intuitively look or 
resemble a prostacyclin-like agent to a pharmacologist/untrained chemist. The 
same could be said of beraprost. If we had the data as we know it now, treprostinil 
would be classed as a potent DP1 and EP2 agonist first and foremost (Table 3 and 
4).  
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Ligands  IP DP TP EP1 EP2 EP3 EP4 FP 
Carbacyclin Human 275 132  23 942 14 352 385 
Mouse 110    1600 31 2300 1200 
Cicaprost Human 17 >1340 >1340 >1340 >1340 255 44 >1340 
Mouse 10   1300  170   
Iloprost Human 11 1035  11 1870 56 284 619 
Mouse 11   21 1600 27 2300  
Beraprost Human 39     680   
Mouse 16     110   
Treprostinil Human 31 4.4  212 3.6 2505 826  
Mouse YES ND ND ND YES ND NO ND 
PGE2 Human  307  9.1 4.9 0.3 0.8 119 
Mouse    20 12 0.8 1.9 100 
PGE1 Human 318 53  90-165 1 6-37 1.4 ND 
Mouse 33   36 10 1 2  
PGD2 Human  1.7   2973 421 1483 6.7 
Mouse  21    280  47 
 
Table 3 - Distinct differences in prostanoid receptor binding affinities (Ki) for prostacyclin analogues compared with prostaglandin E2 (PGE2), PGE1 and 
prostaglandin D2 (PGD2) at human and mouse prostanoid receptors.  Radio ligand binding data (Ki in nM) has been taken from original study references for 
prostacyclin analogues (Kiriyama et al., 1997; Abramovitz et al., 2000; Kuwano et al., 2007; Whittle et al., 2012)  ,for PGE2 & PGD2 (Kiriyama et al., 1997; 
Abramovitz et al., 2000) and for PGE1 from several individual studies (Funk et al., 1993; Bastien et al., 1994; Regan et al., 1994; Wright et al., 1998; Davis & Sharif, 
2000; Sharif & Davis, 2002; Stitham et al., 2007).
  
The lower the number, the higher the affinity of the drug for the receptor. Blank means Ki value >3μM, ND means not 
done, YES indicates evidence for functional activity and NO means the opposite. Table modified from (Clapp & Patel, 2010) to include recently published data from 
(Whittle et al., 2012) and Ki for PGE1. Some Ki’s have been calculated from IC50 and Kd reported in the actual paper.
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LIGANDS Interpretations from Table 3 
Carbacyclin  EP3=EP1>DPIP>EP2    Equipotent EP3 and EP1 
agonist; 10 fold lower potency at IP receptor 
Cicaprost  IP>EP4>EP3   Potent IP agonist but with 
only two fold lower potency at EP4 receptor 
Iloprost  IP=EP1>EP3 >DP1 Equipotent IP and EP1  
receptor agonist 
Beraprost  IP>>EP3              3 fold lower potency at IP receptor 
compared to iloprost, some activity at EP3 receptor   
Treprostinil   EP2=DP>IP>EP1>EP3  ~10x more potent at 
activating EP2 and DP than IP; Essentially 
equipotent as natural ligand PGE2   and PGD2 & 10 
fold lower at activating IP receptor than Iloprost.      
PGE1  
 
EP2=EP4>EP3>DP>EP1>IP Equipotent at EP2 and 
EP4 receptors but 300 fold lower potency at IP 
receptor. Rank order of binding affinity bares no 
resemblance to any of the prostacyclin analogues.   
 
 
Table 4 - Pharmacological profiles of prostacyclin-Interpretation from table 3 
 
1.3.2.1.1 Prostacyclin and vascular tone 
 
Many studies suggest that PGI2 analogues inhibit vascular tone almost exclusively 
through plasma membrane potassium channels, activation of which will inhibit 
calcium influx through voltage-dependent calcium channels (Tanaka et al., 2004; 
Clapp & Tennant, 2005; Orie et al., 2006). Potassium channels are able to influence 
vascular tone because of the very steep relationship between membrane potential 
and calcium influx, with a small change (< 5 mV) capable of enhancing calcium 
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entry by two fold (Clapp & Tennant, 2005). Depending on the vascular bed studied, 
ATP-sensitive (KATP), large conductance Ca
2+
-activated (BKCa), inward rectifier 
have been implicated in the relaxation induced by iloprost, beraprost and 
treprostinil (Clapp et al., 1998; Tanaka et al., 2004; Orie et al., 2006) . This can 
occur through direct coupling via Gs of the IP receptor to the channel, indirectly 
through cAMP-dependent activation of protein kinase A (PKA) or perhaps through 
other G-protein signalling pathways that might be activated by either IP or EP (2 & 
4) receptors. In the lung, KATP and BKCa channels contribute to the reversal by 
iloprost of hypoxic-induced increases in perfusion pressure in the rat (Dumas et al., 
1997) while treprostinil activates a background potassium (TASK-1) current which 
is turned off by hypoxia and ET-1 in human PASMCs (Tang et al., 2009). In 
addition, depressed activity and expression of voltage-gated (Kv) potassium 
channels (in particular Kv1.5) is consistently reported in response to hypoxia, 
serum, anorexic agents, ET-1 and in IPAH (Clapp & Tennant, 2005; Bonnet et al., 
2007; Morrell et al., 2009). Serum and ET-1 will also inhibit KATP channel 
function, though proliferating human PASMCs do still hyperpolarise to 
pharmacological openers of this channel (Quinn et al., 2003). The combined loss of 
potassium function will lead to PASM depolarisation and a sustained rise in 
intracellular calcium, triggering not only vasoconstriction, but cell proliferation and 
a reduction in apoptosis (reviewed in (Clapp & Tennant, 2005; Hassoun et al., 
2009; Morrell et al., 2009)). Thus likely underlying cause for some of the 
beneficial effects of PGI2 therapy in IPAH could be the activation of potassium 
channel. 
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1.3.2.2  Impact of PAH on prostacyclin signalling 
 
Decreased urinary levels of 2,3-dinor-6-keto-PGF1 are found in patients with 
IPAH (Christman et al., 1992) or pulmonary hypertension linked with congenital 
heart disease (Adatia et al., 1993). In IPAH this is associated with a progressive 
loss of PGI2 synthase expression from large to small pulmonary arterial vessels, 
with virtually no expression in plexiform lesions (Tuder et al., 1999). Conversely 
overexpression of PGI2 synthase is protective in monocrotaline- and hypoxia-
induced models of PAH, reducing both medial thickening and pulmonary pressure 
(Geraci et al., 1999; Nagaya et al., 2000). A reduction in IP receptor expression has 
recently been reported in IPAH lungs and in rats following monocrotaline treatment 
(Lai et al., 2008; Falcetti et al., 2010). Such a loss is however unlikely to cause 
PAH as mice lacking the IP receptor gene do not spontaneously develop PH, 
although they are more susceptible to the hypertensive and remodelling effects of 
hypoxia (Hoshikawa et al., 2001). Thus PGI2 synthase and the IP receptor both 
appear protective in the context of PAH. Heightened activity of PDE1 (PDE1A & 
PDE1C) (Murray et al., 2007; Schermuly et al., 2007b) and to a lesser extent PDE3 
has been reported in IPAH (Murray et al., 2007), suggesting this may lead to 
reduced effectiveness of prostacyclin and its analogues.  
1.3.2.2.1 PGI2 as regulators of cell proliferation 
 
Previous studies in normal human PASMCs have shown that prostacyclin 
analogues can inhibit the mitogenic responses to PDGF and serum in a largely 
cAMP-dependent manner, with adenylyl cyclase inhibitors blocking around 75% of 
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the analogue responses in these cells (Wharton et al., 2000; Clapp et al., 2002; 
Falcetti et al., 2010).  The downstream mechanisms are not well understood, but 
prostacyclin analogues appear to inhibit smooth muscle cell proliferation by 
blocking progression from G1 to S phase (Kothapalli et al., 2003; Ohtsubo et al., 
2007). This may occur through phosphorylation of the cAMP response element 
binding protein (CREB) inhibiting cyclin A expression (Kothapalli et al., 2003) and 
up-regulating the inducible cAMP early repressor (Ohtsubo et al., 2007), the latter 
pathway is thought to promote apoptosis as well. There are other mechanisms by 
which cAMP cascades can impede cell growth (figure 1.6). Treprostinil inhibits 
serum-induced cell growth in human PASMCs in part through cAMP-dependent 
activation of ATP-sensitive potassium K
+
 channels (Clapp & Tennant, 2005). In 
aortic smooth muscle cells, cAMP elevating agents inhibit PDGF-mediated cell 
growth through inhibition of the calcineurin and nuclear factor of activated T-cells 
(NFAT) pathway (Jabr et al., 2007). Such a mechanism may counteract the 
elevated NFAT activity reported in IPAH (Bonnet et al., 2007), and for the 
expression of growth-promoting genes, including endothelin-1 (ET-1). 
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Recent studies have shown that PPARγ contributes to the IP receptor-dependent 
antiproliferative effects of treprostinil in HEK-293 cells (Falcetti et al., 2007) and 
to iloprost-induced inhibition of lung tumourigenesis through an IP receptor-
independent mechanism (Nemenoff et al., 2008). In the latter study, pulmonary-
specific over expression of either PGI2 synthase or PPAR resulted in suppression 
of tumour incidence and multiplicity in these lung models (Nemenoff et al., 2008) 
while non-small cell lung cancer cells over-expressing PPARs exhibit significantly 
less invasiveness and metastases. PPAR was shown to be largely responsible for 
 
Figure 1.5. Schematic representation of the cellular pathways by which prostacyclin inhibits vascular 
tone, cell proliferation, platelet activation.  
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antiproliferative effects of treprostinil in human PASMCs derived from IPAH 
patients (Falcetti et al, 2010).    
1.3.3 Endothelin pathway: 
1.3.3.1 Endothelin  
 
Endothelin, a 21-amino acid peptide secreted by the vascular endothelial cells was 
first discovered in 1988 and frequently reported as one of the most potent 
vasoconstrictors (Yanagisawa et al., 1988). There are three different subtypes of 
endothelin, ET-1, ET-2 and ET-3 which are derived from different genes and 
produced by different cell types (Davenport & Kuc, 2002). All three endothelins, 
share structural similarities in that they all have two disulphide bonds, a 
hydrophobic C terminal and a polar side chains of amino acid residues. ET-2 shares 
90% sequence homology with ET-1 whereas ET-3 shares about 71% homology 
(Nakajima et al., 1989). ET-1 has been studied the most extensively and is a potent 
vasoconstrictor of many blood vessels throughout the body, including the lungs 
(Yanagisawa et al., 1988). It is predominantly produced by vascular endothelium 
and to a lesser extent by pulmonary smooth muscle cells (Markewitz et al., 2001), 
lung fibroblasts (Shi-Wen et al., 2004) leucocytes, macrophage (Ehrenreich et al., 
1990) and  circulating fibrocytes (Quan et al., 2006). ET-1 is also produced in 
organs like heart, kidney, pituitary and the central nervous system, though 
production appears extremely low compared to the endothelium (Roux et al., 
1995).   
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1.3.3.2  Endothelin Synthesis 
 
Similar to other functional peptides in the body, ET-1 is synthesized from a large 
inactive precursor protein. This precursor preproendothelin-1 (PPET-1) is cleaved 
by different proteolytic enzymes, finally leading to the synthesis of ET-1 (Kimura 
et al., 1988; Itoh et al., 1988; Corder et al., 1995). Human PPET-1 contains 212 
amino acids (Yanagisawa et al. 1988) and cleavage occurs on the carboxyl side 
pairs of basic amino acids by the action of carboxypeptidases (Denault et al., 
1995b). First, a signal peptide is removed from the PPET-1 by a signal peptidase in 
the lumen of rough endoplasmic reticulum, yielding a precursor of 195 amino 
acids, proendothelin-1 (pro-ET-1) (Denault et al. 1995). Pro ET-1 is converted to a 
38 amino acid peptide big ET-1, by the furin convertase (Denault et al., 1995a). 
Conversion of big ET-1 into the biologically active ET-1 is believed to occur via 
specific metalloproteases called endothelin converting enzymes (ECE) (Levin, 
1995a; Nakano et al., 1997). Under normal culture conditions ET-1 is released 
continuously from endothelial cells by a constitutive secretion pathway. Both ET-1 
and big ET-1 vesicles have been identified in endothelial cells, suggesting that the 
intracellular vesicles are a probable site for the conversion of big-ET-1 to ET-1 by 
ECE under physiological conditions (Harrison et al., 1995). ECEs are membrane-
bound proteases and have structural homology to neutral endopeptidase (NEP) 
(Opgenorth et al., 1992; Turner, 1993). There are two isoforms, ECE-1 and ECE-2, 
though ECE-1 is the predominant one found in humans (Schmidt et al., 1994; Xu et 
al., 1994; Emoto & Yanagisawa, 1995) 
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ECE expression can been attributed to the activity of a converting enzyme located 
on the plasma membrane and intracellularly, and is particularly high in endothelial 
cells where it appears responsible for the conversion of big ET-1 to ET-1 (Corder et 
Figure 1.6.  Production and degradation of ET-1. Prepro-ET-1 is regulated at the transcription 
level and is reduced to BigET-1 by a furin-like enzyme. The majority of BigET-1 is then reduced to 
mature ET-1(21-amino acids) by ECE, or to ET-1 (31 amino acids) by a chymase and subsequently 
cleaved by a metalloprotease (MMP) to yield active ET-1. ET-1 can then exert its biological effects 
through binding to G protein coupled receptors (ETA, ETB). The production of ET-1 can be inhibited 
at several steps of the signalling cascade. The use of ET receptor antagonism and ECE inhibition are 
extensively being studied in conditions with chronically high levels of ET-1. 
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al., 1993; Xu et al., 1994). Specific stimuli can rapidly induce the transcription of 
ET-1 mRNA (Xu et al. 1994). The synthesis and secretion of ET-1 can occur 
within minutes and thus regulation of ET-1 is primarily controlled through 
alterations in gene expression. While unbound, ET-1 has a half-life of less than two 
minutes in plasma; the effect of ET-1 in the body can last for many hours because 
of the irreversible nature of ET-1 binding to its receptor (Levin, 1995a).  
 
There are two receptors that have been identified for ET-1, ETA and ETB and in 
smooth muscle both these receptors cause vasoconstriction mediated through 
increases in intracellular calcium levels (Takuwa et al., 1990; Davenport & Kuc, 
2002). ETA and ETB are G-protein coupled receptors, but the actions mediated by 
the binding at these two receptors are varied. Binding of ET-1 to smooth muscle 
cell ETA and ETB receptors activates phospholipase C (PLC), leading to an increase 
of inositol triphosphate (IP3) and diacylglycerol (DAG) which in turn can release 
calcium from the SR or increase Ca
2+
 flux through voltage gated Ca
2+
 channels 
(Pollock et al., 1995). This increase in DAG and calcium will also stimulate protein 
kinase C to further mediate the mitogenic action of ET-1 (Ohlstein et al., 1992). 
The ETB receptor has additional actions, acting to release endothelium-dependent 
vasodilators, namely through increasing the production of NO and PGI2 (Suzuki et 
al., 1991). 
 
Additionally, ETB receptors have been shown to be responsible for the clearance of 
plasma ET-1 (Dupuis et al., 1996b; Schneider et al., 2007). Under normal 
circumstances, the biological effect of ET-1 results from the balance between the 
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two receptor effects on the vasculature, though the overall result of combined ETA 
and ETB antagonism would be mild dilation of the vasculature (Haynes et al., 1996; 
Shah, 2007). The ETA receptor is predominantly expressed in proximal pulmonary 
arteries, while ETB receptor expression is higher in vascular smooth muscle cells in 
distal resistance vessels (McCulloch et al., 1996). Both endothelin receptors have a 
significant impact on vasoconstriction and proliferation (Bonvallet et al., 1993; 
McCulloch et al., 1996).  
1.3.3.3 Clearance of ET-1 
 
ET-1 elimination seems to be a rapid process happening within minutes, despite 
pressor effects lasting for about an hour (Sirvio et al., 1990; Levin, 1995b; 
Vachiery & Davenport, 2009). There is a sustained increase in cytosolic calcium in 
SMCs coupled with an increase in the sensitivity of the contractile apparatus to 
calcium, resulting in prolonged vascular contraction. The majority (50-70%) of ET-
1 uptake occurs in pulmonary circulation and therefore the lung is considered a 
major organ for clearance of plasma ET-1 (de et al., 1988; Dupuis et al., 1996b). A 
substantial amount of ET-1 synthesis is located in pulmonary tissue and this will 
lead to a neutral arterial-venous oxygen difference in the lungs (Dupuis et al., 
1996b). In animal experiments, it was shown that single pass extraction of ET-1 by 
the pulmonary circulation is completely abolished during selective blockade of the 
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ETB-receptor subtype (Dupuis et al., 1996b). It was also demonstrated that the 
magnitude of increase in plasma levels of ET-1 in endothelial ETB-receptor 
knockout mice (Bagnall et al., 2006) is comparable to the change in ET-1 plasma 
levels after ETB blockade. Taken together, these results indicate that ETB-receptors 
play an important role in the uptake of ET-1. Uptake of ET-1 also occurs in the 
Figure 1.7. Effect of ET-1 in the vasculature. Endothelin-converting enzyme (ECE) 
catalyzes the conversion of ET-1 from its precursor Big ET-1 which then binds to its 2 main 
target receptors, ETA and ETB. Binding of ET to ETA and ETB on VSMC leads to 
vasoconstriction, while binding of ET to ETB on endothelial cells can lead to vasodilation of 
VSMC. In fibroblasts and smooth muscle these receptors will also cause proliferation. In 
certain pathologies expression of the ETB receptor on SMC is up-regulated.  
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kidney, which as in the pulmonary circulation, appears to be mediated through the 
ETB receptor (Fukuroda et al., 1994a). There is insufficient evidence to suggest 
significant uptake of ET-1 occurs in the liver in humans, although a study in dogs 
suggests that the ETB receptor in the liver is an important site for ET-1 clearance 
with close to 85 % extraction occurring in this organ (Dupuis et al., 1999). The 
mechanism of ETB receptor-mediated clearance of ET-1 occurs through 
intracellular lysosomal degradation of the receptor complex (Bremnes et al., 2000). 
1.3.3.4 Role of ET-1 in PAH 
 
ET-1 is frequently reported as a potent mitogen affecting the functions of 
endothelial cells, smooth muscle cells and fibroblasts and is thus likely to play a 
central role in the pathogenesis of PAH. In addition, ET-1 is also responsible for 
cytokine release. The role of the endothelin pathway in the pathogenesis of PAH 
was considered following several studies showing that plasma levels of ET-1 are 
three to four times the upper limit of normal in patients with most forms of PAH 
including IPAH, PAH related to connective tissue disease, heart failure and HIV 
infection (Yoshibayashi et al., 1991; Vancheeswaran et al., 1994; Rubens et al., 
2001; Sitbon et al., 2004). Moreover ET-1-like immunoreactivity was abundant in 
patients with PAH, particularly in plexiform lesions (Gaid et al, 1995). ET-1 
staining was predominantly in the endothelial cells of the pulmonary arteries which 
had medial thickening and there was a strong correlation between the intensity of 
the immunoreactivity and PVR in these patients. Also, elevated ET-1 levels have 
been shown to negatively correlate with haemodynamic variables, 6-min walk 
distance (6MWD) and survival (Rubens et al., 2001).  
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PAH is a disease of excessive remodelling of the intimal layers of the vasculature 
and the ET-1 produced by the endothelial cells, is directed towards the underlying 
smooth muscle cells and fibroblasts, where it can interact with ETA and ETB 
receptors to promote vasoconstriction, proliferation and fibrosis (figure 1.8). A 
smaller amount of ET-1 is released into the lumen of the pulmonary vasculature 
where it can stimulate the endothelial ETB receptors, resulting in the production of 
vasodilatory molecules, such as NO and prostacyclin (McCulloch et al., 1998; 
Davie et al., 2002). Although there is clear evidence for ET-1 contributing to the 
adverse vasculopathy associated with PH, ET-1 is probably produced as a 
consequential effect of the disease and not a primary cause of PH. Chronic ET-1 
infusion causes a reduction in pulmonary vascular reactivity to NO in rats, but does 
not result in PH (Migneault et al., 2005). Furthermore, overexpression of ET-1 
alone does not result in PH in transgenic animals (Hocher et al., 2000) pointing to 
other mechanisms operating alongside to cause PH. Nonetheless, a genetic strain of 
rats deficient in the ETB receptor develop a more severe PAH phenotype associated 
with vessel occlusion in response to monocrotaline compared to treatment in 
control rats, where only moderate PAH and medial thickening takes occurs (Ivy et 
al., 2005).   
1.3.3.5 ECE inhibition 
 
Most ECE inhibitors currently under development also inhibit neutral 
endopeptidase (NEP), resulting in the combined effect of inhibiting ET-1 
production but at the same time having the potential to reduce the catabolism and 
hence clearance of ET-1 (Abassi et al., 1992). In addition, by blocking ET-1 
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generation, ECE inhibitors would act as pseudo ETA/ETB antagonists and perhaps 
importantly, would leave ET-1 clearance unaffected. However, so far, less progress 
has been made in the area of ECE inhibition than endothelin receptor antagonism 
(Doggrell, 2002; Kirkby et al., 2008). 
1.3.3.6  Endothelin Receptor antagonists 
The role of ET-1 in PAH as described earlier along with other supporting evidences 
has led to a rationale therapeutic approach for antagonism of endothelin. At 
present, there are two commercially available endothelin receptor antagonists 
(ETRAs) for the treatment of PAH – bosentan and ambrisentan. The key 
differences between these ETRAs, are in their selectivity for ETA and ETB 
receptors. However, selectivity for ETA and ETB may vary according to the assay 
used for its determination and thus the distinction between their selectivity is 
poorly deﬁned (Verhaar et al., 1998). Different assays have revealed considerable 
variation in reported ETA: ETB ratios. Those for ambrisentan range from 29:1 for 
ET-1-mediated contraction in the rat aorta up to 4000:1 in myocardial membranes 
(Bolli et al., 2004)  while ETA:ETB ratio for sitaxentan and bosentan published so 
far are 6500:1 and 20:1, respectively (Davie et al., 2009).  In 2001, a randomised, 
placebo controlled trial showed beneficial effects of oral bosentan on exercise 
capacity and cardiopulmonary haemodynamics in PAH (Channick et al., 2001). 
Similar effects were seen with ‘BREATH-1’ studies (Bosentan: 
Randomized Trial of Endothelin Receptor Antagonist THerapy), supporting the 
above findings (Rubin et al., 2002). On the basis of these trials, bosentan was 
approved by WHO for the treatment of PAH class II patients. The most common 
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side effect is dose-dependent hepatotoxicity, especially seen in patients who are on 
high doses.  
 
 Additional therapeutic targets used in PAH 1.4
 
1.4.1 Calcium Channel blockers 
 
Calcium channel blockers (CCBs) act to functionally reduce the conductance of 
voltage dependent calcium channel. In PASMCs, this results in the decrease in 
intracellular Ca
2+
 concentration, resulting in pulmonary vascular smooth muscle 
relaxation. Clinical trials involving the use of CCBs in PAH have shown beneficial 
therapeutic effects, with an improvement in survival rate observed (Rich et al., 
1992), since initial observations, it was identified that CCB therapy is only 
effective as a treatment in patients who are vasoreactive i.e. their pulmonary 
vasculature still responds to local mediators via relaxation or contraction (Sitbon et 
al., 2005). Less than 10% of PAH patients exhibit vasoreactivity, and of those, 
many do not have sustained effects of CCB therapy beyond a few months (Reeves 
et al., 1986). Taken together, this indicates that CCBs have limited therapeutic use 
in the treatment of PAH. Moreover, significant adverse events were observed with 
these agents, including negative inotropic effects which resulted in fatal events, 
typically observed in NYHA class IV PAH patients with right ventricular failure 
(Packer et al., 1984a; Packer et al., 1984b).  
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1.4.2 Phosphodiesterase Inhibitors 
1.4.2.1 Phosphodiesterase Type 5 Inhibitors 
 
NO released from PAECs acts in a paracrine fashion on the underlying PASMCs to 
activate the NO/cGMP pathway, resulting in increased levels of the second 
messenger cGMP which in turn decreases intracellular calcium ([Ca
2+
]i) to cause 
vasodilatation. Phosphodiesterases (PDEs) are a class of enzymes which mediate 
the hydrolysis of cGMP and cAMP. Phosphodiesterase type 5 (PDE5) is the most 
abundantly expressed PDE-isoform within the lung, and its activity and expression 
is also reported to be further increased in PAH (Black et al., 2001). Sildenafil, the 
highly selective PDE5 inhibitor has been approved by the WHO for the treatment 
of PAH. It acts by inhibiting the hydrolysis of cGMP, therefore prolonging its half-
life and causing prolonged cellular effects. PDE5 inhibition is reported to inhibit 
PASMC proliferation (Wharton et al., 2005; Demoncheaux et al., 2005) and 
attenuate hypoxia-induced PAH (Zhao et al., 2001). Galie reported improvements 
in both NYHA functional class and exercise capacity in PAH patients when 
administered sildenafil (Galie et al., 2005).  
 
Other approved PDE5 inhibitors in the US are tadalafil and vardenafil (Schroll et 
al., 2012). These  newer agents have potential advantages over sildenafil such as a 
faster onset and longer duration of action, higher selectivity for PDE5, and 
increased absorption (Rosenkranz et al., 2007). Out of the three, sildenafil and 
tadalafil are the most widely studied for their use in the treatment of PAH. A major 
difference between these two agents is that tadalafil is a more selective PDE5 
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inhibitor showing little or no affinity towards PDE1, whereas sildenafil may inhibit 
the latter at the higher end of the therapeutic dose range (Blount et al., 2004). 
1.4.2.2 Phosphodiesterase Type 3 inhibitors in PAH 
 
Phosphodiesterases have a wide distribution in normal tissues. Mammalian PDEs 
are subdivided into 11 distinct families on the basis of substrate specificity, 
sensitivity and sequence homology (Essayan, 1999; Essayan, 2001). 
Phosphodiesterase type 3 (PDE3) enzymes are encoded by 2 different genes termed 
as PDE3A and PDE3B (He et al., 1998) which specifically hydrolyses cAMP but 
can be competitively inhibited by cGMP (Lugnier, 2006) (figure 1.-8).  
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PDE3 enzymes provide a means by which increased intracellular cGMP can lead to 
increased intracellular cAMP by selective inhibition of PDE3. The prostacyclin 
Figure 1.8. Schematic diagram showing the potential cross talk between cAMP and cGMP. 
One can increase cAMP by stimulating Gs coupled receptors like the prostacyclin (IP) receptor 
and/or by inhibiting its breakdown with a phosphodiesterase inhibitor such as a PDE3 inhibitor, 
milrinone or cilostazol. Cyclic GMP can be elevated by stimulating soluble or particulate 
guanylate cyclase with nitric oxide (NO) or atrial naturetic peptide (ANP) and/or by inhibiting its 
breakdown with PDE5 inhibitors such as sildenafil or tadalafil. So using a variety of interventions 
might enhance vasodilator and antiproliferative mechanisms in patients with PAH.  
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analogues are the most efficacious treatment for PAH to date; however the 
drawback is their short biological half-life, especially for epoprostenol and iloprost 
(Olschewski et al., 1996; Schermuly et al., 1999). These agents exert vasodilation 
via enhanced cAMP generation and various PDEs break it down to AMP; thus 
blocking the catabolism of this second messenger ought to prolong the pulmonary 
effects of these agents (Torphy, 1998). PDE 1, 3 4 and 5 are shown to be present in 
the lung parenchyma (Rabe et al., 1994). However, the activity of PDE3 is 
increased in main, branch and intrapulmonary arteries from rats maintained under 
chronic hypoxic conditions and in PH (Maclean et al., 1997). In the same study, 
PDE3 inhibitors also reversed the reduced responsiveness of pulmonary vessels to 
isoprenaline and forskolin in rats with PH.  
Among the PDEs, PDE4, PDE7, and PDE8 selectively hydrolyse cAMP while 
PDE5, PDE6, and PDE9 are selective for cGMP. The other 5 subfamilies (PDE1, 2, 
3, 10, and 11) hydrolyse both cyclic nucleotides with varying efficiency (Table 5) 
(Beavo, 1995; Soderling & Beavo, 2000; Lugnier, 2006; Conti & Beavo, 2007). 
Because of the crucial regulation role of cyclic nucleotides in signalling 
transduction, the concept that PDEs are involved in the pathological process of 
PAH is widely accepted (Theo et al., 2005). Interestingly, expression and activities 
of PDEs were reported to be altered in both experimental and human PAH (Murray 
et al 2000). Expression profiling of single member of the PDE super family in 
healthy and remodelled pulmonary vasculature revealed that PDE1, PDE3 and 
PDE5 isoforms are differentially regulated (Maclean et al., 1997; Schermuly et al., 
2007b).  
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FAMILY CHARACTERISTICS TISSUE DISTRIBUTION INHIBITORS
PDE1 Ca2+/calmodulin-stimulated Heart, brain, lung, smooth muscle 8-methylmethoxy-
IBMX,
phenothiazines
PDE2 cGMP-stimulated Adrenal gland, heart, lung, liver,
platelets
EHNA
PDE3 cGMP-inhibited Heart, lung, liver, platelets, adipose
tissue, immunocytes
Cilostazol, milrinone
PDE4 cAMP-specific Sertoli cells, kidney, brain, liver, lung,
immunocytes
Rolipram, roflumilast
PDE5 cGMP-specific Lung, platelets, smooth muscle Zaprinast, sildenafil,
Tadalafil
PDE6 cGMP-specific Photoreceptors
Sildenafil, Tadalafil,
Vardenafil, Zaprinast
PDE7 cAMP-high affinity Skeletal muscle, heart, kidney, brain,
pancreas,
T lymphocytes
PDE8 cAMP-high affinity Testes, eye, liver, skeletal muscle,
heart, kidney, ovary, brain, thyroid,
pancreas
Dipyridamole
PDE9 cGMP-high affinity Kidney, liver, lung, brain, testes, heart,
thymus, spleen, intestinal smooth
muscle
Sildenafil, Zaprinast
PDE10 Dual (cGMP and cAMP) Testes, brain Papaverine
PDE11 Dual (cGMP and cAMP) Skeletal muscle, prostrate, kidney, liver,
pituitary and salivary glands, testes
Dipyridamole
 
 
 
 Table 5 - Characteristics and distribution of PDEs 
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In preclinical and clinical studies it has been shown that the inhibition of PDE1 by 
8MM-IBMX (Schermuly et al., 2007b) and PDE5 by sildenafil (Schermuly et al., 
2004), stabilizes the second messenger signalling and regulates vascular 
remodelling, vascular tone and optimization of gas exchange, which can improve 
the haemodynamics in PAH. Moreover, in monocrotaline-induced PH rats, 
inhibition of PDE3 and PDE4 isoforms was found to partly reverse the pathological 
inward remodelling in PH (Phillips et al., 2005; Schermuly et al., 2005a). Given 
that higher PDEs (PDE7-11) were defined more recently, further investigations 
should be performed to understand the possible involvements of higher PDEs in 
PAH and to improve the therapy of PAH by pharmacological PDE inhibitors.  
 
1.4.3 Tyrosine kinase inhibitors: 
 
Platelet derived growth factor (PDGF) is one of many growth factors and mitogens 
that contributes to the pathobiology of many vascular diseases including PAH 
(Raines, 2004) . PDGF is expressed by all major cell types from endothelial cells, 
smooth muscle cells, and platelets to macrophages where it behaves as a potent 
mitogen and chemokine. On vascular smooth muscle cells (VSMCs), PDGF can 
promote migration, proliferation and other cellular processes by activating specific 
cell surface receptors and causing their phosphorylation. In the early nineties a few 
research studies suggested a role for PDGF in PAH due to their observations 
showing that PDGF-A and -B were upregulated in pulmonary cells and lung tissue 
in PAH models (Arcot et al., 1993; Katayose et al., 1993). Lung tissue from 
patients with PAH showed similar findings and thus it was postulated that PDGF 
1. Introduction 
65 
 
had an important role in the pathogenesis of PAH (Humbert et al., 1998). Studies 
by Lanner and his group showed that PDGF contributed to hypoxia induced 
proliferation of VSMCs (Lanner et al., 2005). Likewise, inhibition of PDGF 
signalling in animal models of PH showed promising results in perinatal PH in the 
fetal lamb as well as in common PH animal models (Balasubramaniam et al., 2003; 
Schermuly et al., 2005a). Imatinib mesylate is a small molecule tyrosine kinase 
inhibitor capable of blocking the signalling of PDGF, and has been approved for 
the treatment of various malignant disorders such as 
specific chromosomal abnormality philadelphia chromosome-positive chronic 
myelogenous leukemia  (CML), acute lymphoblastic leukemia, and gastrointestinal 
stromal tumours (Cohen et al., 2005). Based on its mode of action, imatinib 
mesylate has been administered in PAH patients (Patterson et al., 2006) and tested 
in animal models of PAH (Schermuly et al., 2005a; Ghofrani et al., 2006) with 
promising results. A phase III trial (IMPRES) has now been completed, with 
statistical improvements in 6MWD, PAP, PVR and cardiac output, though time to 
clinical worsening was unchanged (Reported to the European Respiratory Society 
Annual Congress, September 2011). Given the latter, it remains to be determined 
whether this agent will indeed be approved for treatment of PAH.  
 Approach towards combination therapy  1.5
 
Pulmonary arterial hypertension is a multifactorial disease, suggesting that if 
multiple pathways are targeted together, this ought to be the most effective 
treatment strategy (Benza et al., 2007). Several clinical trials involving the use of 
multiple treatments have been designed and shown promising improvements in 
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both haemodynamic and exercise capacity (Benza, 2008; Ventetuolo et al., 2008). 
The efficacy and safety of the combination of bosentan and epoprostenol was 
investigated using a small group of PAH patients (Humbert et al., 2004a). Although 
hemodynamics and exercise capacity were improved, and data showed a trend for a 
greater improvement in all hemodynamic parameters in the combination-treatment 
group compared to the placebo-treatment group, though no statistical significance 
was demonstrated. Two other randomized controlled trials studying bosentan in 
combination with prostanoid therapy provided mixed results, with one study failing 
to show an improvement while the other indicating the combination is safe and 
possibly effective  (Seyfarth et al., 2005; McLaughlin et al., 2006). 
 
As in many other progressive diseases, patients with PAH may experience clinical 
and hemodynamic deterioration despite on-going initial effective monotherapy with 
the currently available disease-specific PAH drugs (i.e. PDE5 inhibitors, 
prostacyclins, endothelin receptor antagonists). Therefore it is reasonable to 
consider combination therapy. However, because of unknown risks, costs, drug 
interactions, combination therapy needs to be properly evaluated in randomized, 
controlled trials where safety and efficacy with the various possible combinations 
in the various PAH subgroups is demonstrated. The “Pulmonary Arterial 
Hypertension Combination Study of Epoprostenol and Sildenafil” (PACES) study 
is to my knowledge the only study that so far reached significance in terms of time 
to clinical worsening (Simonneau et al., 2008). PACES was a 16-week, 
multinational, randomized, double-blind, placebo-controlled study involving 267 
patients (257 completed the study) with WHO functional classes I–IV and with 
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PAH who were already receiving long-term intravenous epoprostenol therapy. In 
some patients with pulmonary arterial hypertension, the addition of sildenafil to 
long-term intravenous epoprostenol therapy improved exercise capacity, 
hemodynamic measurements, time to clinical worsening, and quality of life of PAH 
patients. 
 
 Aim and outline of the thesis 1.6
 
The aim of the studies presented in this thesis is to test potential treatment options 
in an in vitro model of PAH. 
Phosphodiesterase 3 is one of the major phosphodiesterases to inactivate cAMP in 
the lung. Its heightened activity in PAH contributes to the loss of efficacy of 
beraprost in this disease (Murray et al., 2007). In chapter 3, the effects of the 
prostacyclin analogue, treprostinil and its potentiation in the presence of 
phosphodiesterase 3 inhibitor (cilostazol) with respect to generation of cAMP, cell 
proliferation and vasorelaxation is assessed in experimental settings.  
Lung endothelial ETB receptors promote ET-1 clearance, which can be improved in 
PAH patients by prostacyclin (epoprostenol) monotherapy (Langleben et al., 1999). 
It is unclear if other prostacyclin analogues have similar effects or if smooth muscle 
ETB receptors can regulate ET-1 levels. In chapter 4, I investigated the interaction 
of prostacyclin with the endothelin pathway. In this chapter I have assessed the 
effect treprostinil and endothelin-1 receptor antagonists had on endothelin, 
endothelin receptors and the converting enzyme.  
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A concern with anti-cancer agents like tyrosine kinase receptor inhibitors is the 
high incidence of adverse events including nausea and diarrhoea as well as the 
potential for cardiac toxicity (Ghofrani et al., 2010). Thus anti-cancer agents with a 
more selective mode of action need to be evaluated.  
Mitotic kinesin inhibitors are a novel class of chemotherapy agents with low 
toxicity, whose mechanism in cancer involves disruption of various events in 
normal mitosis thereby promoting cell-cycle arrest and apoptosis. In Chapter 5, I 
assessed a newer anti-cancer agent, ispinesib with classical agents used to treat 
PAH and their effects on the proliferation of human PASMCs. 
Chapter 6 contains general conclusions regarding the results and the possible 
perspective studies for the future.
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 Patient Characteristics and Ethical considerations 2.1
 
Human PASMCs from normal and IPAH patients were used for the study. 
Peripheral PASMCs were isolated from children and adults with IPAH and from 
control adults. Lung tissue was taken with Ethics Committee approval from Great 
Ormond Street Hospital (ICH and GOSH REC 05/Q0508/45), Papworth Hospital 
(REC H00/531/T) and Brompton & Harefield Trust (NHLI REC 01-210) through 
Dr Wharton (Imperial College, London) after patient/relative consent was obtained. 
Cells were obtained from patients with IPAH undergoing transplantation after 
failed treatment (4 children, 5 adults). Treated children received epoprostenol for at 
least 1.3 years while adult patients were on varying prostacyclin therapy for an 
average of 1.2 years. For controls, cells were isolated from donor lungs found to be 
unsuitable for transplantation or from lung resection for suspected malignancy. 
Human endothelial cells (HECs) were obtained from TCS Cellworks 
(Buckingham,UK) and the fibroblast cell lines were generously provided by 
Professor David Abraham (Division of Medicine, Royal free Hospital). 
 Cell Culture 2.2
2.2.1 General materials and equipment used for cell culture 
 
All materials and solutions used for cell culture were sterile unless otherwise used 
for terminating the experiments.  
 MATERIALS 
1. Growth Medium – Two different types of growth medium were used 
throughout this study. 
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 Growth medium - DMEM/F12; (PAA Laboratories, Munich, 
Germany) with 10% Foetal bovine serum (Gibco New Zealand 
breed, Invitrogen, Paisley UK) and 5% solution of 
penicillin/streptomycin (Invitrogen, UK). 
 Growth Medium – Smooth muscle cell basal medium (ZHM-3933, 
TCS Cellworks, Buckingham, UK) with 10% Foetal bovine serum 
(FBS) (Gibco New Zealand breed, Invitrogen UK) and 5% solution 
of penicillin/streptomycin (Invitrogen, UK). 
 Special growth medium to grow primary smooth muscle cells- 
Smooth muscle cell basal medium (ZHM-3933, TCS Cellworks, 
Buckingham UK) with human smooth muscle cell growth 
supplement (ZHS-8951, TCS Cellworks, Buckingham UK) and  5% 
solution of  penicillin/streptomycin (Invitrogen, UK). 
 
2. Phosphate-buffered saline (PBS), Ca2+/Mg2+ free (PBS) (PAA Laboratories, 
Munich, Germany) 
3. Trypsin/EDTA solution (0.05% (w/w) tissue culture grade (Invitrogen, 
Paisley UK). 
 
 GLASSWARE  AND PLASTICWARE 
4. Tissue culture plates – Different types and sizes of tissue culture plates were 
used depending upon the need of the experiment. 
5. Flasks (75cm2 and 125cm2) 
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6. Chambered culture slides - used for staining and immunohistochemistry 
experiments (BD Falcon, Oxford, UK). 
 
 EQUIPMENT 
7. Culture incubator – all culture incubators are maintained to have a 
humidified atmosphere, temperature 37 °C and 5% CO2. The incubators are 
cleaned and decontaminated every 2-3 months.  
8. Working hoods - A clean functional biosafety hood which protects the 
culture by filtering the air which is coming out of the hood and maintains a 
laminar flow. 
9. Water bath - Clean water bath maintained at 37°C to pre-warm the reagents. 
10. An inverted phase contrast microscope - to view the live cell cultures. 
11. A vacuum and suction setup for disposal of medium wastes. 
12. Fridge/freezer – for storage of the reagents and stock solutions. 
13. Centrifuges (Eppendorf, UK). 
 
2.2.2 Isolation and characterisation of human PASMCs  
Human PASMCs were isolated from explanted lungs of IPAH patients receiving a 
bilateral lung or heart and lung transplant. Normal cells were isolated from the lung 
tissue isolated from myeloma patients.  
 MATERIALS  
1. Complete medium to grow primary smooth muscle cells- Smooth muscle 
cell basal medium (ZHM-3933, TCS Cellworks, Buckingham UK) with 
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human smooth muscle cell growth supplement (ZHS-8951, TCS Cellworks, 
Buckingham UK) and 5% solution of  penicillin/streptomycin (Invitrogen, 
UK). 
2.  Hank’s balanced salt solution (HBSS; Sigma/Aldrich, UK) – used for 
collection of the specimen.   
3. Penicillin/streptomycin/gentamycin (3% solution) - prepared from a stock 
solution containing 5000 iu/ml of penicillin/streptomycin and 10,000 iu/ml 
gentamycin. 
4. Enzymatic dissociation solution – A four times concentrated solution of the 
enzymatic dissociation cocktail was prepared and diluted with DMEM/F12 
HEPES (Sigma/Aldrich, Poole, Dorset UK) buffer just before use. The 
cocktail was prepared by dissolving  the following in 10 ml of  DMEM/F12 
HEPES (Sigma/Aldrich, Poole, Dorset UK) 
 5 mg of elastase (Lorne Laboratories, Reading, UK.),  
 10 mg of collagenase (Sigma/Aldrich, Poole, Dorset, UK),  
 2.5 mg of trypsin inhibitor (Sigma/Aldrich, Poole, Dorset 
UK), 
 150 mg of bovine serum albumin (BSA)  
 100 µL of MEM vitamins. 
The dissociation cocktail was then sterilized by filtration and 1 ml aliquots 
were prepared and stored at - 20°C. 
5. Confocal  Microscopy reagents - 
 Antibodies to specific smooth muscle cells antigens. 
 Para-formaldehyde for fixation (Sigma/Aldrich, Dorset,UK). 
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 0.1 % of Triton X-100 solution (Sigma/Aldrich, Dorset, 
UK). 
  3% of BSA solution prepared in 0.01% Triton X-100 
solution 
 4’,6-diamidino-2-phenylindole (DAPI; Vectastain, VECTOR 
LABORATORIES, Peterborough UK) 
The explanted lungs/lung tissue was washed with cold PBS and once with 3% of 
penicillin/streptomycin/gentamycin solution. Distal peripheral pulmonary arteries 
of approximately 250 µm in length were dissected out of the tissue block and 
placed in 3% penicillin/streptomycin/gentamycin sterile solution for 30 min at 4 
°C. After the sterilisation procedure, the artery was pinned to the bottom of the 
dissecting gel plate and the adventitia gently pulled away from the medial layers 
leaving a smooth outer surface and then cut open longitudinally. The endothelium 
was gently scraped off with a sterile scalpel blade and the artery was then cut into 
transverse strips, of approximately 1- to 2-mm wide. These strips were then 
transferred to the pre-warmed (37°C) enzymatic dissociation cocktail and incubated 
for 30 minutes in a shaking water-bath. After 30 min, the cell suspension was 
strained through a 70 micron cell strainer and cells were sedimented by 
centrifugation at 350 g for 5 min. The supernatant was removed and the cell pellet 
was re-suspended in the complete growth medium. Cells were plated in T-25 cm
2 
flasks and incubated at 37 °C in 5% CO2 and media replaced every 3 days. After 
the cells reached confluence, they were washed with PBS (PAA Laboratories, 
Munich, Germany) and trypsinised for further passage. The primary cells were also 
characterised using immunofluorescent staining, confocal microscopy and western 
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blotting (all methods completely described in later chapters) to identify smooth 
muscle specific markers for example α-smooth muscle actin and smooth muscle 
cell marker SM-22. Endothelial cell specific markers, for example CD31 and Von 
Willebrand factor (VWf), were used as negative controls. Primary cultures were 
prepared in large batches and cells were frozen and preserved in liquid nitrogen 
with minimal loss of cell viability over several years. Cells between passages 3 and 
10 were used for all experiments. A few vials of cells were frozen at each passage 
throughout each experiment to provide the possibility and advantage of repeating 
and studying any changes which might occur with increased passage.  
 
2.2.3 Subculture of Human PASMCs from hypertensive and 
normal patients 
2.2.3.1 Reviving of cells  
 
In contrast to the optimal slow rate of freezing, cells were thawed as rapidly as 
possible so as to minimise ice crystal formation and cell damage. A vial of cells 
was removed from the liquid nitrogen tank and carefully immersed in a 37°C water 
bath with gentle agitation until thawed. The content of the vial was then aseptically 
plated in a T75 cm
2 
flask and incubated at 37°C and 5% CO2. The medium was 
replaced with fresh growth medium after 5-6 hours by which this time the smooth 
muscle cells had attached to the bottom of the flask. The medium was changed 
every three days till the culture reached confluency, after which the cells were 
tryspinised and plated according to the need of each particular experiment. 
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2.2.3.2 Subculturing cells  
 
After reaching 80-90% confluence, cells were washed twice with ~5mls of warmed 
sterile PBS (PAA Laboratories, Munich, Germany) and detached using 5ml of 
trypsin/EDTA solution (0.05 % (w/w) Invitrogen, UK) previously warmed to 37
0
C. 
After the cells had become detached at least 10 mls DMEM/F12 (Invitrogen, UK) 
growth medium containing 10% FBS (Gibco New Zealand breed, Invitrogen UK) 
and 5 % penicillin/streptomycin (Invitrogen, UK) was added to neutralize the 
trypsin. The cell suspension was then centrifuged at 350g at room temperature for 5 
min to obtain a cell pellet. The supernatant was then removed and the pellet 
resuspended in 2-3mls fresh growth media. Cells were counted using an automated 
cell counter (see the next paragraph) and plated at appropriate density in 6-well 
plates.  
2.2.3.3 Freezing of cells  
 
A minimum of 0.5 x 10
6 
cells /ml of freezing medium were always used to freeze 
down cells.  
 MATERIALS 
1. Freezing medium  
Two types of freezing mediums were used during this study 
 Freezing medium containing 90% of foetal bovine serum 
(FBS, Gibco, New Zealand breed, Invitrogen UK) and 10% 
dimethyl sulfoxide (DMSO) (Sigma/Alrich, UK) as a 
cryoprotective agent. 
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 Bambanker (Anachem Ltd, Luton, Bedfordshire) serum free 
cell freezing medium - In the later stage of experiments this 
medium was used to freeze down cells. 
2. Freezing vials   
Sterile polypropylene freezing vials were used to freeze cells. 
3. Freezing container  
To maximize viability cells were frozen slowly, ideally with a steady decreasing 
rate of one degree per minute. The freezing container filled with iso-propyl alcohol 
helps to freeze cells at a steady rate and reduce ice crystal formation and damage, 
which is observed when snap freezing cells instantaneously. Before putting into the 
container, cells were washed with PBS (PAA Laboratories, Munich, Germany) and 
then detached from the bottom surface of culture flasks using trypsin/EDTA 
solution (0.05 % (w/w) Invitrogen, UK). After centrifugation at 350g for 5min, the 
supernatant was carefully removed without disturbing the cell pellet. The cells were 
then resuspended in the cell freezing medium at the desired cell density and 
aseptically pipetted into freezing vials. 
 Growth curves and proliferation assays 2.3
 
Cells were plated at a density of 1x10
4
/ml in 6-well plates giving a total of 2x10
4
 
cells per well. The number of plates was dependent on each particular experiment. 
After plating, the cells were incubated at 37°C and 5 % CO2 for 24 hours in growth 
medium. After this period, the wells were washed with 1 ml of PBS (twice) and 
media replaced with basal medium containing no serum to arrest the cells. 48 hours 
later, the cells were stimulated with 10% FBS with or without drug treatments and 
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incubated for 4 days. After 4 days the cells were counted using an automated cell 
counter.  
2.3.1 Cell counters  
2.3.1.1 Sysmex F-520P   
 
For the first 18 months of my study period Sysmex F-520P (Malvern Instruments 
Ltd, Malvern, UK) was used to count cells, which due to technical problems had to 
be replaced by a new and more advanced cell counter (ADAM-MC counter, 
NanoEnTek Inc, Digital Bio, Korea). The cell count analyser, Sysmex F-520P uses 
the direct current electronic resistance method for particle (cell) counting and 
sizing. The counter contains a probe comprising a transducer with an aperture of an 
exact diameter (the standard being 100 μm) and an internal and external electrode. 
The probe is immersed in the cell suspension diluted into an electrically conductive 
diluent, which allows a direct current to pass through the aperture between the 
electrodes. Cells or particles in the suspension are non-conductive and when they 
pass through the aperture, they decrease the flow of current and increase the 
resistance. The Sysmex F-520P particle counter uses a non-mercury diluent-filled 
ballfloat manometer pump. Increased resistance due to cells in the aperture causes a 
change in the voltage between the electrodes which is proportional to the volume of 
the particle or cell. Since a constant current is maintained, the voltage change will 
be directly proportional to the change in resistance according to Ohm’s Law: 
 
E (voltage) = I (current) × R(resistance). 
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2.3.1.2 ADAM-MC counter 
 
The ADAM-MC (NanoEnTek Inc, Digital Bio, Korea) is a fast alternative to 
conventional manual counting methods using a haemocytometer. The principle of 
the technique used in the ADAM-MC is the well-known method of fluorescence 
microscopy, implemented in a small, highly advanced fluorescence microscope 
combined with a CCD camera and software-based image analysis. The excitation 
source is green LED. The emission filter removes all wavelengths from the light 
emitted from the sample except red fluorescence light. The red fluorescent light 
from the particles in the sample will then focused onto the detector (CCD camera). 
Then image analysis software counts the red particles to represent the cell number 
in the sample.   
Adam-MC is based on staining the cell DNA with a fluorescent dye, in this case, 
propidium Iodide (PI). This dye does not enter cells with intact cell membranes, 
only entering cells with damaged membranes. As a result, the nuclei of non-viable 
cells will only be stained. The counter provides two kinds of staining solutions. 
AccuStain Solution ‘T’ is composed of the fluorescent dye (PI) and lysis solution 
which is used for obtaining total cell counts. The lysis buffer will disrupt the 
membrane and allows PI to enter the cells to stain them. AccuStain Solution ‘N’ 
cell is composed of the fluorescent dye and PBS for the counting of non-viable 
cells. With the later solution, live cells remain intact and are not stained; thus only 
the non-viable cells are stained and detected. After treatment with the staining 
solutions, the prepared cells are loaded into the Accu-chip. The viability is 
automatically calculated with installed software using the following equation, 
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Viable cell count/ ml = Total cell count (T1)/ml – Non viable cell 
count (N1)/ml  
Viablity (%) = (Viable cell count / total cell count) x 100 
 
 
4CH chip
Objective lens
Excitation filter
Dichroic filter
Emission filter
CCD camera
Mirror
Lenses
Green LED
 
Figure 2.1. Schematic of the ADAM-MC cell counter.  To count cells using ADAM-MC, cells are 
mixed with a Propidium Iodide (PI) stain and directly pipetted on to a disposable plastic chip. The 
chip is then loaded onto a stage in the counter. A 532nm green laser is automatically focused onto 
the chip and cells that have been stained are detected by a CCD camera.  
2. Materials and Methods 
81 
 
T  = total cell count
N  = non viable cell count
Total cell count
Non viable cell count
PI + lysis soln
PI stained nuclei
PI stained nuclei
PI stained nuclei
Viable cell
PI  soln
T T
N N
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2. Principle of cell counting by ADAM-MC counter.  For total cell count, the cell 
sample is mixed with an equal volume (1 to 1 dilution) of AccuStain Solution T and mixed 
thoroughly by vortexing. This cell lysate (15 μl) is then carefully loaded into the T1 or T2 
channel of the Accu-chip 4X so as to avoid making bubbles. Similarly for non-viable cell count, 
the cell sample is mixed with an equal volume of AccuStain Solution N and mixed thoroughly 
by vortexing. This cell lysate (15 μl) is carefully loaded into the N1 or N2 channel of the Accu-
chip 4X. Solution T’ contains Propidium iodide (PI) along with a lysis solution and will give 
total cell count. The solution N’ does not contain the lysis solution hence the dye will only stain 
those cells whose cell membranes are not intact, viz non-viable cells. Thus the solution N’ will 
give the non-viable cell count. 
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 Cyclic AMP enzyme linked immunoassay 2.4
 
Cyclic 3’5’ adenosine monophosphate is a second messenger, signal transduction 
cascades of which involves cAMP regulating a variety of intracellular processes. A 
rise in cellular cAMP or activated PKA can promote pulmonary vasodilation 
(Haynes, Jr. et al., 1992; Barman et al., 2003) and exert antiproliferative and pro-
apoptotic effects (Tantini et al., 2005). ). Intracellular levels of cAMP depend on 
the balance between cAMP synthesis by adenylyl cyclase (AC) isoforms 
(Willoughby & Cooper, 2007)  and cAMP hydrolysis by PDE enzymes (Baillie 
2009). 
 
2.4.1 Principle of the assay 
 
The cAMP present in a sample competes in a competitive binding fashion with a 
fixed amount of horseradish peroxidase (HRP)-labelled cAMP for sites on a mouse 
monoclonal antibody. The incubation allows the monoclonal antibody to bind to 
the goat anti-mouse antibody coated onto the bottom of the microplate. Washes 
after incubation of the antibody helps to remove any non-specific binding.  The 
substrate solution was used to determine the bound enzyme activity on the 
microplate and the absorbance was read at 450 nm where the intensity of the colour 
is inversely proportional to the concentration of cAMP in the sample. 
2.4.2 Sample preparation and cyclic AMP measurement   
 
Human PASMCs were lysed before assaying according to the following 
manufacturer’s instructions. Cells were grown to ~80% confluence before drug 
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treatment and lysing. For sample preparation, cells were washed twice with cold 
PBS and resuspend in cell lysis buffer (R&D Systems Europe Ltd, UK) to a 
concentration of 1 x 10
7 
cells/ml. A freeze/thaw cycle was used once with gentle 
mixing to lyse all the cells properly. In initial experiments, trypan blue was used to 
confirm that the protocol used completely lysed cells, which it did as cell extracts 
were all stained blue. Lysed cells were then centrifuged at 600 x g for 10 min at 4° 
C to remove unwanted debris. Supernatants were stored at -80° C for cAMP 
estimation at a later stage. Cyclic AMP was measured according to the 
manufacturer’s instructions (R & D Systems Europe Ltd, Abingdon, UK). 
2.4.3 Protein measurement 
 
 MATERIALS  
1. BCA protein assay kit (Thermo Fisher Scientific, Northumberland, UK) 
 BCA solution which contains bicinchoninic acid, sodium carbonate, 
sodium tartarate and sodium bicarbonate in 0.1 M NaOH, pH 11.25. 
 4% cupric sulphate. 
BCA working reagent was prepared by mixing 50 parts of BCA solution 
with 1 part of 4% cupric sulphate just before use. 
2. Bovine serum albumin (BSA)  
The standard colorimetric assay based on the Bradford assay (Bradford, 1976) was 
used on the cell extracts to measure protein. Bovine serum albumin (BSA, 
Sigma/Aldrich, Dorset, UK) was dissolved and diluted to generate a six point 
standard curve (0 to 2 mg/ml) using a clear 96 well plate. Dilutions of the standard 
solution were made in the same buffer as the samples. Specifically, 25 μl of 
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standard and protein sample (in duplicate) was pipetted into individual wells of a 
96 well plate, followed by addition of 200 μl of BCA working reagent to each well. 
The plate was incubated at 37°C for 30 min and the absorbance read at 540 nm in a 
GENios absorbance plate reader (TECAN, Reading, UK). Protein concentration of 
samples was calculated from the standard curve, by first subtracting the 
background reading from the blank, and then finally multiplying by the dilution 
factor of the sample. An example of a standard curve generated during this study is 
shown in the figure 2.3. 
  
 
  Endothelin pathway in IPAH 2.5
2.5.1 Measurement of Endothelin 1 (ET-1) 
 
ET-1 exerts its biological actions through the activation of two receptor subtypes, 
ET-A and ET-B (Sakurai et al., 1990). Both receptors belong to a large family of 
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Figure 2.3. A standard curve generated using a BCA protein assay kit. 
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transmembrane guanine nucleotide-binding protein-coupled receptors (GPCRs). 
The endothelin pathway seems to be involved in pathogenesis of many disease 
states including cancer, fibrosis, heart failure and pulmonary hypertension (Archer 
& Rich, 2000; Kedzierski & Yanagisawa, 2001). ET-1 is elevated in PH and thus is 
an important mitogen to study in the disease. In this study, I sought to elucidate the 
effect of different drugs currently used to treat pulmonary hypertension on ET-1 
levels. 
2.5.2 Sample preparation 
 
 MATERIALS 
1. Growth medium - Smooth muscle cell basal medium (ZHM-3933, TCS 
Cellworks, Buckinghamshire UK) with 10 % foetal bovine serum and 5% 
solution of penicillin/streptomycin (Invitrogen, UK). 
2. Growth arrest medium - Smooth muscle cell basal medium (ZHM-3933, 
TCS Cellworks, Buckinghamshire UK) with 5% solution of 
penicillin/streptomycin (Invitrogen, UK). 
3. RIPA lysis buffer (Sigma/Aldrich, Dorset, UK). 
Cells were cultured in growth medium to ~80% confluence in 6-well plates and 
then placed in medium containing no serum for 48 hours. The growth arrested cells 
were then stimulated with growth medium with or without treatment with different 
drugs. Cell culture supernatants from each well were removed 24 hours later and 
aliquoted into 1 ml vials for storage at -80° C until assayed. Repeated freeze-thaw 
cycles of samples were avoided. Cells were lysed with RIPA lysis buffer to 
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measure protein content. The final amount of ET-1 were quantified to amount of 
protein per well. 
2.5.3 Principle and protocol for the assay  
 
ET-1 levels in cell culture supernatants were measured using the QuantiGlo Human 
ET-1 chemiluminescent immunoassay kit (R&D systems, Minneapolis, USA). It is 
a solid phase ELISA which employs the quantitative sandwich enzyme 
immunoassay technique for measuring ET-1 in the samples. Samples are incubated 
onto a microplate coated with monoclonal antibody specific for ET-1. Washes after 
the incubation of the antibody helps to remove any non-specific binding. An 
enhanced luminol/ peroxide substrate solution when added produces light in 
proportion to the amount of ET-1 bound in the initial step which was measured 
using the luminometer.  
 SDS-PAGE and western blot analysis 2.6
 
SDS-PAGE separates proteins migrating through a SDS -gel under the influence of 
an electric field. When coupled with antibody detection steps, the relative 
abundance of a particular protein in two or more protein extracts can be 
determined.  
2.6.1 Sample preparation  
 
 MATERIAL 
1. Phosphate-buffered saline, Ca2+/Mg2+ free (PBS) 
 (PAA  Laboratories, Munich, Germany)  
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2. Lysis buffer-   
 RIPA lysis buffer (Sigma/Aldrich, Dorset, UK). 
 Phosphatase inhibitor (Sigma/Aldrich, Dorset, UK) 
RIPA buffer was mixed with phosphatase inhibitor just before use (100:1). 
Cells were washed with cold PBS twice followed by addition of lysis buffer and 
spread evenly over the cells using a cell scraper. After 2-3 min, cells were scrapped 
and the cell extracts placed in an eppendorf and centrifuged at 900 g for 15 min at 
4°C. Supernatants were stored at - 80°C until use.  
2.6.2 Principle of Western blotting 
 
Heating of cell lysates with sample buffer and dithiothreitol (DTT) protects 
proteins by reducing disulphide bonds in the protein to thiol groups and covering 
the protein with SDS molecules, forming a negatively-charged complex. Under the 
influence of an electric field, proteins migrate through a gel whose pore size is 
determined by the concentration of acrylamide and cross-linker in the gel. Larger 
proteins are obstructed more than smaller proteins, resulting in a separation of 
proteins largely based on molecular size. During transfer, the protein/SDS complex 
is transferred out of the gel onto a protein-binding membrane under the influence of 
an electric field. For antibody detection, protein-binding sites on the membrane are 
blocked by incubating with 5% milk protein, and the protein of interest is then 
specifically bound with an antibody. This primary antibody is then detected with a 
secondary antibody conjugated to an enzyme. A liquid substrate is then added, 
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which in the presence of the peroxidase enzyme, emits light in a chemiluminescent 
reaction, and this light is detected using photographic film.  
Western blotting is often described as a semi-quantitative technique, with the 
amount of protein originally present in the lysate proportional to the amount of 
peroxidase enzyme bound to protein on the membrane, and thus the amount of light 
generated and area and intensity of the band present on the film. For routine 
western blotting, samples were protein assayed before loading. Blotting with an 
antibody such as GAPDH, total ERK, α-tubulin or β-actin serves as a loading 
control and helps to visually confirm comparable protein loading.  
2.6.3 Protocol of Western blotting 
 
Protein content of the cell lysates was measured using the BCA protocol. 10 μg of 
protein extracted from cell lysates of smooth muscle cells subjected to different 
treatments was assayed for levels of endothelin receptor type B (ETB) and 
endothelin converting enzyme -1 (ECE-1) by Western blotting. Each sample was 
reduced with sample reducing buffer (Life technologies, USA) by boiling at 100°C 
for 3 minutes. The reduced samples were run on a Bis-Tris Gel (either 5%, 7 % or 
10%) in MOPS-SDS running buffer alongside a prestained molecular weight 
marker (Fermantas, Cambridge UK), at 200V for 45 to 60 minutes. The protein was 
then transferred to a PVDF membrane using a Wet Transfer apparatus in 1x 
Transfer buffer (Life technologies, Paisley, UK) containing 10% methanol. The 
transfer was performed at 100V for 1 hr or 25V overnight at 4°C. Following the 
transfer, the proteins on the membrane was blocked in PBS containing 5% 
skimmed milk and 0.1% Tween-20 (PBST) for one hour at room temperature. The 
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primary antibody (Table 2) was diluted in the blocking buffer to the required 
concentration. Following the blocking step, the membrane was incubated with the 
primary antibody overnight at 4°C on a shaking platform (Eppendorf, Stevenage, 
UK). Next morning, the membrane was washed three times with PBST then 
incubated with the appropriate secondary antibody (diluted in 5% milk in PBST) 
for one hour at room temperature. The membrane was washed again three times 
with PBST and then dried in air. The protein bands were visualized using the 
enhanced chemiluminescence plus reagent detection system (GE Healthcare, 
Buckinghamshire, UK) and recorded on hyperfilm (GE Healthcare Life Sciences,  
Buckinghamshire, UK).The exposed hyperfilm was scanned using the HP 
Deskscan system and bands were analysed using the software called ‘Image-J’ 
(Collins, 2007).  
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Target antigen Primary and secondary 
antibodies 
 
ETB  
1° = polyclonal rabbit anti-ETB (1:1000, 
ab39960, Abcam, UK) 
2° = goat anti-rabbit IgG-horseradish 
peroxidase (1:1000, sc-2040, Santa 
Cruz, UK) 
 
ECE-1 
1° = polyclonal rabbit anti-ECE-1 
(1:1000, ab93117, Abcam, UK) 
2° = goat anti-rabbit IgG-horseradish 
peroxidase (1:1000, sc-2040, Santa 
Cruz, Biotechnology, Heidelberg, 
Germany) 
 
β-Actin (loading control) 
1° = monoclonal mouse anti- Actin 
(Sigma/Aldrich, UK) 
2° = goat anti-mouse IgG-horseradish 
peroxidase (1:5000, Santa Cruz 
Biotechnology, Heidelberg, Germany) 
 
Table 6 - Antibodies used for western blotting. 
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 Lung Histology  2.7
 
Tissue blocks from distal portions of the lung tissue samples from diseased and 
control patients were fixed in neutral buffered formalin overnight, transferred to a 
70% ethanol solution the next day and subsequently sent to the Queen Mary’s 
laboratory, (St Bartholomew’s, Barbican, London) for slide preparations. One slide 
of each section was used for Haematoxylin and Eosin (H & E) staining to look for 
gross pathological changes. Briefly H & E staining was performed by immersing 
the slide in hematoxylin solution (made up in PBS pH 7.2) for 5 minutes followed 
by washing 3 times in PBS before being immersed in 1% eosin counterstain 
solution (made up in PBS pH 7.2) for 5 seconds. After the slides were washed 3 
times in PBS, sections were processed through an increasing alcohol gradient into 
xylene and then mounted in diethyl (phenyl) xanthine DPX mounting medium 
(Grale Scientific, Ringwood, Australia).  A coverslip was placed over the section 
and the slide allowed drying. Slides were analysed under normal light microscopy 
with the assistance of Dr. Susan Hall, Institute of Child Health, University College 
London.  
2.7.1 Principle of Immunohistochemistry 
 
Immunohistochemistry (IHC) refers to the process of localizing antigens (proteins) 
in cells of a tissue section exploiting the fundamental principle of antibodies 
binding specifically to antigens in biological tissues. Visualising an antibody-
antigen interaction is then accomplished by the most frequently used method in 
which the secondary antibody is conjugated to an enzyme, such as peroxidase, that 
can catalyse a colour-producing reaction upon addition of an appropriate substrate. 
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Alternatively, the secondary antibody is tagged to a fluorophore, such as 
fluorescein, rhodamine or alexafluor (this is known as immunofluorescent 
staining).  
The advantage of IHC over techniques like enzyme-linked immunosorbent assay 
(ELISA) or Western blotting (which function on the same principle) is the ability to 
identify and locate specific proteins within the tissue structure, which adds a whole 
new dimension to the technique. The target immunogens may sometimes be 
physically “hidden” from the antibody, because of protein folding or formation of 
cross-linking methylene bridges during ‘fixation’. An antigen retrieval step, where 
enzymes or heat are used to re-model the protein structure and break down 
methylene bridges, may be required to visualize some antigens. 
2.7.2 Histology protocol 
 
Paraffin sections on slides were dewaxed and hydrated, by sequential passage 
through the following steps: initially two washes with xylene for 5 min each were 
performed, followed by two washes with 100% ethanol for 3min and a wash each 
with 95% and 85% ethanol for 3min. Finally the racks were placed in distilled 
water for 5 min and the step repeated.  Endogenous peroxidase activity was 
blocked by immersing the slide in 3% hydrogen peroxide (Sigma Aldrich) for 10 
min. The slides were then rinsed in tap water. A boundary was made around the 
tissue section using an immunoedge pen (DAKO, Glostrup, Denmark). Antigen 
retrieval was then performed by trypsin digestion to unmask the antigen sites that 
may have become cross-linked during fixation. A fresh solution of 0.1% trypsin 
and 0.1% calcium chloride was prepared in 5mM Tris buffered saline at 37°C and 
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brought to pH 7.8 with 0.1M sodium hydroxide. Slides were immersed for 10 min 
and then rinsed in PBS three times.  
A blocking step to prevent non-specific antibody binding to proteins in tissue 
preparations was performed by incubation with 5% non-immune goat serum for 30 
min at room temperature. The serum being from the species from which the second 
layer antibody was derived. The primary antibodies were diluted in PBS with 0.1% 
BSA (PBS/BSA) at concentrations recommended in the data sheets for each 
antibody. They were carefully pipetted onto the tissue sections within the boundary 
(~200 μl). The slides were then incubated at 4°C overnight in a humidified 
chamber. For negative controls the serial sections were incubated without any 
primary antibody.  
The next morning, the slides were washed with PBS/BSA and incubated with the 
secondary goat anti-rabbit with biotinylated IgG antibody which was diluted 1:200 
for one hr at room temperature. During this time, the ABC Solution (PK4000, 
Vector Laboratories, Peterborough UK) was prepared as recommended by the 
manufacturer and allowed to stand at room temperature for at least 30 minutes 
before use. The slides were then washed with PBS/BSA once, followed by two 
washes with PBS. The ABC solution was then added onto the tissue sections after 
gently drying off the excess buffer and the slides were then incubated for an hr at 
room temperature. Meanwhile, the DAB substrate solution (D4168, Sigma Aldrich) 
was prepared by dissolving tablets in 1ml or 5ml of PBS and vortexed to prepare a 
homogeneous mixture. The slides were rinsed with PBS. The slides were incubated 
in the DAB solution for 1 to 5 minutes before the reaction was stopped by 
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transferring the slides into water. The stained sections were then counterstained 
with Harris’s haematoxylin solution (HHS32, Sigma/Aldrich) for about 30 seconds 
and then rinsed under tap water until the colour stops leaching.  Afterwards, 
sections were dehydrated by passing through an ascending alcohol gradient (95%, 
and two changes of 100% ethanol), followed by three rinses in xylene before 
finally mounting sections in DPX and covering with them with a cover slip. The 
slides were then left in the fume hood overnight to dry before viewing them under 
the microscope. The next day, the slides were analysed under normal light 
microscopy. 
 Immunofluorescent staining  2.8
 
In total, 2x10
4 
cells/ml were seeded in an 8-chambered slide (BD Falcon, Oxford, 
UK) and allowed to grow until ~70% confluent. The medium was aspirated and the 
cells fixed using 4% of paraformaldehyde (PFA) in PBS, which was added gently 
to each chamber and allowed to incubate for 20 min. After aspirating the PFA, the 
chambers containing fixed cells were then washed with PBS several times. The cell 
membranes were permeabilized by addition of 0.1% Triton X-100 (diluted in PBS) 
to each well. The solution was aspirated after 10 minutes and the cells were washed 
three times with PBS. This was followed by a10 min incubation with a solution 
containing 3% BSA in 0.01% Triton x100, used to block non-specific antibody 
binding to cells.  Primary antibodies were prepared in 3% BSA in 0.01% Triton X-
100. The antibodies used are outlined in Table 3. After the addition of the primary 
antibody, the plate was left overnight at 4°C on the shaking platform. Next 
morning, the cells were washed five times in PBS. The appropriate secondary 
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antibodies prepared in the same blocking solution and added to the permeabilised 
cells and incubated for one hr at room temperature. The wells were again washed 
five times with PBS. Each coverslip was then gently lifted up and flipped over, and 
a drop of 4’,6-diamidino-2-phenylindole (DAPI) solution added to the glass slide.  
Cells were then viewed and subsequently photographed using a confocal 
microscope. Negative controls were obtained by omission of the primary antibody.  
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Target antigen for 
immuno-staining 
Primary and secondary 
antibodies 
 
α-SMA  
1° = Mouse monoclonal anti-α –smooth 
muscle actin  (1:1000, A-2547, Sigma 
Aldrich,  UK) 
2° = Alexafluor-488 goat anti-mouse 
IgG (1:1000, A11001, Invitrogen, 
Paisley, UK) 
 
SM-22  
1° = Rabbit polyclonal anti-SM22 
(1:500, ab14106, Abcam, Cambridge 
UK ) 
2° = Alexafluor-488 donkey anti-rabbit 
IgG (1:1000, A21206, Invitrogen, 
Paisley, UK) 
 
vWF 
1° = polyclonal rabbit anti-human vWF 
(1:400, A0082, Dako, Glostrup, 
Germany) 
2° = Alexafluor-488 donkey anti-rabbit 
IgG (1:1000, A21206, Invitrogen, 
Paisley, UK) 
CD 31 1° = Mouse monoclonal anti-human 
CD-31 (1:400, 89C2, Cell Signaling , 
UK) 
2° = Alexafluor-555 goat anti-mouse 
IgG (1:1000, A-21422, Invitrogen, 
Paisley, UK) 
Table 7 - Antibodies used for Immunofluorescence. 
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 Wire Myography 2.9
2.9.1 Vessel preparation 
2.9.1.1 Laboratory governance 
 
Animals used in this study were cared for in the central animal facility at 
University College London as approved by the UK home office department. All 
experiments were conducted according to the “Guide for the Care and Use of 
Laboratory Animals” published by the US National Institutes of Health (NIH 
Publication No. 85-23, revised 1996). Male Sprague–Dawley rats (180-250g) were 
sacrificed by stunning and cervical dislocation.  
Lungs were removed from and placed in physiological salt solution (PSS) 
containing (in mM): 112 NaCl, 5, KCl, 1.8 CaCl2, 1 MgCl2, 25 NaHCO3, 0.5 
KH2PO3, 0.5 NaH2PO3, and 10 glucose (gassed with 95% O2/5% CO2 to pH 7.4). 
Third order pulmonary arteries were cleaned of connective tissue and cut into 
segments (2 mm long) and mounted on wires in an isometric myograph (510A JP 
Trading, Denmark).  
2.9.2  Small vessel myography 
 
Vessels were continuously aerated at 37 °C in PSS and pre-tensioned to an 
equivalent of ~22 mmHg (3K Pascal) for pulmonary and ~100mmHg (13.3K 
Pascal) for tail arteries. The normalized luminal diameter of each pressurised 
segment was obtained as described previously (Orie et al., 2006) and averaged 
~450 µm in pulmonary and ~750 µm  in tail arteries. An equilibration period of at 
least 1 hr was allowed during which time tissues were contracted with a single 
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application of KCl (100 mM) followed by 2-3 washes  and contracted with 100 nM 
of the thromboxane mimetic, U46619 or 10 µM phenylephrine (PE) for pulmonary 
and tail respectively. Concentration-response curves were constructed in arteries to 
treprostinil with or without pre-treatment with 10 µM cilostazol (for 1 hour). The 
presence of functional endothelium was assessed by examining responses to the 
endothelium-dependent vasorelaxant, acetylcholine (Ach). 
2.9.3  Experimental Protocol  
 
Two vessels were mounted each day and effects of treprostinil compared in 
separate vessels from the same animal. Contractions curve were allowed to plateau, 
before cumulative concentration–response curves (1–30,000 nM) were constructed 
for treprostinil. In all experiments, phosphodiesterase inhibitor was added at least 
60 min before the addition of the contractile agonist. Changes in tone were 
expressed as the percentage of contractile response induced by U46619 or PE, just 
before the addition of the lowest concentration of treprostinil. Where possible, two 
concentration–response curves were obtained in the same preparation separated by 
a washout period of 60 min. With this protocol, there was no apparent time-
dependent change in the response to any of treprostinil. 
 Statistical Analysis 2.10
 
Data are expressed as mean ± standard error of the mean (SEM). The EC50/IC50, the 
concentration at which 50% of cell proliferation/contraction was inhibited and Emax 
(maximal effect) was calculated using a variable slope sigmoidal curve fitting 
routine in GraphPad Prism (version 4.0, Jandel software, La Jolla, USA). For 
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myography, agonist log-concentration curves were constructed and fitted using the 
sigmodial fitting routine in Graph Pad Prism 4. Statistical analysis was performed 
between two groups using a non-paired student t-test or more than two groups 
using one / two ANOVA with Dunnett’s or Bonferroni post-hoc tests. In all 
analyses a p value < 0.05 was considered statistically significant. 
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 Introduction 3.1
 
Once formed, PGI2 binds to specific cell membrane receptors namely IP receptors 
(Hirata & Narumiya, 2011). These receptors are coupled to Gs which stimulates 
adenylate cyclase and increases cAMP levels and cAMP-dependent protein kinase 
A (PKA) activity (Torphy et al., 1982; Kiriyama et al., 1997). The latter mediates 
cAMP-induced decreases in intracellular calcium leading to vascular smooth 
muscle relaxation and vasodilation through a variety of mechanisms (Koike et al., 
2004; Maguire & Davenport, 2005).  Cyclic AMP can also signal through exchange 
protein directly activated by cAMP (EPACs) and PKA can directly phosphorylate 
the transcription factor, CREB (Hirata & Narumiya, 2011) and together they can 
regulate a number of cellular functions, including cell proliferation (Hirata & 
Narumiya, 2011). PGI2 acts via the IP receptor to mediate an acute potent 
pulmonary vasodilation and inhibition of platelet aggregation (Badesch et al., 
2004). There is evidence that the lungs of PAH patients have decreased expression 
of the IP receptor (Badesch et al., 2004; Falcetti et al., 2010). 
 
PGI2 does, however, possess a very short biological half-life (2–3 min) at a 
physiological pH, and after inhalation of aerosolized PGI2, the pulmonary 
vasodilatory effect is lost within 30 min both under experimental conditions and 
when tested in patients (Walmrath et al., 1996). Because the vasodilatory effect of 
the prostanoids is exerted via enhanced cAMP generation, blocking the catabolism 
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of this second messenger might offer amplification of the pulmonary vasodilatory 
effects of these agents.  
 
Not long after the discovery of PGI2, this agent was given to patients with PAH and 
shown to be a potent dilator of both the systemic and pulmonary circulation (Rubin 
et al., 1982), including in a subset of severely diseased patients not responding to 
traditional oral vasodilator therapy at all (Jones et al., 1987). PGI2 was amongst the 
first class of agent in the United States to receive Food and Drug Administration 
(FDA) approval for the treatment of PAH. Therapeutic application of PGI2 results 
in the improvement of hemodynamics in PAH patients, and in randomized, 
controlled trials, has been shown to be of benefit in several clinical trials (Barst et 
al., 1996; Walmrath et al., 1997; McLaughlin et al., 2003). Epoprostenol, being 
chemically unstable, can only be given as a continuous intravenous infusion 
through a central venous catheter. The freshly dissolved drug is inserted into the 
pump system and therefore pain and infection associated with the long-term 
presence of an indwelling intravenous catheter are common (Barst et al., 1996). 
With respect to other PGI2 analogues, these are chemically stable in solution and 
their plasma half-life is much longer: approximately 30 min with iloprost and about 
3-4.5 h with treprostinil (Badesch et al., 2004; Ivy, 2010). The metabolic stability 
order of various analogues is iloprost < beraprost < cicaprost < < treprostinil (Ruan 
et al., 2010). Both iloprost and treprostinil have shown favourable effects in the 
treatment of PAH improving hemodynamics, exercise tolerance and clinical status. 
An impact on survival is assumed, though this has so far only been demonstrated 
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for epoprostenol in controlled trials (Wilkins & Wharton, 2001; Olschewski et al., 
2004; Barst et al., 2009), though in open labelled or in retrospective long-term 
analysis of subcutaneous (SC) treprostinil, survival patterns do nonetheless appear 
similar to epoprostenol (Lang et al., 2006; Barst et al., 2006). Therefore, stable 
long-acting prostacyclin analogues can resolve some of the problems associated 
with IV epoprostenol. This can improve the prospects of long-term pulmonary 
vasodilator therapy.  
 
Clinical studies are now being focused on the potential benefits that prostacyclin 
therapy could provide following the long-term supplementation of exogenous PGI2. 
Until the recent study of Whittle and colleagues, little was known about the 
pharmacology of treprostinil (Whittle et al., 2012; Stacher et al., 2012). Its 
enhanced cAMP generation compared to other analogues in pulmonary smooth 
muscle cells and in mouse alveolar macrophages, suggests signalling through 
additional Gs coupled receptors, largely accounted for in the macrophage study by 
EP2 receptors (Clapp et al., 2002; Aronoff et al., 2007). Treprostinil appeared to be 
more potent than iloprost and beraprost at inhibiting cell proliferation (Clapp et al., 
2002; Aronoff et al., 2007), suggesting additional effects on other receptor or 
intracellular pathways. Both IP and non IP-receptor dependent effects involving 
activation of PPARs have been reported with PGI2 analogues (Falcetti et al., 2007) 
and such transcription factors may be involved in the antiproliferative effects of 
these agents (Hansmann & Zamanian, 2009; Falcetti et al., 2010). 
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Phosphodiesterases have a wide distribution in normal tissues. Mammalian PDEs 
are subdivided into 11 distinct families on the basis of substrate specificity and 
sensitivity and sequence homology (Essayan, 1999; Essayan, 2001). The cGMP-
inhibited cAMP PDE (PDE3) is expressed as two isoforms termed PDE3A and 
PDE3B. The activity of PDE3 is increased in main, branch and intrapulmonary 
arteries from rats maintained under chronic hypoxic conditions (Maclean et al., 
1997). PDE3 inhibitors reverse the reduced responsiveness of pulmonary vessels to 
isoprenaline and the adenylate cyclase activator, forskolin in rats with PH (Wagner 
et al., 1997). It has been shown that cAMP and cGMP dependent PDEs (PDE3 and 
PDE5 respectively) activity is increased in pulmonary arteries from rats with 
chronic hypoxia-induced PH (Maclean et al., 1997) which seemed to be correlated 
with decreased intracellular cAMP and cGMP levels (Sweeney et al., 1995). Real 
time PCR and immunoblotting demonstrated that the expression of PDE1A, 
PDE1C, PDE3B, and PDE5A was enhanced in PASMCs from both IPAH and 
secondary pulmonary hypertension (SPH) patients compared with control 
PASMCs, suggesting that signalling through cAMP and cGMP may be impaired in 
PAH (Maclean et al., 1997; Murray et al., 2002; Schermuly et al., 2007b). Indeed 
cAMP levels stimulated by beraprost were found to be more or less abolished in 
adult IPAH cells compared to normal (Murray et al., 2002). Such increases in PDE 
activity might be responsible for increased proliferation in PAH (Phillips et al., 
2005).  
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The cGMP specific PDE5 is expressed as two isoforms termed PDE5A1 and 
PDE5A2. PDE5 activity is also increased in the branch and intrapulmonary artery 
from rats maintained under chronic hypoxic conditions and also elevated in an 
ovine model of perinatal PH (Maclean et al., 1997; Hanson et al., 1998a). PDE5 
inhibitors cause vasodilatation of ovine pulmonary vessels (Ziegler et al., 1995). 
There is also evidence showing the potential cross-talk between the cAMP and 
cGMP pathways. It has been reported that inhibition of PDE5 causes elevation of 
cGMP which further inhibits PDE3, thereby preventing the hydrolysis of cAMP  
and potentiating cAMP mediated effects (Zaccolo & Movsesian, 2007). The 
crosstalk also exists between the PKG and PKA signalling, whereby cAMP can 
also activate PKG increasing cGMP signalling and the later can further activate 
PKA (Zaccolo & Movsesian, 2007; Stangherlin et al., 2011). 
Smooth muscle cells undergo morphological and functional changes, where 
normally they are purely contractile, but in PH growth factors can convert the 
contractile arterial smooth muscle cells into abnormal proliferative, migratory and 
synthetic phenotype (Rabinovitch, 1997). Therefore in the first part of my study I 
focused on isolation, identification and characterization of the smooth muscle cells 
from distal pulmonary arteries and further used them to study different mechanisms 
involving cell proliferation. 
The prostacyclin class of drugs are used to treat pulmonary arterial hypertension, 
and while evidence suggests they improve survival. But eventually as the disease 
progresses, dose escalation is required. Thus ways are being sort to improve their 
3. Stable prostacyclin analogues in PAH 
106 
 
clinical efficacy. I hypothesise that prostacyclin action could be enhanced by 
inhibition of phosphodiesterase type 3 (PDE3), a major regulator of cyclic AMP 
levels in the lung, whose activity appears increased in pulmonary hypertension 
(Murray et al., 2007). I sought to investigate the action of the PDE3 inhibitor,  
cilostazol, an agent already in clinical use for the treatment of intermittent 
claudication (Liu et al., 2011) where it manages muscle pain and increases exercise 
tolerance in peripheral vascular occlusive disease while favourably modifying the 
plasma lipid profile (Kambayashi et al., 2003). 
 
 Results 3.2
3.2.1 Characterisation of lung tissue and pulmonary arterial 
smooth muscle cells  
 
Lung tissue was obtained from the explanted lung of PAH patients receiving a 
bilateral lung or heart and lung transplant or from donor lungs found to be 
unsuitable for transplantation or from lung resection for suspected malignancy. 
Distal peripheral pulmonary arteries were dissected out and used for the isolation of 
PASMCs (figure 3.1A). Small preacinar and intra-acinar pulmonary arteries were 
thin walled in control lungs whereas in patients with PAH, these were partially or 
completely obstructed by a combination of medial thickening and intimal 
proliferation. Proliferation was also observed in the adventitial layer. In the 
examples shown, the thinly muscularised artery from a control myeloma patient 
stained for smooth muscle markers, -smooth muscle actin (-SMA) and SM-22 
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(figure 3.2A). Likewise strong staining for both markers was observed in the 
medial layer of partially obstructed arteries from a PAH patient (figure 3.2B), with 
the former also showing some staining in the adventitial layer. When PASMCs 
were isolated and subsequently cultured, they displayed hill-valley morphology, 
typical for smooth muscle cells (figure 3.3A). Further characterisation of these cells 
was performed using immunofluorescent staining to identify the same smooth 
muscle specific markers, which strongly stained human PASMCs derived from a 
PAH patient (figure 3.3B). Endothelial cell specific markers, like CD31 and VWf  
which are highly expressed in human endothelial cells (HEC), were used as 
negative controls. Both these endothelial cell markers strongly stained HEC but not 
human PASMCs (figure 3.4)  
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Figure 3.1. Original picture and schematic representation of human lung. A) Photograph of 
a lung lobe from a patient who had PAH with underlying venoocculsive disease. Distal 
pulmonary artery branches (as depicted in picture on the bottom B) were freshly dissected from 
the lung of control (normal) and PAH patients. Small arteries (less than 0.5 mm in diameter) in 
the square magnified in the right corner are used to enzymatically isolate pulmonary smooth 
muscle cells that are shown in culture from a PAH lung (Figure 3.1.B is reproduced with 
permission from (Nationwide Children's Hospital)). 
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Figure 3.2. Immunohistochemical staining of smooth muscle markers in small pulmonary 
blood vessels from a control and PAH patient.  Immunohistochemical staining of smooth 
muscle actin (α-SMA) and SM-22, visualised by diaminobenzidine (brown), in sections 
counterstained with haematoxylin. Sections of representative pulmonary artery of A) a normal 
lung and of B) a lung from pulmonary arterial hypertensive patient (PAH) stained with alpha 
smooth muscle actin (α-SMA) and SM-22 antibodies (staining the intimal-smooth muscle layer). 
Extensive medial thickening observed, showing the severity of disease in PAH versus minimal 
remodeling in normal lung. 
 
A Control 
B PAH 
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Figure 3.3. Characterization of pulmonary arterial smooth muscle cells (PASMCs). (A) Human 
PASMCs grown to 90% confluence in culture and observed with a phase contrast microscope showing 
classic hill and valley morphology. (B) Immunocytochemical staining of PASMCs isolated from PAH lung 
using antibodies against smooth muscle markers α-SMA and SM-22. Human PASMCs isolated from PAH 
lung in the left show positive staining of α-SMA fibers in red and in the right show positive staining of SM-
22 fibers in green. In both cases the nucleus is stained blue with Dapi. 
 
A 
α-SMA SM-22 
B 
40X 40X 
10X 
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Figure 3.4. Endothelial cell markers do not stain human smooth muscle cells (SMCs). 
Immunocytochemistry staining of PASMCs isolated from PAH lung against the endothelial cell 
markers Von Willebrand factor (VWf) and CD-31 which are not expressed in SMCs. Human 
PASMCs isolated from PAH lung in (A) show no staining for VWf or CD-31, while human 
endothelial cells (HEC) shown in (B) showed positive staining for VWF (stained green) and CD31 
(stained red). In all panels, the nucleus is stained blue with Dapi. 
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3.2.2 Effect of prostacyclin analogues on proliferation of 
human PASMCs  
 
As part of the initial process to characterise human PASMCs from normal and 
diseased PAH patients, I assessed the effect of treprostinil on cell growth by 
performing cell proliferation assays with cells cultured for 4 days in DMEM/F12 
containing 9% FBS (figure 3.5). In control PASMCs, serum increased cell number 
significantly (ANOVA, P < 0.001) compared to cells cultured in the absence of 
serum for the same length of time (basal). The growth rate of IPAH cells was 
however 2-3 fold higher than normal cells, indicating a more proliferative 
phenotype of smooth muscle cells obtained from PAH patients. Moreover, IPAH 
cells isolated from children appeared more proliferative than adult IPAH cells 
(P<0.05; Figure 3.5), consistent with the disease being more aggressive in children 
(Barst et al., 2011). Incubation with treprostinil (0.1 nM to 10 µM) significantly 
inhibited human PASMC proliferation, reducing cell number in a concentration-
dependent fashion, though in this set of experiments, treprostinil appeared least 
effective at inhibiting cell growth in control cells compared to previously published 
data (Falcetti et al., 2010) and only inhibited growth by about 25% at 10 µM. The 
antiproliferative activity of treprostinil was also compared with another PGI2 
analogue, iloprost which was assessed under the same experimental conditions. 
Like treprostinil, iloprost also significantly reduced proliferation of human PASMC 
stimulated by FBS (9%). Both agonists displayed marked antiproliferative activity 
in a concentration-dependent fashion, inhibiting proliferation by 45-50% at the 
highest concentration of 10 µM in IPAH cells from children and adults. There was 
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however about a 10 fold difference in the potency of treprostinil to inhibit growth 
when compared with iloprost though this was not statistically significant. A point 
to note was that treprostinil started to significantly inhibit growth at 10 nM (one-
way ANOVA, P<0.05) whereas for iloprost this occurred at 100 nM (ANOVA, 
P<0.05; Figure 3.6).  
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Figure 3.5.  Effect of treprostinil on proliferation of human PASMCs. Cells were grown in 
culture for 24 hours in DMEM/F12 containing 9% FBS before they were growth arrested for 48 
hours in DMEM alone. Cell counting was assessed after 4 days of stimulation with 9% FBS 
with or without treprostinil (concentration-range 0.1 nM to 10 µM) and compared with no FBS. 
Error bars represent mean ± SEM (n=4). Statistical significance was determined using 2-way 
ANOVA with Bonferroni correction. ***=P<0.001 when compared to the basal and #=P<0.001 
when compared to response in normal (control) cells.  
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Figure 3.6. Concentration–response curves to the PGI2 analogues, treprostinil and iloprost. 
Cells were grown in DMEM/F12 containing 9% FBS for 24 hours before they were growth 
arrested for 48 hours in media containing no FBS. Following this, cells were stimulated with 9% 
FBS in the absence and presence of increasing doses of analogues (0.1nM to 10 µM) and cell 
number counted at the end of 4 days. Solid circles, treprostinil and solid triangles, iloprost where 
data has been normalised to FBS response which was taken as 100% growth. Data, from the same 
batch of cells, is shown as mean ± SEM (n =5 isolates), where each curve has been constructed 
using a variable slope sigmoidal fitting routine in GraphPad Prism. Statistical significance was 
determined using one-way ANOVA with Bonferroni correction.  ***= P<0.001, **=P<0.01 and 
*=P<0.05 when compared to growth response with FBS alone. 
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3.2.3 Effects of treprostinil on cAMP  
 
Cyclic AMP levels were assessed in IPAH cells at different time points after 
stimulation with treprostinil (where the analogue was added at time zero) and 
compared to levels obtained with just FBS treatment over the same period. 
Treprostinil produced an elevation in intracellular cAMP levels which increased at 
15 min and peaked at 30 min as compared to growth-arrested (basal; t=0) or the 
equivalent time point with FBS alone. The maximum elevation of absolute cAMP 
levels noticed after a 30 min incubation with 1 µM treprostinil was 13 or 6 fold 
higher in magnitude as compared to either basal or the FBS time point, respectively 
(ANOVA, P<0.001). In contrast to previously published data in normal human 
PASMCs, (Clapp et al., 2002), cAMP levels dropped sharply within an hour. 
Although there was still a trend for elevation in the cAMP levels at 1 to 24 hours 
compared to either basal or FBS time-control, this was not statistically significant 
(Figure 3.7).  
Having established that the peak elevation of cAMP was achieved at 30 min with 
treprostinil, the nature of the receptor causing this increase in cAMP was assessed 
using the specific IP receptor antagonist, RO1183452 (Bley et al., 2006). Cyclic 
AMP levels, which were again significantly elevated with a 30 min application of 1 
µM treprostinil (one-way, ANOVA, P<0.001), were fully reversed with 1 µM of 
the IP receptor antagonist, RO1183452 which by itself did not affect basal cAMP 
levels. Similarly, 100 µM of the adenylate cyclase inhibitor 2, 5 dideoxyadenosine 
(DDA) also reversed this effect of treprostinil (Figure 3.8). 
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Figure 3.7. Time-course of intracellular cAMP changes induced by treprostinil. Human   
PASMCs obtained from IPAH patients and grown to 80-90% confluence, were growth arrested 
for 48 h and stimulated with 9 % FBS with and without 1µM treprostinil for up to 24 hours. 
Cells were then lysed for the estimation of cAMP levels. Results are expressed as pmol of cyclic 
AMP per mg of total protein. Data are shown as mean ± SEM (n = 6). Statistical significance 
was determined  using 2-way ANOVA with post-hoc test correction for multiple comparisons. 
***=P<0.001,**=P<0.01 compared to time 0 value in treprostinil group. #=P<0.01and 
##=P<0.001  compared to corresponding FBS value.  
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Figure 3.8 Cyclic AMP elevation induced by treprostinil is mediated by the IP receptor. Distal 
human PASMCs derived from IPAH patients were grown to 80-90 % confluence, growth arrested 
before being stimulated with 9% FBS with and without different drug treatments. For cyclic AMP 
measurement, cells were stimulated for 30 min with treprostinil (TREP, 1 µM), the IP receptor 
antagonist RO1183452 (IPRA; 1 μM), the adenylate cyclase inhibitor dideoxyadenosine (DDA; 1 
µM) or a combination of treprostinil with inhibitor as shown above. RO1183452 or DDA was given 
1 h prior to addition of treprostinil. Results are expressed as fold increase above basal and shown as 
mean ± SEM (n = 5). Statistical significance was determined using one-way ANOVA with 
Bonferroni correction, where *** =P<0.001 compared to FBS (9%) alone. 
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3.2.4 Effect of phosphodiesterase 3 inhibitor, cilostazol on 
cAMP generated by treprostinil 
 
To simply experiments, and given the lack of effect of FBS on cAMP over time, all 
subsequent experiments were done on growing cells. To test the hypothesis that 
high PDE3 activity is responsible for the short-lived cAMP levels induced by 
treprostinil in IPAH cells, I assessed the effect of the PDE3 inhibitor, cilostazol. In 
the absence of treprostinil, pre-treatment with 1 µM cilostazol for 1 hour caused 
about a 2 fold increase in the basal cAMP level, suggesting increased background 
PDE3 activity in these cells. With treprostinil (1 µM), I observed there was a time-
dependent increase in cAMP level, which regardless of whether combined with 1 
µM cilostazol, peaked at 30 min. Furthermore, in cells treated with treprostinil 
alone, cAMP levels dropped to almost control levels by one hour, but not with 
those pre-treated with cilostazol (Figure 3.9). Indeed, cyclic AMP levels were 
found significantly elevated even after 24 hours in cells treated with the analogue 
in combination with the PDE3 inhibitor (ANOVA, P<0.05) (figure 3.9).  
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Figure 3.9. Cilostazol potentiates the effect of treprostinil on intracellular cAMP levels.  
For cyclic AMP measurement, growing cells were stimulated with Trep (1 µM) or in 
combination with 1 µM cilostazol (PDE3 inhibitor). Cells were pretreated with cilostazol for 1 
hr prior to addition of treprostinil. Results are expressed as pmol of cyclic AMP per mg of 
protein. Data are shown as mean ± SEM (n = 4) and statistical significance determined using 2-
WAY ANOVA with post-hoc test correction for multiple comparisons. 
#=
P<0.001 when 
compared to 9% FBS alone (time = 0), *=P<0.05, **=P<0.01, ***=P<0.001 when compared to 
9% FBS and treprostinil. 
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When similar experiments were repeated using PASMCs isolated from normal 
(control) patients, I found that the cAMP levels produced after treatment with 
treprostinil in similar experimental conditions was significantly higher in normal 
compared to the diseased cells (compare figure 3.9 with figure 3.10). Also, the 
sudden drop observed at an hour with IPAH cells was less pronounced in normal 
cells, such that cAMP levels remained  significantly elevated (~2 fold) compared to 
basal for up to 6 h (ANOVA, P<0.05). There was a trend for sustained elevation of 
cAMP levels at 6 h after treprostinil treatment in normal cells; however the 
difference was not statistically significant (figure 3.10). When combined with 
cilostazol, the peak cAMP levels were not significantly increased, suggesting that 
PDE3 activity may be lower in normal compared to PAH cells (figure 3.9 and 
3.10). Nonetheless, cAMP levels remained substantially elevated at 24 hours.  
I further assessed if cilostazol could potentiate the anti-growth responses of 
treprostinil. As shown, the antiproliferative effect of 1 µM treprostinil was 
enhanced when applied in combination with the PDE 3 inhibitor, cilostazol (1 µM 
or 10 µM) though this was only significant (ANOVA, P<0.001) at the higher 
concentration (Figure 3.11). Furthermore, cilostazol on its own significantly 
inhibited PASMC proliferation, with 10 µM cilostazol inhibiting growth by ~20% 
(one-way ANOVA, P<0.01) (figure 3.11). 
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Figure 3.10. Cyclic AMP generation in normal human PASMCs. For cyclic AMP 
measurement, cells were stimulated with 9% FBS with or without treprostinil (TREP; 1µM) and 
or a combination of 1 µM cilostazol (PDE3 inhibitor) and treprostinil. Cells were pretreated with 
cilostazol for 1 hr prior to addition of treprostinil. Results are expressed as pmol of cyclic AMP 
per mg of total protein. Data are shown as mean ± SEM (n = 4); Statistical significance was 
determined using 2-way ANOVA with post-hoc test correction for multiple comparisons.. 
*=p<0.05, **=p<0.01, ***=p<0.001 compared to 9% FBS alone (time =0). 
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Figure 3.11.  Cilostazol potentiates antiproliferative effects of treprostinil. Cells were grown in 
DMEM/F12 containing 9% FBS for 24 hours and then growth arrested for 48 hours in serum free 
DMEM/F12 before being stimulated with 9% FBS with or without treatment with treprostinil (1 µM), 
cilostazol (1 µM or 10µM) or a combination of both. Cells were counted after 4 days. Data are shown 
as mean ± SEM (n = 4) and shown as % cell proliferation with respect to response to FBS alone. 
Statistical significance was determined by one-way ANOVA with Bonferroni correction. **=P<0.01 
and ***P<0.001 when compared to the solvent DMSO.  
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3.2.5 Effects of treprostinil on vasorelaxation  
 
Treprostinil has been shown to reduce pulmonary arterial pressure, as measured by 
right ventricular systolic pressure (RVSP) and total pulmonary vascular resistance 
in PAH and the efficacy of the treatment in PAH is demonstrated regardless of 
route of administration (Tapson et al., 2006; McLaughlin et al., 2010; Tapson et 
al., 2012). In normal individuals prostacyclin causes potent acute vasorelaxation, 
but the contribution of dilatation of the pulmonary artery in PAH seemed to be 
compromised due to disturbance in vascular homeostasis, and upregulation of 
various factors like PDEs. Therefore I hypothesized that inhibiting PDE3 with 
cilostazol could potentiate the direct vasorelaxant efficacy of treprostinil in 
pulmonary artery. Distal pulmonary and tail arteries were isolated from a rat and 
mounted on a wire myograph and contracted with 100nM of the thromboxane 
mimetic, U46619 or 10µM phenylephrine (PE) respectively. The concentration-
response curves were constructed to treprostinil with or without pre-treatment with 
10 µM cilostazol. As expected, treprostinil significantly relaxed pulmonary artery 
contractions induced by 100 nM of the thromboxane mimetic, U46619 (figure 
3.12). Treprostinil significantly relaxed pulmonary artery contractions, with a 
relaxation observed of ~25% at 10µM. However, pre-treatment with 10 µM 
cilostazol significantly potentiated the treprostinil response at concentrations at or 
above 100nM (P<0.001; n=4, two-way ANOVA) (figure 3.12). Similar effects 
were observed in rat tail arteries, where treprostinil significantly relaxed tail artery 
contractions induced by 10µM PE and this effect was significantly potentiated with 
10 µM cilostazol (P<0.001; n=4, unpaired t-test)  (figure 3.13).  
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Figure 3.12. Cilostazol potentiates the relaxant response to treprostinil in rat pulmonary 
artery. A) After the normalisation procedure, distal vessels were contracted with 1 µM of the 
thromboxane analogue, U46619 followed by sequential application of increasing doses of 
treprostinil in the absence (left panel) or presence (right panel) of cilostazol (10 μM). B) 
Concentration-dependent relaxation by treprostinil in rat pulmonary arteries where effects were 
calculated as the % relaxation of the contraction produced with U46619 just before the addition 
of lowest dose to treprostinil. Data are shown as mean ± S.E.M. and curves generated by fitting 
data using a variable slope sigmoidal fitting routine in GraphPad. *=P<0.05, **=P<0.01, ***=P 
< 0.001, two-way ANOVA with post-hoc correction for multiple comparisons (n = 4) when 
compared to the appropriate control response. 
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Figure 3.13. Cilostazol potentiates the relaxation response of treprostinil in rat tail artery. 
A) After a normalisation procedure, vessels were contracted with 10 µM phenylephrine followed 
by sequential application of increasing doses of treprostinil in the absence or presence of 
cilostazol (10 μM).  Concentration-dependent relaxation induced by pre-contracted rat tail 
arteries was plotted as the % relaxation of the contraction which was measured just before the 
addition of the lowest drug concentration. Data shown as mean ± S.E.M and fitted using a unity 
slope sigmoid function in Graph-Pad Prism. *=P<0.05 and ***=P < 0.001 (two-way ANOVA 
with post-hoc correction for multiple comparison; n = 4). 
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 Summary of key findings 3.3
 
 Cyclic AMP levels peaked within 30 min of treprostinil treatment in IPAH 
cells and dropped close to basal values within one hour. This is in contrast 
to normal human PASMCs, where cAMP levels remained elevated for at 
least 6 h (see also Clapp et al., 2002).  
 
  High activity of PDE3 was assumed as I observed that the peak cAMP 
level was higher with the combination of treprostinil and cilostazol than 
with treprostinil alone in IPAH cells and elevation was significantly 
sustained for up to 24 h.  
 
  In this study I demonstrated that cilostazol could significantly potentiate 
cAMP levels, antiproliferative and relaxation effects of treprostinil. 
  
 High activity of PDE3 might explain in part the ineffectiveness of 
prostacyclins in long-term therapy and I propose that a PDE3 inhibitor 
might potentiate prostacyclin signalling in PAH, possibly constituting a new 
therapeutic paradigm in IPAH. 
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 Discussion 3.4
 
In this study I demonstrated that treprostinil and iloprost had anti-proliferative 
properties on distal pulmonary vascular smooth muscle cells derived from IPAH 
patients. These agents only produced ~50% inhibition of serum-induced growth, 
where previous work from this laboratory showed both these agents to produce full 
inhibition of growth in human PASMCs derived from a 15-year old control female 
(Clapp et al., 2002). Thus it remains to be determined whether the disease impacts 
on the efficacy of these agents, either because the receptor is lost or more readily 
desensitised particularly. Indeed, both activation of thromboxane and endothelin 
receptors can promote IP receptor desensitization (Walsh et al., 2000; Schermuly et 
al., 2007a), and IP receptor expression is reduced in IPAH (Lai et al., 2008; Falcetti 
et al., 2010). However, the actions of PGI2 and its analogues are not specific to the 
IP receptor as they can potently activate other prostanoid receptors including EP1 
for iloprost and EP3 for all analogues (Narumiya, 1994; Orie & Clapp, 2011). 
Therefore if these pathways are up-regulated in PAH, then this may modulate the 
cellular effects of PGI2 and its stable analogues. The EP1 receptor, when activated 
increases intracellular calcium and produces vasoconstriction (Ungrin et al., 2001) 
and blockade of this receptor can enhance analogue responses in aorta (Turcato & 
Clapp, 1999) and in the lung (Schermuly et al., 2007a). The EP3 receptor has 
various splice variants capable of coupling with Gi, Gq- and Gs-type G-proteins 
(Negishi et al., 1993; Namba et al., 1993). In general, EP3 receptor activation leads 
to inhibition of adenylate cyclase, and activation of phospholipase C, and is 
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associated with vasoconstriction. Indeed blockade of EP3 receptors potentiates the 
relaxation induced by cicaprost, iloprost and treprostinil in rat tail and pulmonary 
arteries (Kuwano et al., 2008; Orie & Clapp, 2011; Morrison et al., 2012). 
Moreover, contractile responses to EP3 receptor agonists increase as the pulmonary 
vessel size decreases as well as after monocrotaline treatment (Kuwano et al., 2008; 
Morrison et al., 2012), suggesting EP3 receptors may an important modulator of IP 
receptor function. Finally under certain circumstances, the IP receptor can couple 
with Gq and possibly Gi proteins which would promote vasoconstriction and thus 
limit relaxation to PGI2 (Chow et al., 2003). 
 
There are other cellular pathways through which PGI2 may act. PGI2 synthase is 
heavily expressed in the perinuclear regions of cells, including in smooth muscle, 
and PGI2 once formed, can directly interact with the ligand binding domain of a 
family of transcription factors known as PPARs. Some analogues, including 
beraprost and iloprost but not cicaprost, also bind to and transcriptionally activate 
PPARs (Lim & Dey, 2002; Nemenoff et al., 2008). There is the potential for cross 
talk between this pathway and the IP receptor since both PPARα and PPARβ can 
be activated via protein kinase A (PKA) (Ali et al., 2009). Work from our 
laboratory has shown a novel IP receptor-dependent activation of PPARγ by PGI2 
analogues that appears to be distinct from the known ligand binding effects of these 
analogues (Falcetti et al., 2007). Such a mechanism contributes to the 
antiproliferative effects of treprostinil in HEK cells (Falcetti et al., 2010) and in 
human PASMCs (Falcetti et al, 2012). Surprisingly, PPARγ activation does not 
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appear to necessitate cAMP elevation, nor does the IP receptor always appear to be 
a prerequisite for its involvement in inhibiting cell growth in mouse PASMCs or in 
PASMCs derived from patients with IPAH cells (Falcetti et al., 2007; Falcetti et 
al., 2010).  
 
These antiproliferative effects of PGI2 and its analogues may translate into a 
slowing of disease progression. In animals evidence suggests that iloprost can 
reverse vascular remodelling in a chronic experimental model of PAH in rats 
(Schermuly et al., 2005b). Likewise, treprostinil can reverse remodelling when 
applied after the establishment of PAH with monocrotaline (Yang et al., 2010). 
However, there is little evidence that PGI2 can do this in IPAH. In paediatric 
patients treated with epoprostenol and bosentan, a doubling in the size of lesions 
compared to those without treatment was found when lungs were examined after 
transplant or postmortem (Hall et al., 2011). In other studies, no difference in 
thickness of intima, media, or adventitia or in density of plexiform lesions occurred 
with epoprostenol treatment (Achcar et al., 2006). Thus, the evidence to date 
suggests there is little impact on the remodelling process with PAH treatment. 
 
In this study, I found that treprostinil (1 µM) elevated cAMP levels on average by 
2-3 fold in cultured smooth muscle cells isolated from IPAH patients and that 
maximum elevation occurred at 30 min as compared to untreated cells. Cyclic 
AMP elevation was fully reversed with the IP receptor antagonist RO1183452 (1 
µM), an agent seemingly specific for the IP receptor because it has no significant 
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binding affinity for prostanoid EP or TP receptors, although effects on DP 
receptors were not examined (Bley et al., 2006). The IP receptor seems to be the 
major source of cAMP in human PASMCs for treprostinil. Whether this is the case 
at later time points, where the IP receptor antagonist was not specifically 
investigated, is not clear. The possibility remains however, that other receptors may 
be activated and contribute to cAMP generation. It is known that PGI2 analogues 
can signal through other Gs-coupled prostanoid receptors, including EP4 for 
iloprost (Lai et al., 2008), and EP2 for treprostinil (Aronoff et al., 2007; Whittle et 
al., 2012). Moreover, cAMP was reported to still be generated by these analogues 
in the absence of the IP receptor (Lai et al., 2008; Falcetti et al., 2010).  
In IPAH cells, the peak in cAMP levels was not sustained and dropped close to 
basal levels within an hour. I hypothesize this was due to the higher activity of the 
phosphodiesterase enzymes which break down cAMP (PDE 1, 3, 4). This is in 
contrast to previous observations from our laboratory which demonstrated that 
treprostinil elevated cAMP for many hours in normal human PASMCs (Clapp et 
al., 2002). Moreover, heightened PDE activity contributed to the complete loss of 
beraprost effects on cAMP generation in PAH and SPH which could be rescued by 
treatment with a non-selective PDE inhibitor (Murray et al., 2007). High activity of 
PDE3 was assumed as I observed that the peak cAMP level was higher with the 
combination of treprostinil and the PDE3 inhibitor, cilostazol than with treprostinil 
alone and elevation was significantly sustained for up to 24 h compared. This 
would also be consistent with increases in PDE3 (specifically PDE3C) but not 
PDE4 activity in PASMCs isolated from both IPAH and secondary pulmonary 
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hypertension (SPH) patients (Murray et al., 2007). I  assume the effect of cilostazol 
is specific for PDE3, as it appears to have little effect on PDE4 activity even up to 
concentrations as high as 100 µM (Shakur et al., 2002; Gibson et al., 2006) One 
cannot however rule out that cilostazol may affect PDE1 activity, which is both 
increased in distal pulmonary arteries taken from IPAH and in experimental models 
(Murray et al., 2007; Schermuly et al., 2007b). To confirm high PDE3 activity in 
the disease, these experiments were also repeated using PASMCs isolated from 
normal (control) patients. In these cells, I found that the cAMP levels produced 
after treatment with treprostinil were significantly higher compared to diseased 
cells. Also, the sudden drop observed in an hour with IPAH cells was not as 
obvious in normal cells and the cAMP levels remained significantly elevated 
compared to basal for up to 6 hours. When combined with cilostazol, the peak 
cAMP levels were not increased in normal cells as it was in the IPAH cells, and 
breakdown was relatively less affected, suggesting that the PDE3 activity is 
probably lower in the normal human PASMCs, as compared to the IPAH cells.  
How PDE3 activity might be elevated in PAH is largely unknown, but a number of 
possibilities exist. Phosphatidyl inositol 3 kinase (PI3 kinase), which is commonly 
activated by Gi/Go coupled receptors, is known to upregulate PDE3 as well as 
PDE4 activity leading to enhanced cAMP degradation (Kerfant et al., 2006; 
Alfranca et al., 2006). Indeed results from this laboratory have shown PGI2 
analogue relaxation to be enhanced by PI3 kinase inhibitors and also by Gi/Go 
inhibition with pertussis toxin (Orie & Clapp, 2011). Moreover, TP receptor 
activation impaired endothelium-independent relaxations to agents that elevated 
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cAMP levels via increasing the activity of PDE3, an effect reversed almost entirely 
by cilostazol with some contribution from PDE4 acknowledged (Liu et al., 2010). I 
suggest that high circulating levels of thromboxane that occur in PAH (Christman 
et al., 1992) may also contribute to an increase in PDE3 activity.  
Indeed I observed that relaxation of U466191 contractions by treprostinil in small 
rat pulmonary was potentiated over the whole concentration range with cilostazol, 
whereas in tail arteries, relaxation of phenylephrine-induced contractions increased 
more at the higher concentrations of treprostinil, where EP3 would become 
significantly activated (Whittle et al., 2012; Morrison et al., 2012). Moreover, 
another prostacyclin analogue, iloprost in addition to activating EP3 receptors, is a 
potent activator of EP1 receptors (Ungrin et al., 2001), receptors which can in some 
instances be coupled to Gi (Hirata & Narumiya 2011) and may thus also potentiate 
PDE3 activity through PI3 kinase. Indeed, treprostinil evoked significantly higher 
(6 fold) and more prolonged elevation in cyclic AMP compared with iloprost in 
normal human pulmonary arterial smooth muscle cells (PASMCs) (Clapp et al., 
2002). I did not investigate whether cAMP enhanced by the PDE3 inhibitor 
cilostazol, is meditated by other prostanoid receptors that can be activated by 
treprostinil. Our lab has shown that there may be additional effects of treprostinil 
through other Gs-coupled receptors, including EP2 and DP1 (Whittle et al, 2012).  
In earlier studies, while the maximal antiproliferative effects of the PGI2 analogues 
were more or less comparable, treprostinil was significantly more potent than 
iloprost and beraprost (Clapp et al., 2002), despite all these analogues having 
similar affinities at the IP receptor (Ungrin et al., 2001; Kuwano et al, 2007; 
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Whittle et al, 2012), suggesting additional effects on another receptor or 
intracellular pathway. I hypothesize it might be through other EP receptor subtypes 
coupled to Gs. Studies have shown that in alveolar macrophage of rats, EP2 
antagonist significantly blocked more than half of the increase in cAMP stimulated 
by treprostinil, whereas EP4 antagonist had no significant effect (Lai et al., 2008). 
These effects were also confirmed using EP2 knock-out mice, where treprostinil 
stimulated cAMP rise in rat alveolar macrophage was significantly lower compared 
to the wild type (Aronoff et al., 2007).  
 
High activity of PDE3 (and possibly PDE1) might explain in part the 
ineffectiveness of PGI2 in long-term therapy and I propose that a PDE3 inhibitor 
might potentiate PGI2 effects in PAH. In this study I demonstrated that cilostazol 
could significantly potentiated not only the effect of treprostinil to generate cAMP 
but also potentiated the antiproliferative and vasodilatory effects of the analogue, 
suggesting that this combination could be clinically beneficial for treating 
remodelling in PAH. Cilostazol is already in clinical use for intermittent 
claudication (peripheral vascular occlusive disease) where it increases exercise 
tolerance and favourably modifies the plasma lipid profile, suggesting additional 
beneficial effects in diseases associated with atherosclerosis (Shakur et al, 2003). 
Studies also suggest that cGMP can inhibit PDE3, which can therefore elevate 
cAMP levels. PDE5 is the isoenzyme that selectively degrades cGMP into the 
inactive form. In PAH, lungs have abundant PDE5 and PDE3 expression/activity 
(Murray et al., 2007). Pulmonary arteries have a large amount of PDE5 activity 
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compared to systemic arteries that further increases in experimental forms of 
pulmonary hypertension as well as in patients with PAH. In addition to 
vasodilatation, PDE5 inhibition also reduces DNA synthesis and cell proliferation 
in human PASMCs and stimulates apoptosis, suggesting that PDE5 inhibition also 
has anti-remodelling effects in the pulmonary vasculature (Rabe et al., 1994).  In a 
phenomenon referred to as “cross-talk”, cGMP negatively feeds back on PDE3 and 
this slows the inactivation of cAMP (Omori & Kotera, 2007).   
 
Experimental data indicate that treatment of PAH by manipulating multiple 
pathways concurrently may produce additive benefits. The current therapies for 
PAH are not curative, nor does it normalize pulmonary hemodynamics or 
functional capacity in the vast majority of cases. Thus, there is a possibility that 
combinations of prostacyclin analogues or PDE5 inhibitor (tadalafil, sildenafil) 
with agents that potentiate cAMP-prostacyclin pathway might offer more 
therapeutic efficacy. Preliminary studies suggest that combination of PDE5 
inhibitor with prostacyclins, inhaled NO and natriuretic peptides improve 
pulmonary hemodynamics more than monotherapy (Ghofrani et al., 2002; Ghofrani 
et al., 2003). 
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 Limitations of this chapter 3.5
 
The results contained within this chapter would be strengthened if I had undertaken 
the following:   
1. Alternative techniques for measuring cell proliferation which could include 
measurement of DNA synthesis using: 
a) Radiolabeled 3H-thymidine (Life Technologies, UK). 
b) 5-bromo-2'-deoxyuridine (BrdU), which is available as a commercial cell 
proliferation kit (Merck Millipore, UK) and measures BrdU incorporation 
into cellular DNA. 
 
2. Measurements of apoptosis to determine whether any treatments are pro-
apoptotic. For example, Annexin V can be used to identify cells at an early 
stage of apoptosis. It binds to phosphatidylserine, which very early on in the 
apotopic process translocates to the membrane and becomes exposed at the 
plasma membrane of cells. This process can be determined through using 
fluorescently labelled Annexin V (Life Technologies, UK).    
 
3. Measurement of PDE3 expression (mRNA) and activity (ELISA) to 
confirm the hypothesis that this PDE isoform is elevated in PAH and 
contributes to the reduced effectiveness of prostacyclin analogues to 
increase cyclic AMP in PASMCs obtained from end-stage disease patients. 
 
 
4. Assessment of the characteristics of the lysis buffer to ensure that PDE 
activity was fully inhibited. Because the composition of the lysis buffer 
used in cyclic AMP experiments is proprietary information, and specifically 
the PDE inhibitors (specific or non-specific) that are included are not 
disclosed, their potential influence on the sensitivity and the magnitude of 
final cAMP measurements remains an important undetermined factor which 
could have been verified by supplementing with IBMX   
3. Stable prostacyclin analogues in PAH 
136 
 
5. Optimisation of a defined growth medium, where the identity of all the 
added growth factors are known, would have aided the investigation of the 
proliferation response and allowed a more specific characterisation of the 
interaction with prostacyclin. 
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 Introduction 4.1
 
Endothelin-1 (ET-1) is an endogenous peptide with potent vasoconstrictor, 
mitogenic and profibrotic properties and appears to be implicated as a mediator of 
increased vascular tone and vascular remodelling in PAH (Yoshibayashi et al., 
1991; Giaid et al., 1993). Among all organ systems in the body, the lung has the 
greatest level of ET-1 production from pulmonary vascular endothelium, smooth 
muscle and airway epithelium suggesting that this peptide is an important autocrine 
and/or paracrine modulator of airway function  (Blouquit et al., 2003). 
Immunoreactivity for ET-1 can be detected in most cell types of developing human 
lung including pulmonary vascular endothelial cells, neuroendocrine cells, smooth 
muscle cells, platelets and alveolar macrophages (Fabregat & Rozengurt, 1990; 
Giaid et al., 1991; Yap et al., 2000). In humans ET-1 effects are mediated by 
binding to two receptors ETA and ETB, both of which induce contraction in distal 
pulmonary resistance arteries, whereas the ETA receptor alone appears to mediate 
the response in proximal arteries (McCulloch & Maclean, 1995; McCulloch et al., 
1996). Activation of endothelial ETB receptors releases vasodilators which can then 
act on smooth muscle cells to cause vasodilation (Takayanagi et al., 1991). 
Moreover evidence suggests that selective ETB receptor blockade increases the 
tissue accumulation of intravenously administered radiolabelled ET-1 indicating 
that ETB functions as a clearance receptor (Luscher & Barton, 2000; Kedzierski & 
Yanagisawa, 2001). An upregulation in vascular ETA and ETB expression has been 
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demonstrated in experimental models of systemic hypertension and is associated 
with augmented responses to ET-1. 
 
The proliferative effects of ET-1 on PASMCs isolated from the main human 
pulmonary artery are also considered to be dependent on ETA receptors (Zamora et 
al., 1993), but the contribution of ETA and ETB receptors in regulating the growth 
of cells from distal resistance vessels is more complex. ET-1 has an influence on 
DNA synthesis, cell proliferation and cellular hypertrophy. The mitogenesis caused 
by ET-1 involves activation of multiple transduction pathways, such as the 
production of second messengers, the release of intracellular calcium, and influx of 
extracellular calcium (Kawanabe & Nauli, 2011). ET-1 acts synergistically with 
various regulatory and growth factors to regulate cellular transformation and 
replication (Dube et al., 2000). Several of these factors in turn stimulate the 
synthesis and release of endothelins. The synthesis and release of endothelins are 
also increased in acute and chronic pathological conditions such as atherosclerosis, 
hypertension, and carcinogenesis (Battistini et al., 1993). The endothelin 
converting enzyme-1 (ECE-1) and endothelin degrading enzymes coexist in the 
airway tissue and levels of ECE-1 are elevated in patients with chronic rhinitis and 
idiopathic pulmonary fibrosis (Noguchi et al., 1991; Saleh et al., 1997). Elevation 
in plasma ET-1 levels in patients with various airway diseases and reduction in the 
symptoms when ET-1, ECE-1 and their receptors are antagonized provides 
evidence that these peptides are not only important in normal physiology but also 
in pathogenesis of lung diseases. 
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A striking increase in the expression of ET-1 mRNA and increased plasma levels 
of ET-1 are detected both in patients with most forms of PAH (Stewart et al., 1991; 
Yoshibayashi et al., 1991) and in experimental models of PAH (Stelzner et al., 
1992; Miyauchi et al., 1993). Elevated levels of ET-1 in PAH have been shown to 
be correlated with increased right atrial pressure and pulmonary vascular resistance 
and decreased pulmonary artery oxygen saturation (Cacoub et al., 1993a; Cacoub 
et al., 1993b; Nootens et al., 1995; Galie et al., 2004). Also, immunoreactivity for 
ECE-1 is augmented in the endothelium of lung arteries of patients with pulmonary 
diseases (Saleh et al., 1997; Giaid, 1998). Increased ET-1 is also associated with a 
reduction in expression of endothelial nitric oxide synthase (eNOS) (Giaid & Saleh, 
1995). In patients with IPAH, levels of ET-1 are three to four times the upper limit 
seen in normal patients, and this correlates with worsening of haemodynamic 
parameters, 6MWD and survival (Rubens et al., 2001). Despite a strong correlation 
of ET-1 levels with worsening of pulmonary haemodynamics and survival in 
humans, the overexpression of ET-1 alone does not result in PH in transgenic 
animals (Hocher et al., 2000). This suggests that additional mechanisms must be 
driving the disease process although one cannot ignore that once the disease is 
established, higher levels of ET-1 gives an extremely poor prognosis in IPAH. 
Lung tissue and pulmonary arteries from human subjects with PAH showed 
increased ET-1-binding capacity (Davie et al., 2002). ET-1 expression is increased 
in the lungs of patients with IPAH and secondary PAH, particularly in the small 
muscular pulmonary arteries (Giaid et al., 1993).   
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The lung is considered to be a major organ for clearance of the plasma ET-1 (de 
Nucci et al., 1988; Dupuis et al., 1996a). In animal models, selective blockade of 
ETB receptor in the lung has been shown to abolish the uptake of ET-1 in the 
pulmonary circulation, suggesting that uptake in the lung is solely via the ETB 
receptor (Kelland et al., 2010).  The capacity to clear ET-1 from the circulation in 
animal models and in the human lung is shown to be reduced in various types of 
PAH suggesting that a reduction in ETB receptor activity occurs in PAH (Dupuis et 
al., 2000; Dupuis et al., 1998). This contrasts with another study where endothelial 
ETB receptor mediated clearance appears preserved in many PAH patients (Dupuis 
et al., 1998). It has been reported that smooth muscle cells are an important source 
of ET-1 production in the pulmonary artery of the rat. The expression of big  ET-1 
and ETA receptors was markedly increased in the distal segments in hypoxic rats 
compared to normal conditions (Takahashi et al., 2001). The cause of the 
modifications in the proportion of ETA and ETB receptors by the various 
pathological conditions and the crosstalk between them remains to be established. 
 
The ET-1 system can be dampened by the inhibition of ECE-1 and by the blockade 
of ET-1 receptors. Blockade of the endothelin-receptors, has been shown to be 
an effective strategy in the management of PAH. Despite this, it is not clear 
whether the agents that selectively block ETA receptors are better than those 
blocking both ETA and ETB receptor subtypes (O'Callaghan et al., 2011). Inhibition 
of ECE-1 reduces the production of ET-1 but the effectiveness of these drugs is 
limited by independent pathways contributing to ET-1 formation, such as chymase 
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and metalloproteases (Takahashi et al., 1998). Therefore a more efficient approach 
is to antagonize the ET-1 system by using ET-1 receptor antagonists that can block 
either ETA alone (e.g. sitaxentan) or both ETA and ETB receptors (bosentan). 
Currently, several peptides and non-peptide compounds that block ET-1 receptors 
are available, and some have been tested in both animal models and clinical trials 
in patients with IPAH.  
 
In clinical practice the combination of bosentan with prostacyclins is widespread 
but complicated by difficulties with administration of prostacyclin analogues 
(Wozencraft et al., 2012). Thus, it is important to evaluate the impact of therapeutic 
agents on ET-1 levels either as a monotherapy or in combination. Earlier studies 
suggested that treatment of IPAH with chronic intravenous epoprostenol improves 
the abnormal net balance of pulmonary clearance and release of ET-1 (Langleben 
et al., 1999). Curiously this is the only positive clinical report of prostacyclin use, 
although there was a similar trend shown with iloprost where treating PAH patients 
with inhaled iloprost lead to increased pulmonary clearance of big ET-1 (Wilkens 
et al., 2003). This indicates the need for more studies focussing on monotherapy to 
learn their individual effects and to rule out the possible negative drug-drug 
interaction when used in combination. In view of the possibility that inhibition of 
ET-1 release may be a therapeutically important mechanism underlying the 
antiproliferative effects of prostacyclin analogues (Wort et al., 2001), I sought to 
measure ET-1 production in primary human pulmonary arterial smooth muscle 
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cells (PASMCs). It is unclear if other prostacyclin analogues such as treprostinil 
have similar effects on ET-1 production and also if blockade of smooth muscle ET-
1 receptors can regulate ET-1 levels. Therefore, I sought to assess the effect of 
treprostinil and ET-1 receptor antagonists (ETRAs) on ET-1 levels in adult and 
child PASMCs. Administration of either a non-selective ET-1 receptor antagonist 
(bosentan) or an ETA selective antagonist (ambrisentan) is able to improve 
haemodynamic indices in patients with PAH (Channick et al., 2001). Although it 
remains unclear whether selective blockade of the receptors would be more 
beneficial than a non-selective blockade, this is now more difficult to assess since 
the highly selective ETA antagonist sitaxentan (Davie et al., 2009) has now been 
withdrawn. I have endeavoured to assess the effects of ETA selective, ETB selective 
and non-selective ETA/ETB receptor antagonism alone or in combination with 
treprostinil to study the scope of combination of these agents for IPAH treatment 
and to study the mechanistic pathways involved.  
 
 Results 4.2
4.2.1 Effect of treprostinil and endothelin receptor 
antagonists on ET-1 production 
 
First, I wished to establish if treprostinil inhibited ET-1 production in PASMCs 
isolated from IPAH patients stimulated by serum. ET-1 levels were measured in the 
supernatants of cells from either growth arrested human PASMCs or those 
stimulated with FBS for 24 hours. In the absence of any growth factors, a basal 
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level of ~2pg/mg protein could be detected in the supernatants (figure 4.1). 
Following a 24 hour stimulation with FBS, levels rose 2 fold (p < 0.001), an effect 
completely abolished by the cell permeable ECE-1 inhibitor, CGS 35066 or by 
increasing doses of (1-1000nM) treprostinil (figure 4.1). 
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Figure 4.1. Treprostinil potently inhibits serum-induced ET-1 levels in cultured human 
PASMCs from IPAH patients.  Measurement of ET-1 was made in the supernatant of distal 
PASMC isolates. Growth arrested PASMCs were treated for 24 hr with basal media or 9% 
serum (FBS) in the presence and absence of treprostinil (Trep; 1-1000 nM). CGS 35066 (1 μM), 
an endothelin-converting enzyme (ECE-1) inhibitor was used to validate the assay and confirm 
synthesis of mature ET-1. Data are mean ± SEM, from nine different experiments performed in 
duplicate using five PASMC isolates. ***=p < 0.001 when compared to basal or as shown (one-
way ANOVA with Bonferroni post-hoc correction). 
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In addition, inhibition of serum induced ET-1 release by treprostinil occurred after 
24 h of treatment at a concentration as low as 1 nM (p < 0.001; n=9), with a 
complete return to basal at a concentration between 100 and 1000 nM. Given the 
role of endothelial ETB receptors in clearing ET-1, next I wished to compare the 
effects of selective ETB and ETA receptor inhibition on ET-1 levels in smooth 
muscle cells. When used alone, the ETB receptor antagonists increased ET-1 levels 
significantly compared to  
FBS alone (figure 4.2). The highly specific ETB antagonist BQ788 (100 nM) 
increased ET-1 levels by ~4 fold. Bosentan, the dual antagonist, increased levels by 
3 fold over and above that increased by FBS alone (p < 0.001; n=6). No increase in 
ET-1 production was observed with highly specific ETA antagonist, BQ123 (figure 
4.2). However, the supposedly ETA specific antagonist, ambrisentan also increased 
ET-1 levels to a similar degree to bosentan.  
 
Next I wished to assess whether ETRAs interfered with treprostinil inhibition of 
ET-1 levels, particularly as bosentan and ambrisentan are commonly given 
clinically in combination with prostacyclin (epoprostenol) or an analogue. 
Surprisingly inhibition of serum induced ET-1 release from PASMCs by inhibition 
of ET-1 production with 1 nM treprostinil was not observed in the presence of 1 
µM bosentan (p< 0.001) (figure 4.3). Moreover, bosentan when combined with 1 
µM treprostinil, resulted in a significant reduction in the ability of treprostinil to 
inhibit ET-1, (p< 0.001, n=6) despite the higher analogue concentration (figure 
4.3). To further investigate whether reversal of ET-1 inhibition with bosentan was 
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mediated via ETA or ETB receptors or both, inhibition of serum induced ET-1 
release by treprostinil was assessed in combination with the relatively specific ETA 
receptor antagonists ambrisentan, BQ123 and the selective ETB antagonist, BQ788. 
This effect of bosentan seemed to be related to ETB blockade as combining 
treprostinil with a highly selective ETA receptor antagonist (BQ 123) meant that 
treprostinil could still fully inhibit FBS induced ET-1 levels in a similar manner to 
that without the antagonist. Furthermore the highly specific ETB antagonist (BQ 
788) significantly increased ET-1 levels beyond that of FBS alone despite the 
presence of 1 µM treprostinil. However, ambrisentan which is classified as a highly 
specific ETA antagonist, behaved similarly to bosentan as opposed to behaving like 
BQ 123. This latter observation makes me question the specificity of this drug in 
our system (figure 4.4). Thus the ability of treprostinil to potently inhibit ET-1 
levels in human PASMCs is adversely affected by ETRAs targeting ETB but not 
ETA receptors. The potential upshot clinically might be that when treprostinil is 
used in combination with bosentan and perhaps ambrisentan, this agent may end up 
as being less effective and/or higher concentrations required (close to 100 nM in 
this case) before treprostinil can begin to significantly inhibit serum-induced ET-1 
levels in patients. In contrast, BQ 123 (selective ETA antagonist) did not affect the 
ability of treprostinil to inhibit ET-1 while BQ788, the highly selective ETB 
receptor blocker, showed the greatest antagonism to the treprostinil (figure 4.4).  
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Figure 4.2. ETB but not ETA selective antagonists increase ET-1 levels in cultured human 
PASMCs. Measurement of ET-1 in the supernatants from distal PASMC isolates. The effect of selective 
inhibitors that block either ETA (BQ-123; Ambrisentan) or ETB (BQ-788) receptors or both (bosentan) 
on ET-1 levels measured in the supernatant of PASMCs isolated from IPAH patients.Growth arrested 
PASMCs were treated for 24 hr with 9% serum (FBS) in the presence and absence of clinically relevant 
doses (100 nM) of endothelin receptor antagonists. Data are mean ± SEM, of 6 experiments measured in 
duplicates from five PASMC isolates and normalised to increase in ET-1 induced by 9% FBS. ***=p< 
0.001 versus 9% FBS (one-way ANOVA with Bonferroni post-hoc correction). 
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Figure 4.3. Treprostinil inhibition of ET-1 production in IPAH cells is blunted by the mixed 
ET-1 receptor antagonist, bosentan.. Growth arrested human PASMCs were treated for 24 hr 
with 9% serum (FBS) in the presence and absence of treprostinil (Trep; 1-1000nM), bosentan (1 
µM) or in combination with bosentan (1 µM). Following treatment, ET-1 was measured in the 
supernatants of distal PASMC isolates grown in culture.  Data are mean ± SEM, for nine 
experiments measured in duplicates from five PASMC isolates and normalised to increase in ET-
1 induced by 9% FBS. ***=p < 0.001 as shown (one-way ANOVA with Bonferroni post-hoc 
correction). 
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4.2.2 Role of ECE-1 and ETB receptors  
 
In order to assess the mechanism of mixed antagonists counteracting the effect of 
treprostinil, I examined the effect of these agents on both ECE-1 and ETB 
expression. It is possible that ET-1 levels may not only be regulated through ETB 
Figure 4.4. Treprostinil inhibition of ET-1 production in IPAH cells is blunted by mixed 
ETRAs but not by the highly selective ETA receptor antagonist, BQ123. Growth arrested 
PASMCs were treated for 24 hr with serum (9% FBS) alone or in the presence of treprostinil (1 
µM) with or without endothelin receptor antagonists (ETRA; 100 nM). ET-1 released in the 
supernatants from distal human PASMC isolates was normalised to the ET-1 levels measured in 
growth-arrested cells at the same time point (basal). Data are expressed as mean ± SEM and are 
from nine separate experiments performed using five PASMC isolates. *=p < 0.05, ***=p < 
0.001 versus basal or as indicated (one-way ANOVA with Bonferroni post-hoc correction). 
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receptors, but also by the levels of ECE-1 expression and activity. In four separate 
experiments, ECE-1 protein levels in serum-stimulated human PASMCs were 
significantly higher with bosentan (p < 0.001, n=4) compared to either serum or 
treprostinil (figure 4.5). There was a trend to lower ECE-1 protein levels with 
treprostinil alone, though in the presence of bosentan these were similar to those 
seen with bosentan alone.  Thus ETB receptors as well as promoting clearance may 
also regulate ET-1 levels through changes in ECE-1 protein expression. The ECE-1 
protein levels in the presence of FBS were even more prominently increased with 
ETB antagonist BQ788 increasing by 3 fold. In contrast, ECE-1 expression was not 
significantly changed with either with BQ123 or ambrisentan (figure 4.6). Next I 
investigated if ECE-1 expression may be related to the ability of the ETRAs to 
increase ET-1 levels, as ET-1 itself significantly increased ECE-1 expression in a 
concentration-dependent fashion in these cells after 24 hours of treatment (p< 0.05, 
n=4) (figure 4.7). 
Lung endothelial ETB receptors promote ET-1 clearance, which can be improved 
by PGI2 in PAH patients (Langleben et al., 1999). In view of this, I assessed if 
treatment with treprostinil could affect ETB expression on PASMCs and contribute 
to the mechanism of treprostinil induced inhibition of ET-1 in these cells. There 
was a trend showing increased ETB expression in these cells with treprostinil (1 
µM), but when cells were treated with ETRAs, ETB expression was substantially 
decreased after 24 hours of treatment (p < 0.05, n=4). Surprisingly, ETB expression 
in human PASMCs was affected to more or less the same extent with both specific 
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and non-specific antagonists including with the specific ETA receptor antagonists 
(figure 4.8).  
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Figure 4.5. Bosentan increases endothelin converting enzyme (ECE-1) protein levels in the 
absence and presence of treprostinil.  Growth-arrested cells were stimulated with 9% serum in 
the presence or absence of treprostinil (1 µM), bosentan (1 µM) or a combination of both drugs. 
Representative Western blots of crude homogenates of cultured human PASMCs derived from 
IPAH patients, where 10μg of protein was loaded in each lane is shown in (A).  The blot was 
sequentially stained with an antibody against ECE-1 with a β-actin antibody used as a loading 
control. (B) Bottom figure shows relative protein expression as band intensity compared to β-
actin. Results are mean ± SEM of 4 experiments. *** p < 0.001 versus 9 % FBS (one-way 
ANOVA with Bonferroni corrections). 
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Figure 4.6. ETB receptor antagonists increase ECE-1 protein levels in PASMCs from IPAH 
patients.  Cells were stimulated with 9% serum in the presence or absence of ETRAs (bosentan; 
BQ788; BQ123; ambrisentan), all administered at 1µM. (A) Representative Western blots of crude 
homogenates of cultured PASMCs where 10 μg of protein was loaded in each lane. The blot was 
sequentially stained with an ECE-1 antibody with a β-actin antibody used as a loading control. (B) 
ECE-1 protein levels relative to band intensity of β-actin and shown normalised to ECE-1protein 
levels measured in growth arrested cells. Results are mean ± SEM of 4 experiments. *** =p < 0.001 
versus 9 % FBS (one-way ANOVA with Bonferroni post-hoc correction. 
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Figure 4.7. Endothelin increases ECE-1 expression in a dose-dependent fashion in IPAH 
cultured pulmonary artery smooth muscle cells. Changes in ECE-1 protein levels were measured 
after 24h in distal PASMC isolates in response to increasing doses ET-1 (0.1 – 10nM). (A) 
Representative Western blots of crude homogenates of cultured PASMCs where 10μg of protein 
was loaded in each lane. The blot was sequentially stained with an ECE-1 antibody with a β-actin 
antibody used as a loading control. (B) ECE-1 protein levels relative to band intensity of β-actin and 
shown normalised to ECE-1protein levels measured in cells treated with FBS alone. Results are 
mean ± SEM of 4 experiments. **=p < 0.01, ***=p < 0.001 versus 9% FBS (one-way ANOVA 
with Bonferroni post-hoc corrections). 
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Figure 4.8. Endothelin receptor antagonism decreases the expression of ETB receptors in 
distal pulmonary artery smooth muscle cells from IPAH patients. Changes in ETB receptor 
protein levels were measured  in response to treatment with treprostinil or ETRAs. Growth 
arrested cells were stimulated for 24 hours with 9% FBS in the presence or absence of 
treprostinil (100nM) or ETRAs (bosentan, BQ788, BQ123, ambrisentan) all administered at 1 
µM to cells. (A) Representative Western blots of crude homogenates of cultured PASMCs 
where 10μg of protein was loaded in each lane. The blot was sequentially stained with an ETB 
antibody with a β-actin antibody used as a loading control. (B) ETB protein levels relative to 
band intensity of β-actin are shown normalised to ETB protein levels measured in cells treated 
with FBS alone. Results are mean ± SEM of 4 experiments. *=p < 0.05, **=p < 0.01 and  ***=p 
< 0.001 (one-way ANOVA with Bonferroni post-hoc correction).  
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4.2.3  Effect of ETRAs versus treprostinil on cell 
proliferation. 
 
After assessing the effects of these agents on ET-1 levels, I sought to assess their 
ability to inhibit proliferation of human PASMCs. Treprostinil, as described in the 
earlier chapter, concentration-dependently inhibited proliferation of human 
PASMCs, significantly inhibiting proliferation induced by FBS at concentrations ≥ 
1nM (figure 3.5 and 3.6). Next proliferation assays were performed using ETRAs, 
bosentan, ambrisentan and BQ788. ETRAs only inhibited proliferation in these 
cells at higher doses, with bosentan significantly inhibiting proliferation compared 
to solvent control (DMSO) at 100 nM (p < 0.01, n=5) (figure 4. 9) and ambrisentan 
≥10nM (p < 0.01, n=5) (figure 4.10). Ambrisentan was slightly more effective than 
bosentan, significantly inhibiting proliferation from 10 nM compared to solvent 
control. The selective ETB antagonist, BQ788 appeared the least effective amongst 
the three antagonists, only inhibiting proliferation by ~20% at 1µM (p < 0.01, n=5) 
(figure 4.11). Further when bosentan was assessed in combination with treprostinil, 
no additive/synergistic effect on proliferation of human PASMCs was observed. 
On the contrary there was trend at doses above 0.1nM for these two agents to be 
slightly less effective at inhibiting proliferation compared to treprostinil on its own 
(n=5; figure 4.12). 
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Figure 4.9. Effect of bosentan on FBS-induced growth in human PASMCs derived from 
IPAH patients.  Human PASMCs were grown in 9% FBS for 4 days in the absence and 
presence of increasing concentrations of bosentan (0.001-1000 nM). Data have been 
normalised to the growth response induced by FBS and expressed as % cell proliferation.  
* =p < 0.05 and **=p < 0.01 when compared to solvent (DMSO) control (One-way ANOVA, 
Dunnett’s post-hoc, n=5).   
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Figure 4.10. Effect of ambrisentan on FBS-induced growth in human PASMCs derived 
from IPAH patients.  Human PASMCs were grown in 9% FBS for 4 days in the absence 
and presence of increasing concentrations of ambrisentan (0.001-1000nM). Data have been 
normalised to the growth response induced by FBS and expressed as % cell proliferation.  
*= p < 0.05 and **=p < 0.01 when compared to solvent (DMSO) control (One-way ANOVA, 
Dunnett’s post-hoc, n=5).   
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Figure 4.11.  Effect of ETB selective antagonist, BQ-788 on FBS-induced growth in 
human PASMCs derived from IPAH patients.  Human PASMCs derived from IPAH 
patients were grown in 9% FBS for 4 days in the absence and presence of increasing 
concentrations of BQ 788 (0.001-1000nM). Data have been normalised to the growth 
response induced by FBS and expressed as % cell proliferation. *= p < 0.05 and **=p < 0.01 
when compared to solvent (DMSO) control (One-way ANOVA, Dunnett’s post-hoc, n=5).   
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Figure 4.12. No additive/synergistic effect of bosentan and treprostinil treatment on 
proliferation of human pulmonary arterial smooth muscle cells derived from IPAH 
patients.  Human PASMCs were grown in 9% FBS for 4 days in the absence and presence of 
increasing concentrations of treprostinil (0.001-1000 nM), bosentan (0.001-1000 nM) or a 
combination of treprostinil (0.001-1000 nM) with bosentan (100 nM). Data have been 
normalised to the growth response induced by FBS and expressed as % cell proliferation. 
Mean data are fitted using a variable slope, sigmoidal fitting routine in GraphPad Prism.  
**=p < 0.01 and ***=p < 0.001 when compared to treprostinil (two-way ANOVA, with 
Bonferroni post-hoc correction; n=5).   
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4.2.4 Expression of ECE-1 and ETB in normal versus IPAH 
lung. 
 
In PAH,  the cells from the arterial wall undergo a series of morphological changes, 
including changes in the cellular and matrix components of the three layers - 
intima, media, and adventitia (Tuder et al., 2007). Expansion of the intimal layer of 
arteries due to cellular proliferation and extracellular matrix deposition and these 
proliferating cells are phenotypically smooth muscle cells expressing alpha smooth 
muscle actin (α-SMA) (Graham & Tuder, 2009). Also endothelial dysfunction or 
the loss of proper endothelial function, is a hallmark for PAH (Budhiraja et al., 
2004) and therefore the changes in the intima were studied by staining the cells 
with the endothelial cell specific adhesion molecule, also known as cluster of 
differentiation 31 (CD-31). Using immunostaining techniques, localisation of ECE-
1 staining with the endothelial marker protein CD31, confirmed ECE-1 expression 
in the endothelial cells of both normal (figure 4.13A) as well as in lung sections 
form IPAH patients (figure 4.13B). When localisation of ECE-1 staining was 
compared with the smooth muscle cell marker protein, alpha smooth muscle actin 
(α-SMA), ECE-1 expression appeared far more strongly expressed in the medial 
smooth muscle layer of the IPAH lung compared to that of the normal lung, where 
the ECE-1 stain was very faint (Figure 4.13). When comparison of ETB expression 
in normal and IPAH lungs were performed using similar technique, the differential 
staining intensities in both the intimal layers and in medial smooth muscle was 
significantly increased in IPAH versus normal pulmonary arteries. In IPAH, 
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ETB expression in both the medial smooth muscle and endothelium of pulmonary 
arteries was markedly increased compared with control lung (figure 4.14).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.13. Increased expression of endothelin converting enzyme-1 (ECE-1) in a PAH 
compared to a control lung.  Immunohistochemical staining for the endothelin converting enzyme 
1 (ECE-1) visualised by diaminobenzidine (brown) in sections counterstained with haematoxylin. 
Adjacent sections of representative pulmonary artery of A) a control lung from a 55 year old male 
and B) an 18 year old female patient with idiopathic pulmonary arterial hypertension (IPAH) stained 
with a CD-31 antibody (staining the endothelium), an alpha smooth muscle actin (α-SMA) (staining 
the intimal-smooth muscle layer) and ECE-1 antibody. 
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Figure 4.14. Increased expression of ETB receptor observed in a PAH lung compared to a control 
lung. Immunohistochemical staining for the ETB receptor visualised by diaminobenzidine (brown), in 
sections counterstained with haematoxylin. Adjacent sections of representative pulmonary artery of A) a 
normal lung from a 62 year old male and B) 18 year old female patient with idiopathic pulmonary 
arterial hypertension (IPAH) stained with CD-31 antibody (staining the endothelium), alpha smooth 
muscle actin (α-SMA) (staining the intimal-smooth muscle layer) and ETB antibody. 
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 Summary of key findings 4.3
 
 Treprostinil potently inhibited serum induced ET-1 levels in PASMCs 
isolated from IPAH patients with end stage disease. In contrast, bosentan 
and ambrisentan significantly elevated ET-l levels above that seen with 
serum alone.   
 Inhibition of ET-1 levels by treprostinil was significantly impaired by 
bosentan and ambrisentan, but not by the highly selective ETA antagonism, 
BQ 123. 
 Bosentan, the highly selective ETB antagonist BQ 788, and possibly 
ambrisentan, all increased ECE-1 expression in human PASMCs from 
IPAH patients, while BQ 123 and treprostinil did not. 
 ETB expression was downregulated by all ETRAs, but not by treprostinil.  
 Ambrisentan shows characteristics of mixed antagonism and may reflect 
previously reported variable ETA/ETB binding affinities (29-2000:1) 
(reviewed in (Davie et al., 2009). 
 ECE-1 expression is dramatically increased in the pulmonary arterial 
medial smooth muscle layer of IPAH compared to normal lungs. 
 ETB expression appeared to be markedly increased in both endothelium and 
medial smooth muscle layers of IPAH lungs compared to normal lungs. 
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 Smooth muscle cells appear important in regulating ET-1 levels in two 
ways, one associated with the ETB receptor being linked to ET-1 clearance 
the other through up regulation of synthesis via increased ECE-1 
expression. 
 The potential implication of my work clinically is that higher concentrations 
of prostacyclin agents might be required in order to overcome the increased 
levels of ET-1 associated with current ETRA treatment. 
 
 My data suggest that selective ETA antagonists may possibly be a better 
choice of treatment in PAH when combined with prostacyclin agents such 
as treprostinil. This does however remain to be further investigated.  
 
 Discussion 4.4
 
In this chapter, I have demonstrated that treprostinil could significantly inhibit 
serum induced ET-1 release from PASMCs of IPAH patients and this confirms 
other studies showing inhibition with the prostacyclin analogue, cicaprost. Neil 
Davie and colleagues showed that cicaprost inhibited serum and TGF-β stimulated 
ET-1 production in distal PASMCs isolated from normal patients by approximately 
50% at a concentration of 100nM. This effect was mimicked by forskolin and 
IBMX, suggesting a cAMP-dependent mechanism was bringing about a reduction 
in ET-1 (Davie et al., 2002).  
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On the other hand, prostacyclins like treprostinil can activate non-cAMP dependent 
pathways like PPARγ (Falcetti et al., 2007), which in different studies have been 
shown to inhibit ET-1 levels (Satoh et al., 1999). PPARγ activation can attenuate 
hypoxia-induced activation of HIF-1α, NF-κB and ET-1 signalling pathway 
components (Kang et al., 2011). The cross-talk between PPARγ and nuclear factor 
of activated T-cells (NFAT) was reported in T lymphocytes (Chung et al., 2003). 
Common stimuli of PAH such as hypoxia cause inflammatory responses in the 
pulmonary vasculature and NFAT is a potent activator of T cells regulating the 
expression of many inflammatory genes. This transcription factor is upregulated in 
the pulmonary artery walls and circulating inflammatory cells of PAH patients 
(Bonnet et al., 2007). In PAH, increases in NFAT appear largely responsible for 
the down regulation of voltage-gated (Kv) current and the decreased Kv1.5 
expression reported in human PASMCs from these patients, as well as the 
expression of pro-inflammatory cytokines and growth promoting genes (including 
ET-1) in a number of different cell types (Bonnet et al., 2007).  Endothelin induced 
cardiac hypertrophy is inhibited by activation of PPARγ, which is at least partly 
due to cross-talk between PPARγ and calcineurin/NFAT (Bao et al., 2008). In 
several rat models of hypertension, treatment with PPARγ ligands, reduced ET-1 
expression vasculature (Iglarz et al., 2003). Collectively, these findings suggest that 
PPARγ activation can attenuate expression of ET-1 in cardiovascular tissues in 
response to a variety of stimuli and can attenuate ET-1-mediated signalling in 
selected models. These strategies could be applied to inhibit ET-1 signalling by 
targeting PPARγ in IPAH (Green et al., 2011). Nonetheless, it seems reasonable to 
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postulate that treprostinil might be acting to inhibit multiple steps in the ET-1 
signalling pathway by activating PPARγ and/or inhibiting NFAT. Thus clinically, 
treprostinil might provide both more effective endothelin signalling inhibition and 
simultaneously reduce other pathogenic pathways, to attenuate IPAH pathogenesis 
more effectively then ETRAs (Kang et al., 2011). Activation of PPARγ by 
treprostinil may represent a previously unrecognised target to inhibit enhanced ET-
1 signalling in the pathogenesis of IPAH. Inhibition of ET-1 release may also 
contribute, in part, to the anti-proliferative effects of PGI2 analogues on distal 
human PASMCs (Wharton et al., 2000; Falcetti et al., 2010). 
Next, I demonstrated that inhibition of ET-1 levels by treprostinil was also 
impaired by bosentan and ambrisentan, but not by the highly selective ETA 
antagonist, BQ 123. I also demonstrated that selective ETA receptor blockade in 
human PASMCs might be a better choice of therapeutic agent as this approach did 
not affect ET-1 release in vitro. By contrast selective ETB receptor blockade or 
non-specific blockade of the endothelin receptor might cause adverse effects 
associated with a rise in ET-1 concentrations. Consistent with this notion, plasma 
ET-1 concentrations were elevated upon administration of either bosentan or a 
highly selective ETB receptor antagonist either in heart failure (Cowburn et al., 
2005) or PAH (Hiramoto et al., 2007; Hiramoto et al., 2009) patients. In the former 
study, addition of an ETA selective antagonist on top of established ETB receptor 
blockade, led to pulmonary and systemic vasodilation without further increases in 
plasma ET-1 concentrations. These data suggest that the ETB receptor has a role in 
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the clearance of ET-1 and that blockade of the ETB receptor may not be beneficial 
for patients with heart failure (Cowburn & Cleland, 2001; Cowburn et al., 2005).  
 
Similar conclusions may be postulated for clinical trials which did not achieve 
significance and success. Long-term studies in patients with symptomatic heart 
failure have been conducted (Research on Endothelin Antagonism in Chronic Heart 
Failure (REACH)) and Endothelin Antagonist Bosentan for Lowering Cardiac 
Events in Heart Failure (ENABLE). Both trials were stopped prematurely, due to 
unexpected increases of adverse events without improvements in clinical status, 
possibly due to fluid retention (Mylona & Cleland, 1999; Kalra et al., 2002; Packer 
et al., 2005). Thus one can say that use of endothelin antagonists in heart failure 
have shown disappointing results, the reasons for which are still being studied. In 
another trial, Dr. Talmadge E and co-authors said that the findings of their study 
BUILD-3: A Randomized, Controlled Trial of Bosentan in Idiopathic Pulmonary 
Fibrosis, were "disappointing." They started the trial after a previous study of 
bosentan suggested it extended the time to disease progression or death in 
Idiopathic Pulmonary Fibrosis - although it failed to improve 6-minute walk 
distance (King, Jr. et al., 2008; King, Jr. et al., 2011). One possibility is that the 
effectiveness of the drug is being counteracted by too much ET-1 release from 
different cell types, including fibroblasts. This in turn would have the effect of 
allowing ET-1 to bind tightly to the ETA receptor in a non-competitive fashion. 
ETRAs can prevent ET-1 binding, but do not reverse established agonist–receptor 
complexes in membrane preparations (Hilal-Dandan et al., 1997).  As a result of 
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the tight nature of the agonist–receptor complexes, certain ETRAs cannot influence 
long lasting ETA receptor activation initiated by the peptide. This effect could be 
due to the fact that endothelin binds to its receptor in an allosteric fashion which 
makes it very difficult to be reversed by ETRAs; the latter seemingly can only bind 
to one site on the receptor unlike ET-1 which is able to bind to both high and low 
affinity sites (Christopoulos & Kenakin, 2002).  
      
In this chapter, I also demonstrated that antagonism of endothelin receptors using 
the non-selective antagonist (bosentan), ambrisentan or a highly specific ETB 
antagonist, adversely elevated the ET-1 levels compared to FBS control in 
PASMCs isolated from IPAH patients. IPAH is a multifactorial disease and while 
monotherapy using oral agents can is effective as an initial therapy, it clearly does 
not control the disease in the long term where ultimately lung transplant becomes 
the only option. However, prostacyclin is rarely the upfront monotherapy, and is 
often added on top of bosentan treatment, it is possible this could be a confounding 
factor in the decline of this therapy as the disease progresses. The combined use of 
drugs targeting different pathways is becoming more widespread, although the 
evidence to support such a strategy remains limited (Olsson & Hoeper, 2009; 
Levinson & Klinger, 2011). On the basis of a great number of studies describing 
the role of ET-1 in pathogenesis of many diseases, including PAH (Cacoub et al., 
1993a; Cacoub et al., 1993b; Saleh et al., 1997; Veyssier-Belot & Cacoub, 1999), 
drugs such as bosentan, an oral non-selective endothelin receptor antagonist, were 
developed to reduce the pathophysiological effects of the endothelin system. This 
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provides a rationale for the use of ETRAs for treatment of various cardiovascular 
and pulmonary diseases. Deletion of the ETB receptor gene, produces salt-sensitive 
hypertension, vascular oxidative stress and impaired endothelium-dependent 
vasodilatation (Quaschning et al., 2005) while systemic ETB receptor antagonism 
in healthy men leads to increased PVR and increased plasma ET-1 concentration 
(Strachan et al., 1999). Such studies indicate the lack of potential clinical 
applications for specific ETB receptor antagonists in cardiovascular disease.  
The adverse events observed with ETRA treatment include headache, dizziness and 
oedema but the abnormalities of liver function are of concern in IPAH patients 
(Fattinger et al., 2001). Although use of bosentan requires careful monitoring due 
to this dose-dependent liver toxicity, and is also contraindicated in pregnancy 
because of teratogenicity, nonetheless, outside of the UK, bosentan remains the 
first-line treatment for many IPAH patients, in particularly those in Class II of the 
WHO classification. Although liver toxicity was first reported with bosentan it was 
later also observed with both mixed and selective ETA receptor antagonists (Barst 
et al., 2002). Despite the adverse effects, ETRAs are still widely used in IPAH. 
It has been shown that chronic intrauterine pulmonary hypertension causes the loss 
of ETB-mediated vasodilation, progressive ETA-mediated vasoconstriction, and 
increased lung ET-1 protein content (Giaid et al., 1993). Thus it is important to 
study changes in expression of ET-1 and its receptors as these could contribute to 
the hypertensive and arterial remodelling changes in the lungs after chronic 
treatment for pulmonary hypertension in patients. To examine this, I measured 
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levels of ET-1, ECE-1 and ETB-receptor in lungs and PASMCs isolated from IPAH 
patients. These findings are pertinent because not much is known about the effect 
of different treatments on levels of ET-1 and its receptors in pulmonary 
hypertension, nor have their anti-proliferative properties been compared. An 
imbalance in the NO-cGMP system and ET-1 system, favouring reduced NO 
bioavailability and over production of ET-1 may also contribute to pulmonary 
hypertensive states (Maclean et al., 1997; Hanson et al., 1998b). Indeed, a decrease 
in NO production may lead to increased ET-1 production (Kourembanas et al., 
1993). In addition, increased ET-1 activity is also likely to stimulate pulmonary 
smooth muscle proliferation (Davie et al., 2002), which may further increase PVR 
through increased wall thickness (Zamora et al., 1993). Inhaled nitric oxide 
treatment in PAH is reported to be associated with ET-1 induced reactive oxygen 
species (ROS) production (Wedgwood et al., 2001b). Furthermore, ETA receptor 
stimulation tends to promote cell proliferation and fibrosis mediated by 
ROS generation (Wedgwood et al., 2001a) and this mitogenic effect of ET-1 on 
PASMC can be blocked by antioxidants treatment (Wedgwood et al 2001). 
 
Little is known about the role of ECE-1 in pulmonary hypertension. I compared the 
ECE-1 expression in histological sections of IPAH and normal lung tissue to see if 
expression of the endothelin receptors and ECE-1 change in pulmonary 
hypertension. When compared with normal lung tissue, ECE-1 expression in 
medial smooth muscle of the IPAH lung was substantially increased and so was 
ETB receptor expression. One may speculate that an imbalance of ET-1 production 
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and ET-1 receptor expression contributes to the pathophysiological changes in 
pulmonary hypertension by favouring increased vasoconstriction and smooth 
muscle proliferation. The main drawback of this study was that it could only be 
repeated twice and so could not be quantified statistically. However, observations 
were similar to that reported in PAH patients, who showed immunoreactivity for 
ECE- 1 was augmented in the endothelium of diseased pulmonary arteries (Giaid, 
1998). With respect to ETB receptors, I observed increased expression in the media 
as well as intima in pulmonary artery of IPAH versus control patient, a result 
similar to previous studies that showed ETB-receptor upregulation in distal 
pulmonary blood vessels (Bauer et al., 2002; Davie et al., 2002; Hall et al., 2011). 
Also human PASMCs express both ETA and ETB receptors which couple to 
contraction and proliferation; in endothelium, ETB is linked to vasodilation, though 
ETA, recently detected in the lung endothelium (Hall et al., 2011) may have this 
role, but this is unknown. This suggests a dual beneficial role for ETB receptor in 
PAH, where endothelial dysfunction could be combated through enhanced ET-1 
clearance and nitric oxide release (Wilson et al., 2012). Loss of ETB signalling in 
cultured rat pulmonary endothelial cells has been reported to increase ECE-1 
mRNA expression in (Naomi et al., 1998), which may further contribute to an 
increase in ET-1. In other studies, there is a suggestion of cross talk between ET-1 
receptors which may allow the ETB receptor to adopt functions of the ETA receptor 
when the latter is under selective blockade (Okada et al., 1994; Fukuroda et al., 
1994b). Such studies raise the controversial issue regarding use of selective ETA 
versus mixed ET-1 receptor antagonism in IPAH. Since with some agents such as 
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ambrisentan, selectivity is highly dependent on dose used, future strategies ought to 
employ agents that retain ETA receptor selectivity at the doses used (Battistini et 
al., 2006). In animal models the role of ETB receptor in the context of PAH is also 
complex. In rats increased ET-1 activity led to an up-regulation in the endothelium 
of ETB-dependent vasodilatory, clearance and anti-proliferative pathways whereas  
in animal models ETB deficiency in rats (Ivy et al., 2002) or ETB antagonism in 
sheep (Ivy et al., 2000), results in a severe PAH phenotype following 
monocrotaline treatment. 
I also demonstrated that ETB blockade with either a mixed (bosentan) or a specific 
ETB antagonist (BQ 788) was not very effective at inhibiting proliferation of 
human PASMCs isolated from IPAH patients. ETB receptors on vascular smooth 
muscle cells mediate ET-1 induced remodelling and hypertrophy (Nishida et al., 
2004). Even, studies performed on hypoxic rats suggested a role for ETB in right 
ventricular hypertrophy (Motte et al., 2006). The importance of ET-1 receptor 
mediated pathways in human PAH remains unclear and thus bosentan as well as 
ambrisentan are still widely used for the treatment of this disease due to the 
rationale of significantly elevated ET-1 levels contributing to the pathology in this 
disease. 
However, it is likely that additional mechanisms are involved in mediating the 
effects of ET-1 on distal PASMC proliferation. The desensitization or down-
regulation of pulmonary ETB receptors has been postulated to contribute to the 
development of human pulmonary hypertension (Dupuis et al., 1996a). Recently 
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Kirkby and his group reported that ETB receptor activation may play an important 
role in limiting neointimal lesion formation following acute vascular injury and 
provided evidence that ETB receptors expressed on smooth muscle but not 
endothelial cells were involved in preventing intimal proliferation (Kirkby et al., 
2012). The authors concluded that blockade of selective ETA receptors may be 
preferable to mixed ETA/ETB antagonism for treating the vascular injury caused in 
PAH. 
The first placebo-controlled trial where a combination of bosentan and 
epoprostenol was studied raised questions about their combined efficacy. The trial, 
BREATHE-2 was a 16-week, double-blinded, randomized, placebo-controlled 
prospective trial examining the efficacy of adding oral bosentan at the initiation of 
intravenous epoprostenol therapy (Humbert et al., 2004b). In patients receiving the 
combination, hemodynamic improvement was not significant when compared with 
placebo and epoprostenol, nor was there significant improvement in functional 
class or exercise capacity. In another multicenter trial, COMBI, Hoeper and co-
workers studied patients with IPAH who were stable on bosentan and to whose 
regimen iloprost or placebo was added (Hoeper et al., 2006). The investigators 
planned to enroll 72 patients, but the study was terminated early because the 
interim analysis of 40 patients did not demonstrate efficacy. Interestingly, as in the 
STEP trial, the 3 patients whose condition showed substantial deterioration in all 
objective outcomes were in group receiving combination therapy (McLaughlin et 
al., 2006).  
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A recent study, FREEDOM-C trial, hinted that combining ETRAs with 
prostacyclin analogues might affect the efficacy of the latter (Tapson et al., 2012). 
Patients participating were already on therapy with an ETRA and/or sildenafil 
when oral treprostinil was added on. The study failed to meet clinical outcomes, 
despite the initial trial meeting such endpoints when given as a monotherapy 
(Simonneau et al., 2002). In the TRIUMPH study, patients on treatment with 
sildenafil or bosentan showed a marked improvement in 6MWD with the addition 
of inhaled treprostinil for 12 weeks (McLaughlin et al., 2010). Notably, in this 
study, the improvement in 6MWD was greater in patients receiving sildenafil than 
those receiving an ETRA. Looking at all these studies, one could speculate that 
perhaps prostacyclin monotherapy could be clinically superior, though proper 
crossover trials would be required to confirm this.. Two more phase 3 trials, a 
large-scale trial of oral treprostinil monotherapy (FREEDOM-M) and a second 
combination study (FREEDOM-C2) are currently underway. Results of these 
studies and larger clinical trials with prostacyclin analogue monotherapy might 
throw further light on how to better approach treatment of PAH patients. 
Interestingly, in an open labelled or in retrospective long-term analysis of 
subcutaneous treprostinil, patterns of observed survival versus predicted appear to 
be similar or possibly slightly better (69% at 3 years) than those seen with IV 
epoprostenol involving patients with similar baseline characteristics (McLaughlin 
et al., 2002; Lang et al., 2006; Barst et al., 2006; Skoro-Sajer et al., 2008; Sadushi-
Kolici et al., 2012). In the latter study, this occurred despite a high proportion 
(44%) of patients in WHO functional class IV. Moreover, outcomes were beyond 
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expectations in a group of patients who could tolerate up-titration of treprostinil 
beyond 6 months, with survival being 57% at 9 years, though overall the rate in the 
whole patient group at this time was 35% (Sadushi-Kolici et al., 2012). 
 Limitations of data contained in this chapter 4.5
 
1. One of potential limitations of the work presented in this chapter was that 
the levels of ET-1 were normalised to cellular protein and not cell 
numbers. The main reason for this approach was that cells were lysed for 
western blot experiments so as to be able to assess the effects of different 
treatment on ETB and ECE-1 expression and correlate this directly with 
ET-1 levels. 
2. Another limitation of the current work is that I did not confirm if any of 
the drugs used had cytotoxic effects on cells. Thus measurement of ET-1 
mRNA by qRT-PCR should be assessed in order to confirm results 
obtained in assays and from westerns blots. 
3. To confirm that the ECE-1 inhibitor was actually preventing conversion of 
big ET-1 to ET-1, big ET-1 should have been measured in parallel  to 
confirm the pharmacological mechanism of CGS35066. 
4. To confirm that ETB receptors are regulating ET-1 levels through ECE-1, I 
should measure mRNA levels of both ECE-1 and pre-pro ET-1 and ET-1 
and assess the effect of an ETB selective agonist (sarafotoxin 6c) together 
with a selective ETB antagonist. 
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5. In the ET-1 assays, I have tended to use a single dose of each ETRAs. 
Keeping in mind the complexity with regard to specificity of different 
ETRAs against ETA & ETB, it would have been preferable to assess 
concentration-dependent effects so as to gauge whether the antagonist was 
working selectively or non-selectively on the specific ET receptor 
subtypes.  
6. For immunohistochemistry experiments, controls should have been 
performed to demonstrate that pre-incubation of the antisera/antibody 
against ECE-1 and ETB with antigen, blocked the immunostaining.  
7. Use of IP receptor and PPARγ antagonists and/or adenylyl cyclase 
inhibitors could have been used to establish whether the effects of 
treprostinil on ET-1 synthesis (measured by ELISA/mRNA) is dependent 
upon the IP receptor, PPARγ and/or cAMP elevation. 
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 Introduction 5.1
 
Pulmonary vascular remodelling is characterised by thickening of all three layers 
of the blood vessel wall i.e., fibroblasts, smooth muscle cells, and endothelial cells, 
as well as increased collagen deposition, elastin, and fibronectin (Ishizaki et al., 
1995). In addition, there is extension of new smooth muscle into the partially 
muscular and non-muscular peripheral arteries. This is due to the differentiation of 
precursor cells into smooth muscle cells (Meyrick & Reid, 1980) and is termed 
neomuscularisation. These various alterations in vascular structure are seen in both 
human pulmonary hypertension and animal models of the disease, and take place 
more rapidly than the remodelling of systemic arteries in systemic hypertension 
(Zhao et al., 1996).  The increased production of mitogenic factors by hypoxia can 
cause induction of various transcription factors (e.g., hypoxia-inducible 
transcription factor-1, activating protein-1, and nuclear factor-kB) that control the 
transcriptional activation of genes encoding for growth factors and other mediators 
of mitogenesis.  
 
Extensive remodelling and proliferation appears to be the main factor in PAH and 
thus needs to be targeted to treat the disease. Despite advances in the treatment of 
PAH, dose escalation is required for all of the current medications as the disease 
becomes progressively severe and eventually these therapies are no longer 
effective. Lung transplantation remains the only option for a small group of 
patients, but as few can benefit from such procedures  improvements in treatment 
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are urgently needed. Earlier intervention and the combined use of drugs targeting 
different pathways is becoming more widespread. The rationale being that a 
multifactoral disease like PAH requires the attack of multiple pathways to control 
the disease (Levinson & Klinger, 2011; Vachiery, 2011). Given that vascular 
remodelling results from suppressed apoptosis and uncontrolled smooth muscle, 
myofibroblast and endothelial cell proliferation, key features in the pathology of 
PAH, this disease could be viewed as form of cancer. Recently vascular 
remodelling has been considered a pseudo-malignant disorder and so mediators 
from cancer research have been described as potential targets for therapeutic 
interventions in PAH (Paulin et al., 2011).  
 
5.1.1 Tyrosine kinase pathway in PAH  
 
Several growth factors, including platelet derived growth factor (PDGF), fibroblast 
growth factor 2 (FGF), epidermal growth factor (EGF), vascular endothelial 
growth factor (VEGF) have been implicated in the abnormal proliferation in PAH 
(McMurtry et al., 2003; Hassoun et al., 2009). Levels of PDGF and its tyrosine 
kinase receptor PDGFR, are elevated in PAH patient lung samples (Merklinger et 
al., 2005; Schermuly et al., 2005a; Perros et al., 2008) as are the levels of VEGF 
and KDR (VEGF receptor) in plexiform lesions (Cool et al., 1997). These two 
growth factors act as potent mitogens and chemo-attractants, and through their 
transmembrane tyrosine kinase receptor pathways, activate major proliferative 
signalling pathways resulting in proliferation, migration and resistance to apoptosis 
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(Hassoun et al., 2009). Reversal of lung vascular remodelling rather than 
prolonged vasodilation is the concept underlying the use of tyrosine kinase 
inhibitors in PAH. One of the most promising drugs in this class of agents to 
reverse vascular remodelling in PAH is imatinib mesylate (Gleevec), an anti-
cancer drug already approved to treat chronic myelogenous leukemia (CML) and 
gastrointestinal stromal tumors (Deininger et al., 2005). Imatinib is thought to 
inhibit the PDGFR and thus improve experimental PH induced by monocrotaline 
(Schermuly et al., 2005a; Klein et al., 2008), though other targets such as c-kit may 
play a role (Buchdunger et al., 2000). Mainly in the end stage of PAH, when the 
disease is highly proliferative and drugs fail to cause any significant improvements, 
treatment with imatinib might provide benefit, particularly in reducing PVR 
(Ghofrani et al., 2006; Patterson et al., 2006). In a more recent and larger study, 
where patients who had a baseline PVR of greater than or equal to 1,000 dynes · 
s/cm
5
, improvements in 6MWD, PVR, and CO after imatinib treatment compared 
with placebo were documented, though overall 6MWD was not significantly 
improved in the whole patient group (Ghofrani et al., 2010). Despite these positive 
results, serious adverse events including nausea and diarrhea may restrict the 
widespread use of this drug, and cardiac toxicity still remains a concern with this 
class of agents (Ghofrani et al., 2010). Thus anti-cancer agents with a more 
selective mode of action need to be evaluated.  
 
 
5. Ispinesib as a potential anti-proliferative agent in PAH 
181 
 
5.1.2  Kinesin Inhibitors  
 
Mitotic kinesin inhibitors are a novel class of antiproliferative agents with low 
toxicity. Their mode of action involves disruption of a specific event in normal 
mitosis thereby promoting cell-cycle arrest and driving cells into apoptosis (Purcell 
et al., 2010). In this study I sought to evaluate a novel anticancer compound, 
ispinesib that has already been advanced to clinical trials. This compound is an 
allosteric small-molecule quinazolinone inhibitor of the kinesin spindle protein 
(KSP). Ispinesib affects the mechanochemical cycle of KSP by altering the 
interactions of KSP and microtubules, thereby preventing KSP-driven mitotic 
spindle pole separation (Lad et al., 2008). The main objective of these experiments 
was to evaluate the anti-growth properties of ispinesib in PASMCs derived from 
IPAH patients and establish a rationale for investigating this agent in PAH settings.  
 
Our lab has previously demonstrated that PASMCs these end-stage disease cells 
have an abnormal proliferative phenotype (Falcetti et al., 2010) and thus might be 
particularly responsive to an anti-mitotic agent. In addition, I wished to ascertain if 
established agents used to treat PAH patients might affect the efficacy of ispinesib, 
either positively or negatively, to inhibit smooth muscle growth. Lastly, I wished to 
evaluate anti-growth effects of ispinesib in lung fibroblasts derived from patients 
with fibrotic disease and secondary PAH. Effective therapies are urgently needed 
given the recent failure of bosentan to meet the primary outcome in the recent 
clinical trial (BUILD-3) conducted in patients with idiopathic pulmonary fibrosis 
(King, Jr. et al., 2011).  
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 Results  5.2
 
5.2.1 Effect of ispinesib on cell proliferation 
 
The effect of ispinesib (developed and supplied by Cytokinetics, San Francisco, 
USA) on cell proliferation stimulated by FBS (9%) was investigated in human 
PASMCs isolated cells grown in culture for 4 days (figure 5.1). Under control 
conditions, FBS (with or without 0.02% DMSO) significantly (one way ANOVA, 
P < 0.001) increased cell number from basal on average by 6 fold in 5 different 
patient isolates (Figure 5.1A). Ispinesib started to inhibit growth at concentrations 
of 0.01 nM, though cell number was only significantly inhibited at or above 1 nM 
(one way ANOVA, P<0.01). Inhibition by ispinesib of the growth promoting 
effects of FBS was concentration-dependent and this agent appeared to have little 
to no effect on cell viability (up to 1 µM) as measured by propidium idodide (figure 
5. 1A). A higher concentration (10 µM) did however cause cells to lift off the 
bottom of the dish and was thus deemed to be cytotoxic at this concentration (not 
shown).  
Given that mitotic kinesins appear to be highly expressed only in proliferating cells 
(Sakowicz et al., 2004), I then investigated whether ispinesib responds in a similar 
or less effective manner in normal distal human PASMCs. In this way, I might be 
able to establish a dose-range that effectively targets cells responding abnormally 
to growth factors (e.g. PDGF), a hallmark of PAH disease (Rhodes et al., 2009).     
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Figure 5.1. Effect of ispinesib on cell number and viability in distal human PASMCs derived 
from IPAH (A) and control (B) patients. Cells were grown in 9% FBS for 4 days in the absence 
and presence of increasing concentrations of ispinesib. Graphs show total and viable cell count as 
assessed by propidium iodide in an automated cell counter (ADAM). *=P<0.05, **=P<0.01 
compared to appropriate DMSO control (One-way ANOVA, Dunnett’s post-hoc, n=4-5). 
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Using the same protocols described above (page 77), I found that ispinesib only 
began to significantly inhibit growth at 100 fold higher concentrations in normal 
compared to IPAH cells. A concentration of 1 nM was the lowest concentration 
showing inhibition of growth though significant inhibition  occurred only at the 100 
nM concentration and above (figure 5.1B).                                                                 
Given the inherent variability in cell proliferation rates, particularly between adult 
and child PAH (Falcetti et al., 2010), a generally accepted way to present cell 
proliferation data are to normalise data to % change relative to the growth response 
induced by FBS alone (set at 100%). As cell isolates from different patients grow at 
different rates, this increases data variability potentially masking significant 
antiproliferative effects at the lower concentrations in any given patient cell isolate. 
When such analysis is done, ispinesib was found to significantly inhibit growth at 
concentrations as low as 0.01 nM in IPAH cells (figure 5. 2A), while in normal 
cells this occurred at 1 nM (figure 5.2B). When data were fitted using a variable 
slope sigmoidal fitting routine within GraphPad, the extrapolated EC50 and EMax 
value for ispinesib was -8.78 ± 0.65 and 2.1 ± 15.5% n=5, respectively in IPAH 
cells (Figure 5.2C). In contrast, at the highest dose examined (1 µM), ispinesib was 
only able to inhibit cell growth by ~50% in normal human PASMCs as opposed to 
85% (2-way ANOVA P<0.01) in IPAH cells. The lower efficacy in normal cells    
occurred across the whole concentration-response range (figure 5.2C) despite a 
similar potency of ispinesib (extrapolated EC50 value being -8.58 ± 0.53, n=4). This 
is presumed to occur because of the lower expression of KSP in normal PASMCs 
cells rather than a decrease in binding of ispinesib to this protein.        
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Figure 5.2. Ispinesib inhibits cell proliferation induced by FBS in distal human PASMCs 
derived from IPAH and control patients.  Cells were grown in 9% FBS for 4 days in the 
absence and presence of increasing concentrations of ispinesib. Effect of ispinesib on FBS-
induced growth in human PASMCs derived from IPAH (A) and normal patients (B) where data 
are expressed as a % change in cell proliferation relative to the growth response induced by 9% 
FBS. In C, data from A & B have been fit using a variable slope sigmoidal fitting routine in 
GraphPad Prism. Significant difference was determined using one-way ANOVA, Dunnett’s 
post-hoc (n=4-5) in A & B and using 2-way ANOVA with Bonferoni corrections (n=4-5) in C. 
*=P<0.05 and **=P<0.01 when compared to solvent (DMSO) control or the appropriate 
ispinesib concentration. 
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Figure 5.3. Comparison of antiproliferative effects of current therapeutic agents 
compared with ispinesib in human PASMCs derived from IPAH patients. Data are 
expressed as % change in cell proliferation relative to the growth response induced by 9% 
FBS. Extrapolated EC50 values were obtained from fits to data using a variable slope 
sigmoidal-curve fitting routine in GraphPad Prism.  += P<0.05 compared to iloprost; ##= 
P<0.01 compared to treprostinil and *P<0.05, **P<0.01, ***P<0.001 compared to ispinesib. 
Statistical comparisons made using 2-way ANOVA, with posthoc Bonferroni correction (n=5 
from same patient isolates). 
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Although both prostacyclin analogues and ET-1 receptors antagonists are reported 
to be antiproliferative in the context of PAH, so far there has been no direct 
comparison between these groups of drugs in the same experimental setting. 
Comparing these agents along with ispinesib, the extrapolated maximal response 
(EMax) in IPAH cells was in the order: Ispinesib > treprostinil > iloprost > 
ambrisentan ≥ bosentan. Bosentan had the lowest potency (EC50 44 nM) and like 
ambrisentan, had a lower maximal inhibitory effect (EMax 71.0 ± 3.2%) on growth. 
Both were also significantly less effective than treprostinil or iloprost (table 1 & 
figure 5.3). Furthermore, iloprost was weaker at inhibiting cell growth than 
treprostinil giving a significantly lower EMax (56.5 ± 6.8% versus 37.4 ± 8.7%).  
5.2.2 Ispinesib combined with other drugs used to treat 
PAH  
Treatment of IPAH patients with ispinesib is likely to be given with an existing 
background therapy. Thus I evaluated the concentration-response of ispinesib in 
combination with two standard therapies, treprostinil and bosentan. Doses of these 
agents were chosen on the basis of measured plasma concentrations likely to be 
achieved in patients although bosentan levels may actually be closer to ~0.75 µM 
(Burgess et al., 2008) and treprostinil may reach 50 nM in some patients (McSwain 
et al., 2008). Combined treatment with treprostinil (10 nM) shifted the ispinesib 
concentration-response to the left by 3 log units, such that significant 
antiproliferative effects were now observed at 1 pM, regardless of whether cell 
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number or % cell proliferation was used to determine statistical difference 
(compare figure 5.4 B & C).  
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Figure 5.4. Enhancement of the antiproliferative effects of ispinesib by treprostinil in human 
PASMCs derived from IPAH patients. Cells were grown in 9% FBS for 4 days in the absence and 
presence of increasing concentrations of ispinesib, treprostinil or ispinesib in combination with 10 
nM treprostinil (B).  Data are shown as cell number in A & B and % cell proliferation in C where 
data from A & B and figure 5.3 have been used. *=P<0.05, **=P<0.01 compared to appropriate 
DMSO control (One-way ANOVA, Dunnett’s post-hoc, n=5) in A & B. In C data are fit using a 
variable slope sigmoidal function in GraphPad Prism and statistical analysis performed using 2 way 
ANOVA. 
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Figure 5.5. Treatment with bosentan at a therapeutic dose synergistically enhances the 
antiproliferative of ispinesib across a wide concentration range. Human PASMCs derived 
from IPAH patients were grown in 9% FBS for 4 days in the absence and presence of increasing 
concentrations of ispinesib, bosentan or a combination of ispinesib and 100 nM bosentan. Data in 
A & B are shown as actual cell number while in C this has been normalized to the FBS growth 
response and fitted using a variable slope sigmoidal fitting routine. *P<0.05, **P<0.01, 
***P<0.001 compared to FBS and DMSO in A & B (One-way ANOVA with Dunnetts posthoc, 
n=5) or compared to combination of ispinesib and bosentan (Two-way ANOVA with posthoc 
Bonferroni conrrection, n=5) in C. Bosentan data used for comparison is taken from figure 5.3.  
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The potentiating effect was seen over the whole concentrating range (0.001 - 1000 
nM) and appeared additive at concentrations <1 nM but converged at higher 
concentrations. The effect on ispinesib responses was even more marked with 
bosentan. A significant antiproliferative effect was now observed well below 1 pM 
(figure 5. 5B). This was associated with a 400-fold increase in potency (EC50 4.5 
pM) compared with ispinesib alone (table 2). Moreover, the potentiating effects of 
bosentan were synergistic at <100 nM, and the combination produced some cell 
death at 1 µM ispinesib. Thus both treprostinil and bosentan at clinically relevant 
doses are able to potentiate the antiproliferative effects of ispinesib in human 
PASMCs from IPAH patients. 
 
Next I wished to investigate the time course over which ispinesib significantly 
inhibited proliferation of IPAH cells. This was performed to serve as a preliminary 
guide for what dose and duration of exposure in patients might be required with 
ispinesib in order to have a significant inhibitory effect on growing smooth muscle 
cells. For these studies, we used cells in the growing phase and then treated them 
with a near maximal anti-proliferative dose of ispinesib (100 nM) over a time range 
of between 0-96 h both in the absence and presence of bosentan (figure 5.6). Under 
these conditions, ispinesib (100 nM) inhibited cell proliferation as early as 10 hr 
with complete growth inhibition occurring at 24 hr. Inhibition was maintained for 
more or less up to 2 days, with less cell growth seen between 2-4 days, even though 
growth was still significantly (P<0.001) depressed.  
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Figure 5.6. In the presence of bosentan, ispinesib growth arrests human PASMCs for a 
significantly longer time. Human PASMCs derived from IPAH patients were grown in 9% 
FBS for 8 days with ispinesib (100 nM) or in combination with bosentan (100 nM) added at day 
4 which is depicted as t=0 on the graph. Data are expressed as fold change in proliferation 
normalised to growth in FBS alone at t=0. **P<0.01, ***P<0.001 compared to FBS and 
ispinesib in combination with bostentan. Two-way ANOVA with post-hoc Bonferroni 
correction at corresponding time point. 
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Next I  wished to establish (a) if incubation of cells with bosentan and ispinesib 
prevented the waning effect over time compared to ispinesib alone and (b) if the 
time taken for this agent to have an inhibitory effect on cell growth occurred more 
quickly. Ispinesib (100 nM) in combination with bosentan (100 nM) completely 
inhibited growth with a similar time course (figure 5.6), though in contrast to 
treatment with ispinesib alone, this growth arrest was maintained for up to 4 days in 
culture. Thus combination therapy is likely to produce growth inhibition that is 
better maintained.  
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5.2.3 Role of ETA & ETB receptors in mediating bosentan 
synergy with ispinesib 
In order to establish whether the synergy observed with bosentan was due to specific 
inhibition of either the ETA or ETB receptor or both, cells were treated with 
ambrisentan, a relatively selective ETA receptor antagonist (Davie et al, 2009), 
BQ788, a highly selective ETB antagonist or a combination of both these drugs with 
ispinesib. Co-incubation of either antagonist with ispinesib produced no significant 
potentiation and there was even a trend towards a lower maximal response with each 
(figure 5.7). It is likely that potentiation of ispinesib effects on cell growth requires 
ETA & ETB to be blocked simultaneously, as a triple combination with ambrisentan 
and BQ788 did cause a significant shift in the concentration-response curve 
compared to ispinesib alone (figure 5.8). However, bosentan was still significantly 
more effective than even this combination (figure 5.8) over the concentration range 
of 1 pmol to 1000 nM. The reason for this is unclear but may relate to incomplete 
blockade of ETA/B receptors with the ambrisentan and BQ788 combination.    
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Figure 5.7. Potentiation of anti-growth effects of ispenesib is not observed with either 
selective ETA or ETB receptor blockade. Human PASMCs derived from IPAH patients were 
grown in 9% FBS for 4 days in the absence and presence of increasing concentrations of 
BQ788 (an ETB antagonist), ambrisentan (a relative selective ETA receptor antagonist), 
ispinesib or a combination of ispinesib with either ET-1 antagonist (100 nM). Data have been 
normalised to the growth response induced by FBS and expressed as % cell proliferation. Mean 
data are fitted using a variable slope sigmoidal fitting routine in GraphPad Prism. 
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Figure 5.8. Blockade of both ETA & ETB receptors is required to potentiate the effects of 
ispinesib.  Human PASMCs derived from IPAH patients were grown in 9% FBS for 4 days in 
the absence and presence of increasing concentrations of ispinesib, a combination of ispinesib 
and 100 nM bosentan  (data from figure 5.5) or a triple combination of ispinesib, ambrisentan 
and BQ788. Data have been normalised to the growth response induced by FBS and expressed 
as % cell proliferation. Mean data are fitted using a variable slope sigmoidal fitting routine in 
GraphPad Prism. *P<0.05, **P<0.01, ***P<0.001 when triple combination compared to 
ispinesib and bosentan or ispinesib alone (Two-way ANOVA with posthoc Bonferroni 
correction; n=5). 
 
5. Ispinesib as a potential anti-proliferative agent in PAH 
195 
 
5.2.4 Antiproliferative effects of ispinesib on lung 
fibroblasts      
 
Pulmonary fibrosis can often be associated with PAH. The incidence of PAH 
increases with severity of fibrotic disease and ranges between 28% and 62% in 
patients diagnosed with pulmonary fibrosis (Mura et al., 2012) or connective 
tissue disease (Yaqub & Chung, 2013). Prognosis and response to therapies is 
considerably worse in these patients compared to IPAH patients. It would 
therefore be of interest to assess the effects of ispinesib in lung fibroblasts derived 
from patients with PAH and also compare it with agents used to treat IPAH. In 
cells stimulated with 9% FBS, ispinesib significantly inhibited cell growth at 
concentrations as low as 0.01 nM in lung fibroblasts from patients with idiopathic 
pulmonary fibrosis (IPF) and secondary PAH (figure 5. 9A). With respect to 
treprostinil, a 100 fold higher concentration was required to begin to significantly 
inhibit growth (figure 5. 9B). However neither agent affected cell viability. 
Furthermore, ispinesib was a 100 fold more potent than treprostinil and was 
significantly more antiproliferative, inhibiting growth with an EC50 value of 0.03 
nM and 4 nM, respectively (figure 5.10). Compared with effects of ispinesib in 
human PASMCs from IPAH patients, there was also a trend towards a lower 
maximal inhibitory effect in fibroblasts (EMax 25% versus 2%; n=4).  
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Figure 5.9. Effect of ispinesib and treprostinil on cell proliferation induced by FBS in human lung 
fibroblasts derived from patients with pulmonary fibrosis and secondary PAH. Cells were grown in 
9% FBS for 4 days in the absence and presence of increasing concentrations of ispinesib or treprostinil. 
Graphs show total and viable cell count as assessed by propidium iodide. *=P<0.05, **=P<0.01, 
***P<0.001 compared to appropriate solvent (DMSO) control (One-way ANOVA, Dunnett’s post-hoc, 
n=5). 
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Figure 5.10. Effect of ispinesib and treprostinil on cell proliferation induced by FBS in 
human lung fibroblasts derived from patients with pulmonary fibrosis and secondary 
PAH. Cells were grown in 9% FBS for 4 days in the absence and presence of increasing 
concentrations of ispinesib or treprostinil and data expressed as % cell proliferation normalized 
to growth response induced by FBS alone. In A & B **=P<0.01 compared to appropriate 
DMSO control (One-way ANOVA, Dunnett’s post-hoc, n=4). In C the EC50 for both agents 
was derived by fitting data with a variable slope sigmoidal-curve using GraphPad Prism and 
statistical difference assessed using 2-way ANOVA (n=4). 
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To ascertain whether there was synergy between ispinesib and bosentan, I 
assessed the antiproliferative effects of ispinesib in combination with bosentan in 
pulmonary fibroblasts isolated from PAH patients. As observed in PASMCs, this 
combination was significantly more potent at inhibiting proliferation in fibroblasts 
compared to ispinesib alone (figure 5.11). The combination of agents shifted the 
dose response curve to the left by 1 log unit and now full inhibition of growth was 
observed at 1 µM ispinesib.  
Figure 5.11. Bosentan potentiates the anti-proliferative effects of ispinesib on cell 
proliferation induced by FBS in human lung fibroblasts derived from patients with 
pulmonary fibrosis and secondary PAH.  Cells were grown in 9% FBS for 4 days in the 
absence and presence of increasing concentrations of ispinesib with or without bosentan (100nM) 
and data normalized to the growth response induced by FBS. Data are expressed as mean ±S.E.M 
(n=4) and EC50 derived by fitting data with a variable slope sigmoidal-curve using GraphPad 
Prism. Statistical difference was assessed using 2-way ANOVA (n=4). 
 
5. Ispinesib as a potential anti-proliferative agent in PAH 
199 
 
 
 
Table 8 - EC50 and Emax values for ispinesib, ET-1 antagonists and prostacyclin analogues on 
cell growth in human PASMCs and lung fibroblasts. PASMCs were derived from control (Con) 
or IPAH patients and fibroblasts from patients with either idiopathic pulmonary fibrosis and  
secondary PAH or IPAH. Values extrapolated from data presented in figures 5.2, 5.3, 5.10. 
*=P<0.05, ***=P<0.001 and +=P<0.05 when compared to ispinesib and treprostinil, respectively in 
IPAH group (one way ANOVA with Bonferroni correction for multiple comparisons). #=P<0.05 
when compared to ispinesib in control PASMCs or lung fibroblasts (unpaired Student t-test).   
Drug (s) pEC50 EMax (%) 
IPAH (n=5)   
Bosentan -7.35 ± 0.59 73.8 ± 7.3***
+
 
Ambrisentan -8.08 ± 0.25 71.0 ± 3.2***
+
 
Iloprost -8.28 ± 0.41 56.5 ± 6.8** 
Treprostinil -8.64 ± 0.47 37.4 ± 8.7** 
Ispinesib -8.77 ± 0.60 2.1 ± 15.5 
Con PASMC (n=4)   
Treprostinil -8.42 ± 0.27 70.2 ± 3.1 
Ispinesib -8.58 ± 0.53 43.8 ± 9.34  
Lung Fibroblasts 
(n=4) 
  
Treprostinil -8.43 ± 0.74
#
 52.3 ± 11.1 
Ispinesib -10.45 ± 0.19 25.1 ± 3.3 
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Drug (s) pEC50 EMax (%) 
Ispinesib -8.78 ± 0.65 2.1 ± 15.5 
Ispinesib + Bosentan -11.34 ± 0.29**  0 ± 5.4 
Ispinesib + BQ788 -10.55 ± 0.34 28.0 ± 5.1 
Ispinesib + 
Ambrisentan 
-10.49 ± 0.30 25.8 ± 4.8 
Ispinesib + 
Ambrisentan + BQ788 
-10.02 ± 0.49 0 ± 9.4 
 
Table 9 - Potency and efficacy of ispinesib in combination with various ET-1 receptor 
antagonists at inhibiting proliferation in IPAH cells.  Values extrapolated from data presented in 
figures 5.7, & 5.8. **=P<0.01 when compared to ispinesib alone (one-way ANOVA with 
Bonferroni correction for multiple comparisons.  
 
 Mechanism of action of KSP inhibitors 5.3
 
Having established that ispinesib was an effective antiproliferative agent,  I sought 
to ascertain if the mechanism of action of ispinesib is through its known inhibitory 
effects on the kinesin pathway rather than through a novel mechanism in this 
experimental setting in a non-cancerous, but highly proliferative cellular 
phenotype. In order to assess this, we compared a compound SB-743921 
(CK0929866) with an identical mechanism of KSP inhibition and a similar 
pharmacophore to ispinesib with its less active enantiomer (CK0929867), 
compounds developed and supplied by Cytokinetics (San Francisco, USA). The 
biochemical IC50 for KSP inhibition for the more active enantiomer was recently 
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measured by Cytokinetics as 2 nM while that of its less active enantiomer to be 176 
nM (Cytokinetics, published conference proceedings; 
http://aacrmeetingabstracts.org/cgi/content/abstract/2006/2/B11). Thus if the 
mechanism of antiproliferative action is by inhibiting KSP in our experimental 
setting then an 80 fold difference in potency should be reflected in a shift in the 
potency/effectiveness of the two compounds against cell proliferation. Indeed, 
CK0929867 was significantly less effective at inhibiting cell proliferation, and 
depending on whether Emax was freely fitted or constrained to zero, the decrease in 
potency (EC50) was either 4.5 or 57 fold, respectively (figure 5.12). We suspect it 
to be closer to the latter given that 10 µM CK0929867 appeared to be cytotoxic/ 
apoptotic at this dose, suggesting that an intermediate dose (e.g. 3 µM) may have 
caused complete inhibition of cell growth.  
 
The function of KSP at the earliest stage of mitosis is to mediate centrosome 
separation with the formation of a bipolar mitotic spindle, thus facilitating 
chromosome alignment and segregation during cell-division. Failure of KSP to 
function normally leads to cell cycle arrest in mitosis with a classic monopolar 
mitotic spindle (Blangy et al., 1995; Kapoor et al., 2000). In order to confirm that 
this is indeed the mechanism of action of ispinesib, immunostaining was performed 
using antibodies directed towards alpha-tubulin which should show whether the 
organization of microtubules is affected due to KSP inhibition.  
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Figure 5.12. Comparison between SB-743921 (pharmacophore of ispinesib) & CK0929867 (less 
active enantiomer) on cell proliferation. Cells were grown in 9% FBS for 4 days in the absence 
and presence of increasing concentrations of CK0929867 (A) or SB-743921 (CK0929866) (B) and 
data normalized to growth response to FBS. *=P<0.05, **=P<0.01, ***=P<0.001 when compared to 
CK0929867 (two-way ANOVA, Bonferroni post-hoc, n=5). EC50 and Emax given in C were derived 
by fitting data with a variable slope sigmoidal-curve using GraphPad Prism.  
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Figure 5.13. Immunofluorescence confirming the mechanism of inhibition of cell division by 
ispinesib. Human PASMCs isolated from IPAH patients were treated for 24 hours with 9% FBS 
in the absence or presence of 10 nM ispinesib with or without 100 nM Bosentan, followed by 
immunofluorescence staining as per methods. Confocal images taken at 10 and 100 x 
magnification showing immunofluorescence staining in cells using antibodies against the 
microtubule marker alpha-tubulin (stained in green), the centromere marker gamma-tubulin 
(stained red) and the chromosome marker dapi (blue).  
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This was indeed the case, as incubation of cells with 10 nM ispinesib in the absence 
or presence of 100nM bosentan for 24 hr produced the expected formation with a 
monopolar   arrangement of the chromosomes clearly observed (figure 5.13, middle 
panel) which were also visibly disordered (figure 5.13, right panel). If KSP is not 
affected, then the chromosomes would be expected to proceed to arrange 
themselves in a bi-polar fashion on the formed spindle, a pre-requisite for effective 
cell-division. It was not possible to capture this normal phenotype in growing cells 
at our 24 hr time frame, either because the mitotic phase is short lived and hard to 
capture, or it occurs in a different time window to mitotic arrest with ispinesib. 
 
 Summary of key findings 5.4
 
 The mitotic kinesin inhibitor, ispinesib, is a potent (EC50 ~2 nM) and 
effective inhibitor of serum-induced proliferation in human pulmonary 
arterial smooth muscle cells (PASMCs) derived from patients with 
idiopathic pulmonary arterial hypertension (IPAH).  
 Under the same experimental conditions, ispinesib was significantly more 
efficacious (but not more potent) than prostacyclin analogues (iloprost or 
treprostinil) and even more effective than endothelin receptor antagonists, 
bosentan or ambrisentan.  
 In contrast, ispinesib was 100 fold more potent (EC50 0.036 nM) than 
treprostinil at inhibiting cell proliferation in lung fibroblasts derived from 
patients with primary or secondary PAH. The enhanced potency may relate 
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in part to the higher proliferative capacity of fibroblasts compared to 
hypertensive PASMCs, though there was a trend for less maximal growth 
inhibition with the former. 
 Ispinesib was significantly less efficacious in normal human PASMCs over 
a wide concentration range, which suggests that this agent may be more 
effective against a cell type with a more proliferative phenotype. 
 The mixed ET-1 receptor antagonist bosentan synergistically enhanced the 
potency of ispinesib by 400 fold in human PASMCs from IPAH patients, 
and by 10 fold in fibroblasts isolated from patients with IPF and secondary 
PAH. The stable prostacyclin analogue treprostinil also showed 
enhancement in human PASMCs, though effects on cell proliferation with 
ispinesib appeared additive.  
 Blockade of ETA receptor with ambrisentan or the specific ETB with 
BQ788 did not enhance the effect of ispinesib in IPAH cells, but 
combining the two did show synergy. Thus blockade of both ET-1 
receptors appears required to potentiate the effect of ispinesib.  
 When ispinesib was combined with a clinically relevant concentration of 
bosentan, complete growth arrest was maintained for at least 4 days after 
the original application in IPAH cells. I suggest this could slow disease 
progression by inhibiting the exaggerated proliferation of vascular smooth 
muscle cells in later stages of the disease. Patients on background therapy 
with bosentan or treprostinil could therefore derive greater benefit than 
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those treated with ispinesib alone due to enhanced efficacy and duration of 
response or both.   
 As in tumour cells, ispinesib appeared to inhibit cell proliferation of 
PASMCs from IPAH patients by inhibiting the kinesin spindle motor 
protein. A comparison between the KSP inhibitor SB-743921 (an identical 
mechanism of action, closely related analog of ispinesib) and CK0929867 
(its less active enantiomer) showed the latter to be less effective in cell 
proliferation assays, while immunofluorescence showed that ispinesib 
produced the expected phenotype of disordered chromosomes. 
 
 Discussion 5.5
 
Pulmonary arterial hypertension and cancer share certain features, in that both 
diseases involve abnormal cellular growth. In the case of PH, these abnormal cells 
are those that line the blood vessels which undergo abnormal phenotypic changes 
and stimulate growth allowing further proliferation, and thickening of the vessel 
walls.  It involves hypertrophy and/or hyperplasia leading to thickening of all three 
layers of the blood vessel wall, as well as extracellular matrix deposition and 
formation of plexiform and neointimal lesions (Rabinovitch, 2008). Evidence 
suggests that a number of interleukins and cytokines which could serve as 
chemoattractants, proangiogenic and proproliferative effectors (Coscoy, 2007) are 
also found in human plexogenic lesions in PAH (Cool et al., 2003; Coscoy, 2007). 
Shear stress, hypoxia and/or various mediators like angiotensin II, ET-1, 5-HT, 
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growth factors, and inflammatory cytokines, increased serine elastase activity, 
carcinogens and others (Rabinovitch, 2007; Rabinovitch, 2008) are involved in the 
remodelling of the pulmonary vasculature. Tissue hypoxia, a key feature of both 
PAH and cancer, inhibits the release of anti-mitogenic factors (Madden et al., 
1986) and increases the production and/or release of mitogenic factors e.g., 
interleukin-1 from pulmonary artery smooth muscle cells (Cooper & Beasley, 
1999) and growth factors (ET-1 and PDGF) from endothelial cells (Dawes et al., 
1994; Gong et al., 2011). Sustained hypoxia can cause the recruitment of cells with 
enhanced growth, migratory and pro-mitogenic features in the wall of distal 
pulmonary arteries (Frid et al., 2009; Burke et al., 2009). Factors that appear to 
drive these phenotypic changes, include platelet-derived growth factor, and other 
mitogens such as the chemokine stromal cell derived factor SDF-1/CXCL12 and 
interestingly the calcium binding protein and a mediator of metastasis, S100A4 
(Frid et al., 2009). Thus PAH and cancer share many elements of pathophysiology.  
 
In my experiments using the anticancer drug candidate, ispinesib, I have shown it 
to have potent and efficacious antiproliferative effects in PASMCs isolated from 
IPAH patients at the end-stage disease. It inhibited growth with an EC50 of ~2 nM 
thus having a similar potency (Ki 1.7 nM) to that found for inhibiting KSP motor 
domain ATPase activity (Lad et al., 2008). The potency of ispinesib to inhibit 
proliferation of IPAH cells, was higher than when tested in a panel of 50 breast 
cancer cell lines, where ispinesib exhibited EC50 sensitivities between 7.4 and 600 
nM, although sensitivity mostly fell within a 10-fold range, between 7.4 and 80 nM 
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(Purcell et al., 2010). Ispinesib was however 100 fold less effective at inhibiting 
proliferation of slower growing normal cell lines suggesting that the main target for 
this agent is likely to be the cells with fast uncontrolled growth rate. Indeed, KSP 
was found to be most abundant in proliferating human tissues (e.g. thymus, tonsils, 
testis, esophageal epithelium, and bone marrow) and was absent from cultured 
postmitotic human central nervous system neurons (Sakowicz et al., 2004). 
Mitosis, being an important process for cell division of tumour cells, has long been 
identified as a key target in cancer chemotherapy. The mitotic spindle mediates the 
mechanical aspects of mitosis and KSP functions exclusively to form it in 
proliferating cells. KSP has been reported to be overexpressed in tumour tissue 
compared to normal tissues, making it an attractive target for proliferative diseases 
(Moores et al., 2002; Sakowicz et al., 2004). Drugs inhibiting KSP affect 
chromosome segregation by arresting cells in the G2/M phase of the cell-cycle and  
causing apoptosis (Sakowicz et al., 2004; Marcus et al., 2005; Miglarese & 
Carlson, 2006). Ispinesib alters the ability of KSP to bind to microtubules and 
inhibits its movement by preventing the release of ADP without stopping the 
release of the KSP−ADP complex from the microtubule (figure 5.14B). Thus, this 
agent works exclusively in mitosis and does not affect non-dividing cells, 
displaying a unique phenotype known as the monopolar spindle initially shown 
with monoastrol in tumour cells (Kashina et al., 1996; Kapitein et al., 2005; Peters 
et al., 2006; Lad et al., 2008). This phenotype was also observed following 
treatment of human PASMCs with ispinesib for 24 h. In addition, ispinesib is 
highly selective for KSP, since other mitotic kinesins are not inhibited by this 
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agent, even up to concentrations as high as 20 µM (Lad et al., 2008), which may 
explain in part the lower side-effect profile of this agent compared to other cancer 
drugs that are anti-mitotic.   
 
Instead of checking a single dose of the drug, I assessed the full concentration-
response range in order to obtain a reliable EC50 for antiproliferative effect of 
ispinesib on PAH cells. When compared with current treatments under the same 
experimental conditions, it was significantly more efficacious (but not more potent) 
than prostacyclin analogues (iloprost or treprostinil) or endothelin receptor 
antagonists (ambrisentan), agents currently approved to treat PAH. Interestingly 
when ispinesib was combined with the mixed ET-1 receptor antagonist, bosentan, 
the potency (EC50 4 pM) and ability of ispinesib to inhibit growth in IPAH cells 
was synergistically enhanced. Likewise, ispinesib has been shown to synergise with 
other types of anti-mitotic agents as well as inhibitors of the epidermal growth 
factor receptor, HER-2 (Purcell et al, 2010), suggesting certain combinations may 
be particularly effective at growth causing  arrest in otherwise resistant cells. 
 
When I look into the literature for a possible explanation for this synergy between 
ispinesib and bosentan, there are a few parallels to the situation here. Endothelin-1 
is one of the major mitogens which is elevated in cancer, where ETA receptors 
appear to play a major role in driving carcinomas through multiple cell growth and 
survival pathways, involving amongst other things, Bcl-2 and the EDGF receptor 
(Lalich et al., 2007).  
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Normal mitosis - a stable bipolar spindle (metaphase) 
Ispinesib treatment - cell cycle arrest with a monopolar spindle 
A
B
Ispinesib
 
  
 
 
 
 
 
 
Figure 5.14. Schematic for mechanism of inhibition of cell division by ispinesib A) Kinesin 
spindle protein 5 (KSP) plays a vital role in the formation of a bipolar mitotic spindle which is 
required for cell cycle progression through mitosis. Thus normal mitosis when progressed will 
have a stable bipolar spindle formation in the metaphase.  B) Ispinesib is an anticancer agent that 
has been shown to cause mitotic arrest and growth inhibition in several human tumour cell lines. 
Ispinesib alters the ability of KSP to bind to microtubules and inhibits its movement by 
preventing the release of ADP without preventing the release of the KSP−ADP complex from the 
microtubule. This causes cell cycle arrest by forming a monopolar spindle. 
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Although I found bosentan alone to have limited efficacy to inhibit proliferation of 
PASMCs of IPAH patients, there was synergy when combined with. Likewise, in 
the study performed by Berger and colleagues, showed that exogenous ET-1 did 
not act as a growth factor for human melanoma cells, but blockade of ET-1 
receptors potentiated the effects of anti-cancer agents and helped decrease 
proliferation and induce apoptosis in defined melanoma cells (Berger et al., 2006). 
This suggests that combination therapy of ET-receptor antagonists with alkylating 
agents that promote DNA damage may be more effective in inhibiting cell 
proliferation. Antagonists of the ET receptors sensitised human tumour cells to Fas 
ligand-mediated apoptosis, thus helping the anti-cancer drug to penetrate a more 
resistant cellular phenotype (Peduto et al., 1999). Lastly in a rat model of 
pancreatic fibrosis and cancer, bosentan exerted both antifibrotic and antitumor 
affects in vitro (Fitzner et al., 2009; Jonitz et al., 2009), demonstrating that this 
agent can inhibit proliferative processes of different origins. 
 
However, when I evaluated the onset and time-course of ispinesib effects in 
growing cells, I found that while ispinesib was able to completely growth arrest 
cells, its effects began to significantly wane at 72 h. The reason for this is 
unknown, but may involve either drug resistance or a re-entry into the cell cycle as 
previously shown for KSP inhibitors in some circumstances (Gascoigne & Taylor, 
2008; Shi et al., 2008). In contrast, the same concentration of ispinesib combined 
with a clinically relevant concentration of bosentan, was able to maintain complete 
growth arrest, for at least 4 days after the original application. Taken together, this 
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may suggest that ispinesib could be of benefit in slowing disease progression by 
inhibiting the exaggerated proliferation of vascular smooth muscle cells in later 
stages of the disease particularly in those patients already on background therapy 
with bosentan. One possibility is that both compounds work in concert to reduce 
the expression of the anti-apoptotic protein, Bcl2. Previous experiments have 
shown that ispinesib to reduce phospho-Bcl2 and Bcl-XL consistent with increased 
induction of apoptosis (Purcell et al., 2010). In the same study, ispinesib treatment 
was also associated with increased cleavage of caspase-3 (a marker of apoptosis), 
decreased staining for Ki67 (a marker of active proliferation), and decrease in 
tumour cellularity. Likewise synergy could be found with ispinesib and bosentan in 
pulmonary fibroblasts isolated from patients with secondary PAH. The shift in the 
concentration-response curve was however only 10-fold, presumably because 
ispinesib was already particularly potent (EC50 36 pM) on its own in these cells 
which I found to grow at a faster rate than PASMCs. Recently bosentan failed the 
trial of IPF, possibly due to adverse events associated with high doses of the drug 
(Gunther et al., 2007). It is tempting to speculate that this combination of ispinesib 
with low dose of bosentan could potentially work in IPF or when associated with 
PAH.   
The stable prostacyclin analogue treprostinil also boosted the action of ispinesib, 
though effects on cell proliferation appeared additive. Higher levels of ET-1 are 
associated with PAH and this potent mitogen could be responsible for making the 
cells more proliferative (Davie et al., 2009). In my previous chapter I demonstrated 
that treprostinil was a potent inhibitor of ET-1 levels in the nano-molar range in 
5. Ispinesib as a potential anti-proliferative agent in PAH 
213 
 
IPAH cells and this effect could possibly make the cells less resistant and more 
sensitive to ispinesib in a manner similar to bosentan. Alternatively, both drugs 
could inhibit proliferation by affecting different individual pathways. A major 
mechanism whereby prostacyclin or its stable analogues inhibit smooth muscle 
growth is to block G1 phase progression by blocking the degradation of p27 and the 
activation of cyclin E-cdk2 (Kothapalli et al., 2005) and such a mechanism could act 
in concert with the anti-mitotic effects of ispinesib. Like in PAH, a lower expression 
of prostacyclin synthase (PGIS) has been found in malignant cells compared to 
normal cells (McLemore et al., 1988; Hubbard et al., 1989), and so its loss may 
contribute to tumour genesis. Indeed, pulmonary-specific over expression of 
prostacyclin synthase was reported to result in suppression of tumour incidence and 
multiplicity in lung cancer models (Nemenoff et al., 2008). Due to its cardio-
protective effects, prostacyclins have also been considered for use in combination 
with anticancer drugs to take care of the cardiac damage that many of these drugs 
can cause (Wang et al., 2011). Thus, the same theory could be applied using 
anticancer therapies in combination with cardio-protective prostacyclin analogues in 
PAH (O'Callaghan & Gaine, 2007). Adding to the increasing body of evidence that 
prostacyclins are also vasoprotective and have regenerative effects on the 
endothelium (Hamblin et al., 2009; Katusic et al., 2012), points to another potential 
benefit of combining these two class of agents. Thus patients on background therapy 
with bosentan or treprostinil could derive greater benefit than those treated with 
ispinesib alone due to enhanced efficacy, duration of response or both. 
Cardiovascular protection with treprostinil may also be of benefit. 
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Drugs in current use for the treatment of PAH are based around their properties as 
vasodilators, including Ca
2+
-channel antagonists, prostacyclin and its stable 
analogues and NO or agents to increase NO bioavailability (Homer & Wanstall, 
1998; Wanstall & Jeffery, 1998; Rubin & Morrell, 2011). As vasodilators, each of 
these drug types acts by opposing any abnormal vasoconstriction. Since abnormal 
vasoconstriction becomes progressively less important and vascular remodelling 
progressively becomes more important as the disease advances (Reeves et al., 
1986), an alternative, and possibly more fruitful approach is to target pulmonary 
vascular remodelling. Indeed <15% of PAH patients are responsive to any type of 
vasodilator therapy at all, and of those, only ~6% respond to long-term oral 
calcium channel blocker therapy (Sitbon et al., 2005), suggesting therapeutic 
benefit comes from mechanisms unrelated to hemodynamic effects. Even though 
prostacyclins are shown to be antiproliferative (Falcetti et al., 2010) as well as anti-
remodelling in experimental PAH (Schermuly et al., 2004; Yang et al., 2010), they 
do lose their efficacy as the disease progresses. This perhaps could be due to 
desensitisation of the receptor and/or phenotypic changes of those cells which 
might develop some kind of resistance towards less aggressive treatments. Patients 
in functional class III or IV who fail to improve or deteriorate with monotherapy 
can be treated with combination therapy; atrial septostomy; or transplantation (lung 
or heart-lung). However, to date, only lung transplantation offers a cure for PAH, 
which in itself comes with its own risks and chances of organ rejection. Current 
rationale for using chemotherapeutic drugs in PAH has been on the basis that they 
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inhibit growth factors induced or upregulated in the disease. Initial experimental 
studies on pulmonary hypertension demonstrated positive effects of epidermal 
growth factor and PDGF receptor inhibition on hemodynamics, remodelling and 
survival (Merklinger et al., 2005; Schermuly et al., 2005a).  Imatinib, which is an 
inhibitor of the tyrosine kinases PDGF receptor, BCR-ABL, and c-kit, indicated 
beneficial results in individual clinical case reports from patients with pulmonary 
arterial hypertension (Ghofrani et al., 2009). This and other studies have led to a 
Phase 3 randomized, placebo-controlled clinical trial of imatinib in PAH known as 
IMPRES (ClinicalTrials.gov identifier: NCT01179737). The results reported at the 
annual European respiratory society meeting, September, 2011, found that treated 
patients had a placebo-adjusted mean increase in 6MWT which was associated 
with statistically significant improvements in pulmonary arterial pressure, cardiac 
output and pulmonary vascular resistance, though not time to clinical worsening. 
Nonetheless, despite some encouraging results, there is still some concern that 
long-term treatment of imatinib could be associated with left ventricular 
dysfunction and heart failure (Kerkela et al., 2006), although this did not seem to 
be a major problem in a recent clinical trial (Ghofrani et al., 2010).  
 
Most of the chemotherapeutic agents so far being seriously considered in PAH are 
targeted towards specific growth factor or mitogen pathways which are known to 
be elevated in the disease, but PAH is a multifactorial disease and inhibition of a 
single mitogen or selective growth factors might not necessarily demonstrate the 
most desired effect on remodelling. To this end the multi-kinase inhibitor sorafenib 
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has recently been assessed and appears to have a greater effect on RV systolic 
pressure and cardiac hypertrophy compared to imatinib in a rat monocrotaline 
model of PAH, the superior effect being attributed to blocking of the 
serine/threonine kinase, Raf-1 (Klein et al., 2008). This drug is now being 
evaluated clinically (Gomberg-Maitland et al., 2010). However, another broad 
spectrum tyrosine kinase inhibitor, dasatinib, while decreasing PDGF-induced 
proliferation in addition to multiple growth factor-induced PASMC proliferation 
through inhibition of Src phosphorylation in experimental PAH, is nonetheless 
associated with severe precapillary pulmonary arterial hypertension cell in patients 
treated for chronic myelogenous leukemia (Montani et al., 2012). Several other 
molecules, which were originally developed as anti-cancer agents, have also been 
investigated in animal models of PH and have shown positive outcomes, and thus 
are likely to lead to clinical evaluation in patients with PAH, particularly those 
molecules that are already licensed medicines. Some examples of such molecules 
are cell cycle inhibitors rapamycin (Paddenberg et al., 2007), anti-apoptotic drugs 
which are survivin inhibitors (McMurtry et al., 2005) and elastase inhibitors 
(Cowan et al., 2000). Thus several cancer drugs are in the pipeline to be further 
evaluated in PAH, though it remains to be determined whether side effects 
outweigh clinical improvement and survival and the potential to cause PAH with 
some agents is a concern. In terms of KSP inhibitors, their major advantage could 
be their low side-effect profile with neutropenia being the commonest side effect 
with none of the documented neuropathy, mucositis, or alopecia that is observed 
with many anti-cancer therapies (Gomez et al., 2012).  
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All class of agents used to treat PAH are expected to promote inhibition of vascular 
smooth muscle cell growth (Rabinovitch, 2008; Rhodes et al., 2009) and the 
antiproliferative effects of prostacyclins and endothelin antagonists are recognised 
as an important property of these agents in ACCF/AHA 2009 Expert Consensus 
Document on Pulmonary Hypertension (McLaughlin et al., 2009). When agents 
from these two classes of agents were compared against their ability to 
inhibiteserum-derived growth of human PASMCs derived from IPAH patients with 
endstage disease, the mixed ETRA, bosentan or the selective ETA antagonist 
ambrisentan, only weakly inhibited growth compared to either iloprost or 
treprostinil. Significant inhibition with bostentan or ambrisentan only occurred at 
concentrations at or above 10nM (ambrisentan) or 100 nM (bosentan) compared to 
1 nM with the two prostacyclin analogues. Thus, while ET-1 is a potent smooth 
muscle mitogen and driver of vascular smooth muscle proliferation and may 
contribute to enhanced proliferation in PAH through increased smooth muscle 
receptor expression (Davie et al, 2009), a number of pro-proliferative signalling 
pathways involving growth factors, cytokines, metabolic signalling, and matrix 
remodelling have been identified in the pathobiology of PAH (Rabinovitch, 2008; 
Hassoun et al., 2009) which may be more sensitive to inhibition by prostacyclin. I 
speculate that prostacyclins have a much stronger inhibitory effect on cell 
proliferation, because they are able to inhibit growth through multiple pathways, 
including through both membrane and nuclear receptors (Clapp & Patel 2010). 
Clinical observations support the idea that endothelin antagonists are less effective 
5. Ispinesib as a potential anti-proliferative agent in PAH 
218 
 
than prostacyclins, where time to clinical worsening with endothelin antagonists 
appears much shorter than for the prostacyclin class of drug, with many patients 
requiring prostacyclin therapy after 1-2 years (McLaughlin et al., 2009). Moreover, 
significant effects on long term survival have only really been shown for the 
prostacyclin class of drugs (McLaughlin et al., 2009; Rhodes et al., 2009; (Sadushi-
Kolici et al., 2012).  
 
I found that treprostinil was a significantly more effective inhibitor of cell growth 
compared to iloprost in IPAH cells. This concurs with a previous study from our 
laboratory, where the rank order of prostacyclin analogues to inhibit normal human 
PASMC proliferation was treprostinil (UT-15) >iloprost>beraprost (Clapp et al., 
2002). Indeed examining the potency and efficacy of these prostacyclin analogues 
in this cell type using a similar in vitro assay to here, has been able to predict 
clinical efficacy in PAH (Gomberg-Maitland & Olschewski, 2008). Moreover, our 
laboratory has previously demonstrated that compared with treprostinil, iloprost is 
a less effective agent at increasing intracellular cyclic AMP (Clapp et al., 2002) 
despite having an 8 fold higher affinity (Ki 32 versus 3.6 nM) for the human 
prostacyclin (IP) receptor (Whittle et al., 2012). This can best be explained by the 
differential pharmacology now recently appreciated, with treprostinil unexpectedly 
having a higher affinity at the prostaglandin E2 (EP2) and D2 (DP) receptor (Ki 3.6 
and 4.4 nM, respectively) than even the IP receptor (Whittle et al., 2012). Given the 
plasma concentrations achieved with intravenous or subcutaneous treprostinil in 
5. Ispinesib as a potential anti-proliferative agent in PAH 
219 
 
patients range between 2.5 to 25 nM (McSwain et al., 2008), suggests these 
prostanoid receptors will be activated within the therapeutic window. Moreover, 
the ability of treprostinil over iloprost to inhibit smooth muscle proliferation in vivo 
may be even more marked, as the upper plasma concentration that is achieved with 
iloprost is >1 nM (Krause & Krais, 1986).  
 
In summary, I described the successful antiproliferative effect of KSP inhibitor 
ispinesib in experimental settings of pulmonary arterial hypertension. The 
combined use of ispinesib with existing treatments in PAH to inhibit the mitotic 
pathway could be beneficial in tackling pulmonary vascular remodelling in PAH 
and may provide an option to treat pulmonary arterial hypertension and the 
associated right heart remodelling. 
 
 
 
 
 
 
 
5. Ispinesib as a potential anti-proliferative agent in PAH 
220 
 
 Limitations of this chapter 5.6
 
1. As with every cancer drug, cytotoxicity and apoptosis of different cell 
types should be considered as potential unwanted-side effects. Therefore 
experiments are needed to assess cytotoxicity of ispinesib, including 
whether this agent causes apoptosis of smooth muscle and endothelial 
cells.  
2. In future work, I will explore how bosentan is sensitising and potentiating 
the effects of ispinesib. As a first step, I plan to use FACs analysis to 
identify if bosentan is causing cells to growth arrest in a different or 
similar phase of the cell cycle, or if it is preventing cells from re-entering 
the cell cycle.        
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Most of the targets described in my thesis have been implicated in the proliferative 
processes of the PASMCs. However, establishing which of these targets and 
potential treatment options is the most relevant and potentially the most efficacious 
in the setting of PAH requires further investigation. The purpose of my 
experiments was to explore the anti-proliferative pathway and the interaction of 
two or more mediators that might interfere with proliferation in human PASMCs 
isolated from patients with IPAH. Specifically, I aimed to investigate mechanisms 
in which multiple proliferation pathways might be linked or affected and thus 
might serve targets for future drug development for PAH.  
 
 Stable prostacyclin analogues in PAH 6.1
 
In the first chapter I have assessed the stable prostacyclin analogue treprostinil with 
respect to its ability to generate cAMP and inhibit proliferation of PASMCs. I 
demonstrated that despite being a chemically stable prostacyclin analogue, cyclic 
AMP levels were not well sustained after treprostinil treatment in human PASMCs 
isolated from IPAH patients compared to control human PASMCs, where cAMP 
levels remained elevated for several hours (Finney et al, 2002). Phosphodiesterase 
3 enzymes hydrolyse the second messenger cyclic 3’5’ AMP to 5’-AMP 
inactivating this critical second messenger, thus playing an important role in cell 
signalling. In the work described in this thesis I have investigated the potential of 
the phosphodiesterase 3 inhibitor, cilostazol in combination with treprostinil and 
showed that cAMP levels were not only higher, but that elevation was also 
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significantly sustained for up to 24 h, indicating high activity of PDE3 may play a 
vital role in prostacyclin analogues signalling in PAH. Cilostazol potentiated the 
effects of treprostinil, whether it was generation of cAMP, inhibition of SMC 
proliferation or vasodilation of arteries. Thus PDE-3 seems integral for regulating 
the many different cellular effects of prostacyclins.   
 
While prostacyclin appears to be important in the normal pulmonary vascular 
transition, dysregulation of the prostacyclin pathway has also been reported in PAH 
(Konduri, 2004; Lakshminrusimha et al., 2009). Pre-treatment with milrinone, 
another PDE3 inhibitor, restores relaxation to prostacyclin to levels similar to that 
seen in control by restoring the expression of the prostacyclin synthase and the 
prostacyclin IP receptor in a sheep model of PAH (Chen et al., 2009; 
Lakshminrusimha et al., 2009). Use of cilostazol has shown very encouraging 
outcomes in animal models of PAH (Chang et al., 2008; Sun et al., 2009). 
Combination therapies of existing drugs with these emerging agents could be one 
interesting option to improve the efficacy and decrease side effects of these drugs 
in PAH patients. It is important to note that PAH is a multifactorial disease and so 
most promising agents should ideally combine regression of vascular remodelling 
with vasodilatator and anti-inflammatory effects, specifically within the pulmonary 
circulation. Cilostazol has been reported as a successful anti-inflammatory agent in 
different diseases including pulmonary disorders (Deree et al., 2008; Osawa et al., 
2012). Cilostazol is approved for the treatment of intermittent claudication (Liu et 
al., 2011), significantly reducing muscle pain. As we know, one of the main side-
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effects associated with prostacyclin is pain, thus cilostazol, if combined with this 
agent, may help manage pain associated with the treatment. Cilostazol is also used 
clinically for peripheral vascular occlusive disease where it increases exercise 
tolerance and favourably modifies the plasma lipid profile (Kambayashi et al., 
2003). Cilostazol is more selective at inhibiting PDE3 whereas milrinone can 
inhibit PDE4 in addition to PDE3. This has been demonstrated in normal rabbit 
heart where inhibition of PDE4 by milrinone partly contributes to the greater 
cardiotonic effect of milrinone when compared to cilostazol. However, the lower 
level of PDE4 activity in failing human heart suggests that factors other than 
inhibition of PDE4 by milrinone may even contribute to differences in cardiotonic 
action when compared to cilostazol. Cilostazol appears to preferentially act on 
vascular elements like platelets and coronary blood flow, consistent with its 
beneficial and safe clinical outcomes in patients with intermittent claudication 
(Shakur et al., 2002; Kunz et al., 2006). This should be tempered with the 
observation in a trial of PDE3 inhibitors, where treatment with milrinone 
significantly increased mortality rates in heart failure (Amsallem et al., 2005, 
Cochrane Database Syst Rev, CD002230.). It could be argued that PDE3 inhibitors 
are unlikely to translate into clinical practice, accepting that with milrinone, failure 
may relate to the fact that it inhibits both PDE3 and PDE4 together (Shakur et al., 
2002), exacerbating heart failure potentially because of reduced systemic pressure. 
In this chapter I have provided evidence suggesting use of cilostazol in 
combination with prostacyclins as a possible new therapeutic regime in IPAH 
which should be explored. 
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Future studies: 
 The therapeutic mechanism, leading to the beneficial effects of prostacyclin 
and its analogues in patients with PAH, is largely unknown. The exact 
mechanisms, by which cell proliferation is inhibited, still needs to be 
determined, although recent work from this laboratory suggests 
involvement of  PPARγ (Falcetti et al., 2007). In my future research I would 
like to explore the mechanistic pathway of prostacyclin further evaluating 
different possible targets for treprostinil using receptor binding studies or 
immunofluorescence techniques to tease out the role of membrane versus 
nuclear receptors as specially detailed below. 
  I also wish to explore more on how different phosphodiesterases may play 
a role in PAH. I have demonstrated that the acute effect of prostacyclin on 
cAMP is mediated mainly through IP receptor. I hope to test the hypothesis 
that other Gs coupled receptor pathways, for example the EP2 or DP1 
receptor pathway (Whittle et al, 2012) may play a role particularly in the 
presence of PDE inhibitor in cells where treprostinil is given chronically. It 
is also possible that there is an up regulation of phosphodiesterase 3 or other 
phosphodiesterase enzymes (PDE1, PDE4, and PDE7) which might be 
responsible for reducing the effectiveness of prostacyclin. 
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Other opposing receptor pathways like thromboxane A2 or EP3 receptor, 
which act through Gi inhibiting cAMP, might be responsible for the 
increasing ineffectiveness of prostacyclins as the disease progresses in 
PAH. Given also that activators of PKC are known to cause receptor 
desensitization, could be one possible mechanism for the desensitization or 
down regulation of IP receptor in long term therapy. EP3 and/or TXA2 
receptors can also increase PDE3 activity through activation of PI3 kinase, a 
well-known target for receptors coupled to Gi. Thus I wish to assess the 
effects of specific EP3 and/or TXA2 antagonists along with treprostinil on 
cAMP generation, phosphodiesterase activity and on proliferations of 
human PASMCs. In addition, I wish to test this combination in vivo, 
particularly with an advanced model of PAH with heart failure. 
  
 Prostacyclin interaction with the endothelin 6.2
pathway 
 
The observation that circulating plasma levels of the vasoactive peptide ET-1 are 
raised in patients with PAH, and that ET-1 production is increased in the 
pulmonary tissue of affected individuals, makes it a particularly interesting target 
for a therapeutic intervention in PAH. Clinical trials with ETRAs showed that they 
provide symptomatic benefit in patients with PAH, but time to clinical worsening is 
relatively short with this class of drugs (Attina et al., 2005). However, the role of 
ETRAs in the treatment of pulmonary hypertension whether used alone or 
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combined with other classical drugs like prostacyclins or PDE inhibitors remains 
incompletely understood. In chapter 4, I have demonstrated that the prostacyclin 
analogue, treprostinil, at a therapeutically relevant dose, could inhibit release of 
ET-1 induced by serum. In contrast, ETRAs significantly increased ET-1 levels 
over and above that induced by serum alone. This mirrors what happens clinically 
when giving these compounds, although it is not clear whether up-regulation of 
ET-1 levels is maintained with chronic treatment of these agents. Paradoxically, 
treprostinil in combination with ETRAs was less effective at inhibiting ET-1 levels. 
The other important observation was that this increase in the ET-1 levels with the 
ETRAs treatment seems to be an effect relating to agents interacting with the ETB 
receptor as the ET-1 levels were not increased with specific ETA receptor blockade. 
This study suggests that the potential deleterious effects of ETB receptor blockade 
in the treatment of pulmonary hypertensive disorders is an important point to be 
considered during treatment of PAH patients. One can speculate that ET-1 
concentration at 24 h after a single bolus of bosentan depends on ET-1 clearance 
through ETB receptor, similar to that shown in the earlier studies (Dupuis et al., 
1996a). I have also demonstrated that this sustained elevation of ET-1 further 
affects the expression of ETB receptors in PASMCs. The level of expression of ETB 
receptors in pulmonary vessels in PAH patients may thus affect responsiveness to 
ETRAs. We can conclude that the ETB receptor contributes to chronic regulation of 
pulmonary vascular tone and therefore loss of ETB receptor activity may adversely 
affect patients in PAH. Also the measurement of ET-1 concentration after ETRA 
administration might predict responsiveness to chronic treatment and will be useful 
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in determining the effectiveness of various conventional combination therapies in 
PAH. 
 
Future Studies: 
 I wish to repeat similar studies in endothelial cells to assess whether the ET-
1 levels and the expression of its receptors are affected with the 
conventional treatments used in PAH.  
 I would also like to assess the mechanism of inhibition of endothelin, 
whether this is through NFAT/calcineurin, HIF-1 and/or PPARs and if 
such pathways are translated in animal models of PAH. 
 Lastly, studies using ETB knock-out mice may provide some more insight 
into the importance of this receptor in PAH. 
 
  Ispinesib as a potential anti-proliferative agent in 6.3
PAH 
 
Vascular remodelling which is characterised as smooth muscle cell proliferation and 
migration, contributes to the pathology of pulmonary hypertension. This can be 
driven by growth factors, vasoconstrictors, inflammatory mediators, and /or vascular 
changes such as increased shear stress or injury (Mandegar et al., 2004). Based on 
therapies used in other proliferative diseases such as in cancer, new agents tested in 
PAH patients aim to inhibit excessive proliferation and/or to induce apoptosis in 
PASMCs, thus contributing to the reversal of pulmonary vascular remodelling and 
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subsequently decreasing pulmonary artery pressure (Schermuly et al., 2005a; Klein 
et al., 2008). In the final chapter, I determined the antiproliferative effect of a newer 
anti-cancer drug, ispinesib which acts by inhibiting mitotic kinesins. Ispinesib 
proved to be a very potent inhibitor of human PASMCs isolated from IPAH 
patients. I also demonstrated that under the same experimental conditions, it was 
significantly more efficacious than currently approved agents such as prostacyclin 
analogues (iloprost or treprostinil) and even more effective than ETRAs (bosentan 
or ambrisentan), used to treat PAH. Ispinesib, when assessed in normal cells, was 
significantly less efficacious at inhibiting cell proliferation, indicating that the drug 
is more likely to target a cell type with a more proliferative phenotype. I also 
demonstrated that the effectiveness of ispinesib was improved significantly when 
combined with treprostinil or bosentan, which were given at doses close to the upper 
limit of those measured in the plasma of patients. The synergy observed with 
bosentan seemed drug related at first since neither specific ETA nor ETB blockade 
produced such synergy unless ispinesib was combined with ambrisentan and BQ788 
so as to presumably block both receptors. I further confirmed that ispinesib appeared 
to inhibit cell proliferation of PASMCs from IPAH patients by inhibiting the kinesin 
spindle motor protein, as it does in tumour cells. Whether this single mechanism 
accounts for the synergy with bosentan remains to be determined. This contrasts the 
synergy I observed with treprostinil, which based on Western blot experiments, is 
likely to occur despite the up-regulation of the ETB receptor and may simply 
synergise because it is a good inhibitor of ET-1 production. In summary, my data 
suggest that ispinesib is an effective inhibitor of smooth muscle and fibroblast 
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proliferation in cells derived from patients with primary or secondary pulmonary 
arterial hypertension. Given, its superior effects on cell growth to current therapies, 
its enhancement when combined with bosentan and treprostinil, and its low 
incidence of side effects, strongly suggests that ispinesib ought to have beneficial 
effects in pulmonary arterial hypertension and may even be superior to imatinib, 
based not only a better selectivity profile, but on a reduced side-effect profile. Given 
that treatments for lung and systemic fibrosis are largely ineffectual, this agent may 
well have a wider clinical application that should be explored in the future. To this 
end, Cytokinetics have applied to the FDA to obtain approval for a small-scale 
clinical to be conducted, based on the data presented in chapter 5.      
 
Reversal of lung vascular remodelling rather than prolonged vasodilation is the 
concept underlying the use of tyrosine kinase inhibitors in PAH (Klein et al., 2008). 
Long term effects of imatinib are complex despite the potential beneficial effects, 
probably because it targets multiple tyrosine kinases, such as PDGF receptors and c-
kit (Souza et al., 2006; Ghofrani et al., 2009). However, another broad spectrum 
tyrosine kinase inhibitor, dasatinib, while decreasing PDGF-induced proliferation in 
addition to multiple growth factor-induced PASMC proliferation in experimental 
PAH, causes severe precapillary pulmonary arterial hypertension cell in patients 
treated with this agent for chronic myelogenous leukemia (Montani et al., 2012). 
Indeed broad spectrum agents will actually cause PAH suggesting the balance 
between inhibiting cell growth and allowing for endothelial regeneration is finely 
balanced.   
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Future Studies: 
 I wish to assess the mechanism behind synergy of ispinesib with current 
therapeutic agents like treprostinil and bosentan.  
 It is reported that ispinesib inhibits proliferation by inhibiting/ arresting 
cells in G2/M phase of the cell cycle, I wish to further assess if the drug 
does the same in experimental settings of PAH and also whether 
combining with agents like bosentan facilitates this process of ispinesib. 
 In future, I also wish to assess this agent in animal models in order to 
determine its safety and adverse effect profile in an in vivo setting of PAH. 
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 Clinical Perspective: 6.4
 
 
Anti remodelling
Anti-inflammatoryVasodilators
PDGF inhibitors
Elastase inhibitors
Ispinesib
TKI inhibitors
PPARγ agonists
ETRAs
Prostacyclins
PDE5 inhibitors
Ispinesib + bosentan
Treprostinil +cilostazol
Ispinesib + treprostinil
 
 
 
 
 
 
All in all we can summarise that PAH, being a multifactorial disease, needs to be 
managed with agents that can target multiple pathways, without interfering or 
counteracting the respective roles of individual agents. With respect to this thesis I 
can propose the following: 
Figure 6.1 Schematic representation of the summary of the possible therapeutic interventions I 
studied in this thesis with regard to anti-remodelling, vasodilator and anti-inflammatory targets 
for pulmonary arterial hypertension. 
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1 Treprostinil, if used in combination with cilostazol, can potentially not only 
target proliferation and vasodilation (treprostinil effects), but might also 
control inflammation and pain (cilostazol effects). Thus this might be a 
potential combination for the treatment of PAH to be explored. 
 
2 Our data, accepting that it comes from in vitro experiments, does not support 
the use of bosentan combined with treprostinil as bosentan not only 
counteracted ET-1 inhibition by treprostinil but also did not potentiate the 
antiproliferative effects of the drug. 
 
 
3 Ispinesib in combination with bosentan may be a potent inhibitor of 
remodelling in PAH. 
 
4 Ispinesib if used in combination with treprostinil may control remodelling, 
vasoconstriction as well as inflammation, possibly through activation of 
PPARγ.
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